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The effects of interleukin-6 in a rat model of 
hepatocellular carcinoma
D iarm uid  M  M oran
Abstract
Interleukin-6 (IL-6) is integrally linked to normal hepatic growth and liver 
regeneration The aim of the present study was to determine the expression and 
function of IL-6 signalling pathways m a rat model of hepatocellular carcinoma (HCC) 
In these studies HCC was charactensed by dysregulated expression of IL-6 
signalling components in vivo and in vitro, including downregulated expression of the 
IL-6 receptor and increased IL-6 production and secretion Recombinant human IL-6 
(rhIL-6) treatment of isolated rat HCC cells and hepatocytes in vitro led to the 
activation of janus kinase-signal transducer and activator of transcription (Jak-STAT) 
and Ras-mitogen activated protein kinase intracellular signalling pathways Cyclin 
dependent kinase (cdk) inhibitor expression was increased m HCC cells after treatment 
with IL-6, an effect that was not observed m isolated hepatocytes Decreases m cdk 
activity after rhIL-6 treatment result m a G0/G1 growth arrest in HCC cells
As a result of these in vitro studies, an algmate based cell microencapsulation 
system was developed to provide continual in vivo rhIL-6 delivery in a rat model of 
HCC CHO cells transfected to supra-express rhIL-6 were encapsulated m algmate and 
implanted in HCC tumour burdened rats resulting m high serum levels of biologically 
active rhIL-6 Recombinant human IL-6 was detected in both normal and tumour liver 
tissues resulting m activation of the Jak-STAT pathway Due to tumour volume 
variability, no conclusions on the effects of rhIL-6 on tumour progression in vivo could 
be determined However, rhIL-6 treatment did result in increased total hepatic weight 
Collectively this study demonstrates a role for IL-6 m HCC progression and 
identifies algmate encapsulated CHO cells as an effective method for rhIL-6 delivery in 
vivo which has potential in the study of normal and abnormal liver growth
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Chapter 1: Introduction
1.1 Hepatocellular Carcinoma
1.1.1 Epidemiology
Hepatocellular carcinoma (HCC) accounts for approximately 85% o f the 
primary malignant tumours o f the liver (Kew, 2002) Hepatocellular Carcinoma is the 
fifth most common malignancy m the world and is the third most common cause o f 
cancer related death worldwide (Okuda, 2000, Parkm et a l , 2001) The age adjusted 
worldwide incidence is between 5 5-14 9 per 100,000 population The occurrence o f 
this malignancy is more prevalent m men than women with an incidence ratio o f 
approximately 3 1 respectively (Kew, 2002) Furthermore, incidence increases with 
age, presentation usually being rare before the age o f forty m developed countries 
(Kew, 2002, Bosch et a l , 1999) HCC is most prevalent m regions o f eastern and 
south-eastern Asia and sub-Saharan Africa (> 15 per 100,000 population) (Kew, 2002, 
Bosch et a l , 1999) Recent analysis reports the incidence o f HCC has nearly doubled in 
the U SA over the past two decades (Bergsland and Venook, 2000) while in Japan the 
levels o f HCC have increased by 15-20%  over the past three decades (Kew, 2002) 
These increases are related to higher incidence o f Hepatitis C virus (HCV) infection 
and chronic alcohol abuse, two o f the mam causal factors o f HCC (Kew, 2002)
1.1.2 Aetiology
Cirrhosis o f the liver represents the major underlying factor predisposing the 
development o f HCC The underlying cause o f this cirrhosis affects the level o f
1
associated nsk o f HCC development For example viral hepatitis related macronodular 
cirrhosis poses a greater cancer risk than alcohol induced micronodular cirrhosis (el- 
Serag, 2001) Furthermore HCV related cirrhosis carries a greater cancer nsk than 
cirrhosis with underlying Hepatitis B virus (HBV) infection (el-Serag, 2001) 
Approximately 75-80% of worldwide HCC cases are related to chronic infection with 
the hepatitis viruses, HCV and HBV (Bosch et a l , 1999) In addition to hepatitis 
infection and chronic alcohol abuse, aflatoxm exposure (from infected food) represents 
a common cause of hepatic cirrhosis (Kew, 2002, Bosch et a l , 1999)
1 1.2.1 H epatitis C virus
Approximately 170 million people worldwide are seropositive for anti-HCV 
and, of these, an estimated 127 million are chronically infected (Ray Kim, 2002) 
Markers o f HCV infection are found in 28% to 76% of HCC cases in Europe, with an 
increasing gradient from north to south, and in 80 to 90% of HCC cases in Japan (el- 
Serag, 2001) In other parts o f Asia and Africa, HCV infection is related to only 20% of 
HCC cases due largely to the prevalence o f HBV infection m these areas (Bosch et a l ,
1999)
Hepatitis C virus is a RNA virus o f the flaviviridae family This virus has no 
reverse transcriptase activity and does not integrate itself into the host genome As such 
HCV should, in theory, have no direct oncogenic potential (Romeo and Colombo, 
2002) However, chronic HCV infection leads to the development o f liver fibrosis, and 
ultimately cirrhosis, which predisposes the liver to develop HCC (el-Serag, 2001) 
More recently, direct oncogenic effects of HCV infection have been elucidated It has 
been suggested, based on both clinical and epidemiological studies, that HCV may be 
more hepatocarcinogemc than HBV (Okuda, 2000, Ikeda et a l , 1993) The HCV 
genome is translated into a 3000 ammo acid polyprotein that is cleaved into a number
2
of proteins with different functions The HCV core protein has transcriptional 
regulating functions on different cellular genes including the proto-oncogene c-myc 
suggesting involvement m the deregulation o f normal cell growth (Ray et a l , 1995) 
Furthermore, transgenic mice expressing the HCV core protein develop hepatic 
tumours that first appear as adenomas containing fat droplets m the cytoplasm A more 
poorly differentiated neoplasia then evolves within the adenomas presenting the 
‘nodule in nodule’ histopathological feature typical o f early HCC patients with chronic 
HCV infection (Moriya et a l , 1998) Other possible mechanisms for the carcinogenic 
effects o f HCV core protein include its ability to inhibit both Fas and Tumour Necrosis 
Factor-a (TNF-a) mediated apoptosis (Marusawa et a l , 1999) and its ability to 
constitutively activate a mitogen activated protein kmase/extracellular signal regulated 
kinase (MAPK/ERK) signalling cascade (Hayashi et a l , 2000) In addition, the HCV 
non structural proteins NS3 and NS5A have been shown to have direct oncogemc 
potential as indicated by their ability to promote anchorage independent growth when 
expressed in fibroblasts and tumour formation m nude mice (Sakamuro et a l , 1995, 
Ghosh et a l , 1999)
1 1 2  2 H epatitis B Virus
Hepatitis B virus is among the most common diseases m the world with an 
estimated 350 million chronically infected earners worldwide (Maddrey, 2001) 
Hepatitis B virus infection is the mam causal factor for HCC globally and the 
geographical distribution of HBV infection closely reflects that o f HCC (Bosch et a l ,
1999) Hepatitis B virus infection levels at their highest are greater than 8% in regions 
such as Asia, Afnca and the Western Pacific while in Western Europe, North Amenca 
and Australia the levels are lower than 2% of the population (Maddrey, 2001) A 
landmark cohort study m Taiwan of over 22,000 HBV surface antigen (HBsAg)
3
seropositive males showed that chronic HBV infection precedes HCC development and 
that the relative risk o f development o f HCC is approximately 100 fold greater for these 
earners (Beasley et a l , 1981)
Cirrhosis as a consequence of chronic HBV infection is the principal factor 
predisposing to HCC development m these patients (el-Serag, 2001) Unlike HCV, 
HBV is a single stranded DNA virus o f the hepadnavirus family that is integrated into 
the host genome Integration o f HBV DNA may activate cellular proto-oncogenes or 
suppress growth regulating genes m cis however, no consistent integration sites have 
been observed (Lok, 2000) The HBV X gene encodes a viral protein that plays a 
central role m HBV infection and m hepatocarcinogenesis Transgenic mice expressing 
the entire HBV X gene under its own regulatory elements developed HCC beginning 
with multifocal areas of altered hepatocytes, followed by appearance of benign 
adenomas and then malignant carcinoma (Kim et a l , 1991) The HBV X protein is a 
transcriptional factor that can alter the expression of many cellular genes including a 
subset of oncogenes such as c-m yc and c-m yb as well as tumour suppressor genes such 
as APC, p53 , p21wafl/cip} and WT1 m primary human hepatocytes (Wu et a l , 2001) 
r Furthermore, the X protein has the ability to sequester the tumour suppressor p53 in 
vitro and can block p53 mediated apoptosis in vivo which contnbutes to the 
development o f preneoplastic and neoplastic hepatocytes (Huo et a l , 2001)
Overall, HBV infection causes 80% of HCC throughout the world however only 
a minority o f chronic HBV carriers develop HCC m their lifetime This indicates the 
possible involvement o f other cofactors for the development o f HCC
1 1 2  3 Aflatoxins
Aflatoxms are mycotoxins from Aspergillus flavus  and Aspergillus parasiticus 
and are the most potent naturally occumng carcinogens known They are common,
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particularly in Asia and sub-Saharan Africa, where nuts and meals are often stored 
under hot and humid conditions allowing foi growth of these moulds (Romeo and 
Colombo, 2002) The contamination o f foodstuffs with Aflatoxm B1 correlates with 
HCC incidence m areas where there is high levels of HBV infection (el-Serag, 2001) A 
specific mutation at codon 249 of the tumour suppressor gene p53  is common in HCC 
tissue of patients who have ingested high levels o f aflatoxins (Ozturk, 1991) While this 
may account in part for the oncogemc effect of aflatoxms it appears that the synergistic 
cancer causing effect o f this toxin m association with HBV infection presents a greater 
HCC risk (Sun et a l , 1999)
1 1 2  4 E thanol
Ethanol has no mutagenic properties however it is associated with an increased 
risk o f cancer in several organs (Romeo and Colombo, 2002) The hepatocarcinogemc 
effects of chronic alcohol intake are most likely a result o f the alcohol mediated liver 
cirrhosis (el-Serag, 2001) Ethanol metabolism results in the development o f reactive 
oxygen species and carbon centred free radicals which can cause peroxidation o f the 
polyunsaturated side chains of membrane phospholipids Cell membrane peroxidation 
ultimately results m liver cell damage, inflammation and often immunologically 
mediated liver injury (Day, 1996) Alcohol has also been identified as a strong 
synergistic cofactor m HBV and HCV mediated liver carcinogenesis (Stickel et a l , 
2002)
1,1.3 Natural History of HCC
The molecular mechanisms of hepatocaicmogenesis remain poorly understood 
Hepatocytes have a high level of metabolic function which is affected by many 
expressed genes As a result these genes are expected to undergo much more complex
alterations during carcinogenesis than m other cancers (Okuda, 2000) There are 
currently no consistent genetic sequences of events that lead to HCC formation with 
much of the past research indicating that there are multiple pathways to its development 
(Feitelson et a l , 2002) There are however a number o f molecular changes that occur m 
high frequency within cirrhotic tissue and small tumours which may constitute the early 
stages o f hepatocarcmogenesis (Feitelson et a l , 2002) Overall it is apparent that 
hepatocarcinogenesis is a multistep process which leads to progressive loss of 
differentiation, loss of normal cell adhesion, degradation o f the extracellular matnx and 
constitutive activation of selected survival and growth promoting pathways
1 1 3  1 Pathology
Hepatocarcmogenesis initiated by HBV, HCV or environmental carcinogens 
usually follow the same sequence of necroinflammatory changes, hepatitis, fibrosis, 
cirrhosis, hepatocellular adenoma and finally HCC (Lim, 2002) It was first reported in 
1986 that early HCC evolved in adenomatous hyperplastic nodules within the context 
o f chronic hepatitis and/or cirrhosis (Arakawa et a l , 1986) Since then it has been 
established that these dysplastic nodules will become malignant m approximately half 
of these patients and should be considered an absolute precursor of transformation 
(Takayama et a l , 1990) Early histological changes which precede malignant 
transformation m these nodules include an increase in cellulanty (nuclear crowding), an 
irregular, thin trabecular pattern with frequent acmus and pseudogland formation This 
early HCC is well differentiated, from which less well differentiated HCC develops 
(Okuda, 2000) As this small HCC becomes dedifferentiated the number of portal tracts 
decrease and the number o f mtratumoural arterioles increase (Nakashima et a l , 1999) 
As the tumour grows the cells invade the neighbouring portal tracts and the fibrous 
stroma of the cirrhotic liver (Okazaki et a l , 1997) Elevated levels o f MMP1 are seen at
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this point o f development allowing the tumour to break down the extracellular matrix 
of the portal tract tissue and permitting further tumour growth (Okazaki et a l , 1997) 
The result o f this process is a large, poorly differentiated tumour capable o f vascular 
invasion
1 1 3  2 M olecular M echanism s o f H CC
An extensive study of HCC resulting from three of the mam aetiological factors 
HCV infection, HBV infection and chronic alcohol intake indicates common 
molecular/genetic changes (Edamoto et a l , 2003), R bl, p53 and Wnt being the mam 
pathways affected Typically tumours associated with alcoholism have more frequent 
alterations o f Rbl and p53 pathways than those caused by HCV infection The most 
common alterations were p l 6}NK4A methylation, loss o f Rbl expression through 
promoter methylation and Cyclin D1 amplification (Edamoto et a l , 2003) Microarray 
analysis o f differential gene expression in HCC shows upregulation of the MAPK 
pathway as well as genes associated with an activated cell cycle (Okabe et a l , 2001) 
The downregulated genes mamly encode hepatocyte specific gene products and 
detoxification enzymes producing a less differentiated phenotype (Okabe et a l , 2001) 
Later m hepatocarcmogenesis tumour cells undergo increasing levels o f chromosomal 
aberrations including loss of gene heterozygosity (Kimura et a l , 1996)
P 1 6 INK4A normally inhibits cyclin dependent kinases (cdk) 4 and 6  which block 
G1 phase progression via dephosphorylation of Rb, the latter of which binds to and 
inactivates E2F1 (Feitelson et a l , 2002) Germ line mutations o f this tumour suppressor 
protein have been identified in adult cases of HCC m Switzerland suggesting familial 
HCC however, this concept of inheritable HCC is relatively new and requires 
confirmation (Chaubert et a l , 1997) Diethylmtrosamme-thioacetamide treatment of 
Fischer rats, which induces HCC, also causes hypermethylation o f the p l 6!NK4A exon 1
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in the later stages o f carcinogenesis, further highlighting its importance in this process 
(Lim, 2002)
Mutations o f P-Catemn are commonly observed in the early development of 
HCC and disruption of this Wnt signalling protein affects the expression of its target 
genes including c-myc, c-jun, cychn D1 and fibronectin (Calvisi et a l , 2001) p-Catenin 
is an important submembranous protein that functions m cell-cell adhesion Its mutation 
disrupts normal cell-cell interactions and strongly stimulates hepatocellular growth 
(Feitelson et a l , 2002, Cadoret et a l , 2001)
P53 is the most common molecular target m human carcinogenesis However, a 
study of primary HCCs from many different origins shows that frequency of mutation 
of this tumour suppressor was low (Buetow et a l , 1992) Usually mutations of p53 are 
recognised only m advanced stages o f HCC and it is not a prerequisite for 
hepatocarcmogenesis (Teramoto et a l , 1994) The most common mutations of p53 in 
HCC are the G to T transversions m codon 249 caused by aflatoxin exposure (Ozturk, 
1991)
1.1.4 Diagnosis and Treatment
Generally, small HCC tumours cause few symptoms and the large functional 
reserve of the liver tends to delay symptomatic presentation (Johnson, 2000) As a 
result tumours usually present late and the cancer is generally large once discovered 
The insidious nature o f HCC m addition to tumour size and location represent the major 
limiting factors m the treatments available for the HCC patient
1 1 4  1 D iagnosis
Continuous surveillance of cirrhotic patients is recommended in order to decrease 
tumour related deaths This surveillance involves ultrasonography and the measurement
of serum alpha-fetoprotein (AFP) levels every six months (Bruix et a l , 2001) 
Screening is usually only earned out m patients that can potentially be treated (Bruix et 
a l , 2001) Ultrasonography can detect lesions as small as 0 5cm making it good for 
screening in cirrhotic patients (Okuda, 2000) However its level o f detection of small 
nodules is low and other imaging techniques such as helical computerised tomography 
(CT) and magnetic resonance imaging (MRI) with contrast enhancement tend to 
provide greater accuracy of diagnosis (Johnson, 2000)
Serum AFP is elevated above the normal reference range of O-lOng/mL in SO­
SO0/© of patients at the time of presentation making it a useful HCC marker (Johnson,
2000) Hepatocellular Carcinoma specific isoforms of AFP have also been discovered 
which are proving useful in differentiating between benign liver disease and HCC 
(Breborowicz et a l , 1981) However, many HCC tumours do not produce AFP or do so 
minimally (Okuda, 2000) Protein induced by vitamin K absence or antagonist II 
(PIVKA II) is also proving to be a viable marker o f HCC in the absence of AFP levels 
(Kuromatsu et a l , 1997)
1 1 4  2 T reatm ent and Prevention
Surgical resection, including complete hepatic transplant, remains as the most 
common treatment for HCC however, the majonty o f tumours are unresectable at the 
time of presentation This is primarily due to the size and location o f the tumour, the 
presence o f extrahepatic metastases and complications due to associated cirrhosis 
(Johnson, 2000) Tumour recurrence tends to complicate greater than 70% of cases at 5 
years post resection representing both de novo tumours and true recurrence, usually due 
to secondary metastasis (Bruix and Llovet, 2002) The use o f post operative adjuvant 
therapy using a synthetic retinoid polyprenoic acid has resulted m decreased tumour 
recurrence and increased survival in tumour lesected HCC patients (Muto et a l , 1996)
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Liver transplantation can theoretically cure HCC and underlying cirrhosis m the 
absence o f vascular tumour invasion (Suehiro et a l , 2002) In patients with early HCC, 
cadaveric liver transplantation can achieve a 70% 5 year survival rate with a recurrence 
rate below 15% (Bruix and Llovet, 2002) However, there is a shortage of liver donors 
and the wait time involved tends to worsen the results o f the liver transplantation (Bruix 
and Llovet, 2002) Moreover, immunosuppression after liver transplantation is also 
associated with increased recurrence (Bruix and Llovet, 2002) Living donor 
transplantation is the most feasible alternative however this procedure is associated 
with a high level o f surgical morbidity for recipients (Suehiro et a l , 2002)
Percutaneous treatments, which involve the destruction o f neoplastic cells by 
chemical substances or by modifying the temperature o f the tumour, are the best option 
for unresectable HCC Percutaneous ethanol injection has been reported to give long 
term survival rates as high as 70% m cirrhotic patients with small (<3cm diameter) 
tumours (Rust and Gores, 2001) These are similar survival rates as those seen for 
surgical resection however tumours recur in more than half o f the patients two years 
post treatment (Rust and Gores, 2001) Other percutaneous treatments such as 
microwave coagulation or cryoablation are associated with many complications and do 
not tend to show significant survival advantage (Aguayo and Patt, 2001)
Palliative treatments such as arterial embolisation and systemic chemotherapy 
have been applied in more advanced tumours Chemoembolisation with agents such as 
gelatin causes tumour de vascularisation which m turn cuts off the tumours nutnent and 
oxygen supply inducing extensive tumour necrosis Randomised studies demonstrate 
this therapy can induce HCC shrinkage however, it does not show any overall survival 
advantage (Aguayo and Patt, 2001) Systemic chemotherapy using single agents or 
combination therapies have not shown any clear advantage in terms of overall survival 
(Bergsland and Venook, 2000) The innate resistance o f these tumours to
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chemotherapeutic agents may be due, at least m part, to the drug metabolising functions 
of hepatocytes and the overexpression of multidrug resistance protein m these tumours 
(Di Maio et a l , 2002)
Due to the poor success rates of most therapies the prevention of HCC 
development offers the greatest hope This includes the avoidance o f exposure to 
carcinogens, avoidance of hepatitis infection and/or prevention of cirrhosis 
development in viral hepatitis Vaccination against HBV infection will greatly reduce 
HCC incidence worldwide A mass vaccination program against HBV was introduced 
in Taiwan, firstly for all children o f mothers that were HBV carriers in 1984, and then 
universally in 1986 HBV carriage in these children has decreased approximately 10 
fold and there has been a 50% reduction in the occurrence and mortality rate o f HCC in 
those immunised (Chang et a l , 1997) In the case o f HCV infection there is currently 
no vaccine available and hence the prevention of the progression of chronic HCV 
infection to cirrhosis is more important (Foms et a l , 2002) Interferon a (IFN-a) or its 
L-nucleoside analogue lamivudme (ribavirin) therapy has eradicated HCV infection m 
patients with persistent infection who are sustained responders to these drugs 
(Bergsland and Venook, 2000) A large retrospective study demonstrates that patients 
with chronic HCV infection show a significantly reduced incidence of HCC when 
treated with IFN-a (Ikeda et a l , 2001)
1.1.5 Summary
HCC is one o f the most common life threatening malignancies in the world 
This cancer generally arises from well defined causal factors which are viral hepatitis 
infection, aflatoxin exposure and chronic alcohol abuse Despite the identification of 
these aetiological agents, hepatocarcinogenesis remains poorly understood The 
molecular mechanisms leading to the development o f HCC have only been partially
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established and a great deal of further research remains to be performed Currently 
surgical resection, including liver transplantation, offers the best cure for HCC, 
however, these therapies are hindered by tumour recurrence and/or donor shortages A 
lack of suitable therapeutic strategies has led to a greater focus on prevention of HCC 
using antiviral agents and vaccination Overall the outlook for HCC patients is bleak, 
however, a better understanding of the molecular and genetic basis o f this cancer 
should lead to the development o f more efficacious therapies
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1.2 Interleukin-6
1.2.1 Introduction
Cytokines are a group of low molecular mass proteins that are critical for cell­
cell communication in multicellular organisms Unlike hormones they are not stored in 
glands but are rapidly synthesised and secreted by different cell types, usually in 
response to specific stimuli Cytokines are generally pleiotropic and carry out their 
actions in an auto-, para- or endocrine manner via specific cell surface receptors They 
usually act m the picomolar/nanomolar range and their target cells are often adjacent to 
the producer cells making it difficult to detect cytokines in serum Cytokines regulate 
growth, survival, differentiation and effector functions m target cells (Vilcek, 2003)
Interleukins are a group of cytokines that are produced by lymphocytes, 
monocytes and many other cell types in response to both antigenic and antigen non 
specific stimuli Interleukins modulate inflammation and immunity by regulating 
growth, mobility and differentiation o f lymphoid and other cell types (Vilcek, 2003)
Interieukin-6 (IL-6) was first cloned m 1980 dunng an effort to isolate the 
virally induced protein Interferon-P (IFN-p) and was subsequently named IFN-P2 
(Weissenbach et a l , 1980) An antigen-non specific B cell differentiation factor that 
induced B cells to produce immunoglobulins was later discovered and named B-cell 
stimulatory factor 2 (BSF-2) This protein was identical to IFN-P2 and was identical to 
other independently cloned proteins such as hepatocyte-stimulating factor, 
hybndoma/plasmacytoma growth factor and 26KDa protein (Naka et a l , 2002) All of 
these names were resolved to the protein’s current name, mterleukm-6
1.2.2 Structure of Interleukin-6
Human IL-6 has a molecular weight of between 21-28 KDa depending on the 
extent o f post-translational modification including glycosylation and phosphorylation
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(May et a l , 1988b, May et a l , 1988a) The IL-6 peptide contains 212 amino acids (aa) 
o f which a 28 aa hydrophobic signal peptide is cleaved resulting in the mature, 184 aa 
IL-6 protein (Keller et a l , 1996) The protein contains four cysteines and two potential 
N-linked glycosylation sites (Hirano et a l , 1986) X-ray crystallography and nuclear 
magnetic resonance (NMR) spectroscopy indicates the presence of a four-a-helix 
bundle arranged m an “up-up-down-down” topology (Hemnch et a l , 1998) Mouse and 
rat IL-6 share approximately 42% and 58% homology respectively, to human IL-6 at 
the ammo acid level however, they do not possess N-glycosylation sites and may only 
be O-glycosylated (Northemann et a l , 1989, Van Snick et a l , 1988) Human IL-6 can 
stimulate responsive cells from both rats and mice, probably due to the highly 
conserved central region of the protein common to each species (Keller et a l , 1996) A 
virally encoded form of the IL-6 protein is produced by the human Kaposi’s sarcoma 
associated herpesvirus (KSHV) This protein is 204 aa long and shares 25% sequence 
homology with human IL-6 at the ammo acid level The protein is considered to be a 
response to the host defence systems by the virus and is possibly involved in virus- 
induced neoplasia (Burger et a l , 1998, Moore et a l , 1996)
1.2.3 Expression of Interleukin-6
The human IL-6 gene is located on chromosome 7p21-pl4, contains four introns 
and five exons and is approximately 5 Kb long (Yasukawa et a l , 1987) The gene 
contains three transcription initiation sites or TATA-like sequences (Yasukawa et a l ,
1987) The promoter of the IL-6 gene contains several cw-acting response elements 
including those for AP-1, nuclear factor IL-6 (NF-IL6), NF-kB and the multiple 
response element (MRE) (Keller et a l , 1996) The expression of IL-6 can be induced 
by various factors including tissue plasminogen activator (TPA), tumour necrosis factor 
(TNF), interleukin-1 a (IL-la) and serum, all of which augment expression through the
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MRE (Ray et a l , 1989) The IL-6 promoter can be repressed by various combinations 
of cw-acting and trans-acting elements including retinoblastoma protein binding to the 
retinoblastoma control element (RCE) and the effects o f various steroids such as 
glucocorticoids, oestrogens and androgens (Keller et a l , 1996)
Interleukm-6 can be produced by both lymphoid and non-lymphoid cells such 
as monocytes, T cells, B cells, fibroblasts, mesangial cells, endothelial cells and several 
tumour cells (Naka et a l , 2002) In normal individuals the circulating level o f IL-6 in 
the blood is typically m the pg/mL range (Yamamura et a l , 1998) These levels are 
moderately elevated m some cancers such as adult T cell leukaemia/lymphoma (median 
IL-6 concentration is 8pg/mL) and melanoma where the levels correlate closely with 
tumour burden (Mouawad et a l , 1996, Yamamura et a l , 1998) Large increases in 
circulating IL-6 levels are seen after surgery where blood concentrations often range 
between 30-430pg/mL (Sakamoto et a l , 1994)
1.2.4 The Interleukin-6 Receptor
1 2  4 1 C lass I C ytokine R eceptors
The functional IL-6 receptor is a complex of two transmembrane glycoproteins 
that are members o f the class I cytokine receptor superfamily The mam characteristic 
o f the receptors in this family is the presence of at least two fibronectin type III 
domains in the extracellular region (Keller et a l , 1996) One of these domains contains 
four conserved cysteines while a second type III domain shows a Trp-Ser-x-Trp-Ser 
(WSxWS) motif (Heinrich et a l , 1998) Cytokine receptors m this group include 
leukaemia inhibitory factor receptor, ciliary neurotrophic factor-receptor a, oncostatin 
M receptor p, interleukin-11 receptor a and the IL-6 receptor components, interleukin-6 
receptor a (IL-6Ra) and glycoprotein 130 (gpl30)
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The human IL-6Ra was first cloned from a human natural killer cell line, YT 
(Yamasaki et a l , 1988) and then was later cloned from the hepatoma cell line, HepG2 
(Schooltmk et a l , 1991) Human IL-6Ra is an 80 KDa transmembrane glycoprotein 
consisting of 468aa The mature protem, which is 449 aa, has a 339 aa extracellular 
region, a 28 aa transmembrane domain and an 82 aa intracellular region (Yamasaki et 
a l , 1988) The extracellular domain has two tandem fibronectin type III motifs which 
contain the four conserved cysteine residue and the WSxWS motif that are 
characteristic of this receptor family (Yamasaki et a l , 1988) The intracellular domain 
does not possess intrinsic kmase activity (Yamasaki et a l , 1988) and requires 
association with gpl30 for active signalling The IL-6Ra receptor component is 
expressed by many cell types including CD4+ and CD8+ T cells, hepatocytes, neurons, 
neutrophils and osteoblasts (Keller et a l , 1996)
Human IL-6Ra also exists m a soluble form that was first identified in unne 
(Novick et a l , 1989) Soluble IL-6Ra (sIL-6Ra) is a 55 KDa protem that arises via 
proteloytic shedding of the membrane bound receptors or through alternative mRNA 
splicing (Heinrich et a l , 1998) This alternative form of IL-6Ra can form active 
signalling complexes with IL-6 and membrane bound gpl30, thereby acting as an 
agonist m IL-6 signalling (Taga et a l , 1989, Cichy et a l , 1996) In healthy patients, the 
circulating levels o f sIL-6Ra typically ranges from 75-80ng/mL (Honda et a l , 1992, 
Gaillard et a l , 1993) The^blood concentration o f sIL-Ra is elevated in many diseases 
including myeloma (130-190ng/mL) (Gaillard et a l , 1993) and human
immunodeficiency virus (170ng/mL) (Honda et a l , 1992) The cell types expressing 
membrane bound IL-6Ra do not fully represent the cell types that can respond to IL-6 
since sIL-6Ra in the presence of IL-6 can theoretically induce signalling m all cell 
types expressing gpl30 alone (Peters et a l , 1996)
1 2 4 2 IL -6R a
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Glycoprotein 130 is the signal transducing component o f the IL-6 receptor The 
molecular weight o f the membrane bound form of gpl30 ranges from 130-145 KDa 
depending on the extent o f glycosylation (Hibi et a l , 1990) Human gpl30 is an 896 aa 
long glycoprotein comprised of a 597 aa extracellular region, a 22 aa transmembrane 
domain and a 277 aa cytoplasmic segment (Hibi et a l , 1990) There are six type III 
fibronectm domains m the extracellular region in addition to the expected WSxWS 
m otif and the four conserved cysteine residues (Hibi et a l , 1990) The cytoplasmic 
segment does not possess intrinsic tyrosine kmase activity but does contain at least 
three boxes to which cytoplasmic tyrosine kinases can bind (Murakami et a l , 1993) 
The intracellular tail o f gpl30 also contains six tyrosme residues which act as docking 
sites for vanous signalling proteins during IL-6 type cytokine signalling (Yamanaka et 
a l , 1996, Stahl et a l , 1995) Glycoprotein 130 is ubiquitously expressed (Imada and 
Leonard, 2000)
Glycoprotein 130 can also exist in a soluble form referred to as sgpl30 This 
form of the protein is the product o f alternate mRNA splicing and occurs at a 
concentration o f approximately 400ng/mL in the blood of healthy individuals (Narazaki 
et a l , 1993) This protein acts antagonistically in IL-6 signalling and may function as a 
physiological buffer of circulating sIL-6Ra activity (Hemnch et a l , 1998) The soluble 
form of gpl30 can only bind sIL-6Ra when IL-6 is present (Hemnch et a l , 1998)
1.2,5 Interleukin-6 Signalling
Interleukin-6 is a member o f a family o f related cytokines collectively termed 
IL-6 type cytokines This family includes IL-6, leukaemia inhibitory factor, oncostatin 
M, ciliary neurotrophic factor, cardiotrophin-1, interleukin-11 and cardiotrophin-like
1 2 4 3  G p l3 0
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cytokine The common characteristic between these cytokines is that they all activate 
gpl30 to induce signalling (Heinrich et a l , 1998)
1 2  5 1 The Jak-ST A T  Pathw ay
Interleukin-6 signalling is initiated by the binding of IL-6 to IL-6Ra at the cell 
surface (Figure 1 1) Interleukm-6 binds to IL-6Ra with a very low affinity, however, 
this interaction triggers the formation of a high affinity complex compnsing two 
molecules each of IL-6, IL-6Ra and gpl30 (Ward et a l , 1994, Hibi et a l , 1990) 
Signalling occurs when two tnm enc complexes associate to form a hexamer where 
disulphide-hnked homodimerisation of gpl30 can occur (Ward et a l , 1994, Ward et a l , 
1996, Murakami et a l , 1993) Glycoprotein 130 associated tyrosine kinases, Janus 
kinases (Jaks), become activated upon stimulation Janus kinases are intracellular 
tyrosine kmases with molecular masses o f 120-140 KDa The members of this protein 
family are Jakl, Jak2 and Tyk2 which are widely expressed and Jak3 which is 
predominantly found in haematopoietic cells (Imada and Leonard, 2000) The Jaks 
associate with the membrane proximal boxl/box2 region of the cytoplasmic tail of 
gpl30 (Heinrich et a l , 1998) The dimerisation induced by ligand binding brings 
associated Jaks within proximity leading to their activation via inter- or mtra- molecular 
tyrosine phosphorylation within the activation loop of their kmase domains (Feng et a l , 
1997) Interleukm-6 signalling leads to the activation of Jak l, Jak2 and/or Tyk2 
(Lutticken et a l , 1994, Narazaki et a l , 1994, Stahl et a l , 1994) The extent to which 
each Jak is activated varies among cells and may reflect levels o f expression of each 
Jak (Stahl et a l , 1994, Matsuda et a l , 1994)
Activated Jaks phosphorylate tyrosine residues in the cytoplasmic tail of gp 130 
which in turn become docking sites for Signal Transducers and Activators of 
Transcription (STATs), primarily STAT3 and STAT1 (Stahl et a l , 1995) Seven
1 8
Figure 1 1 T he Jak-ST A T  Pathw ay. IL-6 signalling is initiated by the binding of IL- 
6 to IL-6Ra which can then recruit gpl30 to form the IL-6 signalling complex Gpl30 
associated Jaks are activated by phosphorylation which then proceed to phosphorylate 
tyrosine residues in the gpl30 tail STATs are recruited to the tail o f gpl30 and are 
phosphorylated Phosphorylated STATs form dimers and translocate to the nucleus 
where they modulate gene expression SOCS proteins can bind Jaks and activated 
tyrosine residues in the gpl30 structure inhibiting IL-6 signalling while PLAS inhibit 
IL-6 signalling through interference with STAT dimers
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mammalian STAT genes have been identified, STAT 1, 2, 3, 4, 5a, 5b, and 6 
(Bromberg and Chen, 2001) With the exception of STAT4 which is expressed only in 
myeloid cells and the testis, STATs are ubiquitously expressed (Bromberg and Chen,
2001) They have various domains in their structure including an oligomerisation 
domain and a leucme-zipper-like domain at the N terminus, a DNA binding domain in 
the middle, an Src homology 3 (SH3)-like domain, a SH2 domain and a transactivation 
domain at the C-terminus (Heinrich et a l , 1998, Bromberg and Chen, 2001) STATs 
bind to the phosphorylated tyrosme residues in gpl30 via their SH2 domains and do so 
only when these residues occur as part of specific ammo acid sequences (Stahl et a l , 
1995, Gerhartz et a l , 1996) STAT3 binds to phosphorylated tyrosine residues in a 
pYXXQ m otif (Stahl et a l , 1995, Gerhartz et a l , 1996) while STAT1 only binds 
tyrosine in the more restricted pYXPQ sequence m gpl30 (Gerhartz et a l , 1996) Upon 
binding, STAT1 and STAT3 are tyrosme phosphorylated by the Jaks at activating 
residues withm their kmase domains (Bromberg and Chen, 2001, Imada and Leonard, 
2000) Activated STAT1 and STAT3 can form homo- and/or hetero- dimers 
Dimerisation is a prerequisite for DNA binding (Shuai et a l , 1994) Active STAT 
dimers translocate to the nucleus where they modulate gene transcription (Zhang et a l , 
1995, Heinrich et a l , 1998) Activated STATs bind to DNA gamma interferon 
activation site (GAS) elements/motifs (TTN5AA) m the promoter regions of target 
genes leading to the stimulation or repression of their expression (Seidel et a l , 1995) 
Serine phosphorylation of STAT1 and STAT3 partially regulates this transactivation 
domain activity (Zhang et a l , 1995) The kmase responsible for senne phosphorylation 
appears to depend on both the signalling pathway and cellular context Many senne 
kinases have been implicated in this modification o f STATs including ERKs 
(extracellular signal regulated kmases), p38 and JNK (Zhang et a l , 1995, Imada and 
Leonard, 2000)
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In addition to the Jak~STAT pathway,* the Ras-MAPK pathway can also be 
activated following IL-6 binding (Figure 1 2) SH2 containing protein tyrosine 
phosphatase 2 (SHP2) is an ubiquitously expressed tyrosine phosphatase which 
contains two SH2 domains at its N terminus (Heinrich et a l , 1998) This phosphatase 
binds to activated gpl30 receptors through its SH2 domains and forms a link to the 
MAPK pathway (Stahl et a l , 1995) SHP2 is rapidly recruited to the second phospho- 
tyrosme from the membrane m the tail o f gpl30 and becomes phosphorylated in a 
Jakl/Jak2 dependent manner (Fukada et a l , 1996, Schaper et a l , 1998, Yin et a l ,
1997) Subsequently, activated SHP2 interacts with a Grb2-SOS Growth factor receptor 
bound protem/Son of Sevenless (Grb2-SOS) complex and/or the scaffold protein Grb2- 
associated binder-1 (Gab 1) (Schiemann et a l , 1997, Holgado-Madruga et a l , 1996, 
(Schiemann et a l , 1997, Holgado-Madruga et a l , 1996, Fukada et a l , 1996, Takahashi- 
Tezuka et a l , 1998) Recruitment o f the guanine nucleotide exchange factor, SOS, to 
the receptor converts inactive Ras-GDP to active Ras-GTP (Seger and Krebs, 1995) 
Ras phosphorylates the senne threonine kmase, Raf-1, which once activated can serine 
phosphorylate MEK (mitogen activated ERK kinase) In turn MEK phosphorylates 
both tyrosine and threonine residues m ERKs leading to their activation (Seger and 
Krebs, 1995) The active ERKs then phosphorylate various targets, including 
transcription factors and other kinases which proceed to regulate gene expression 
(Seger and Krebs, 1995)
1 2 5 3 Integration o f IL-6 Signalling Pathw ays
Overall, the balance and interplay of the Jak-STAT and Ras-MAPK pathways 
ultimately determines the outcome of IL-6 signalling in each cellular context For 
example, IL-6 induces growth arrest and macrophage differentiation of the myeloid
1 2 5 2 T he R as-M A PK  P athw ay
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Figure 1.2 The Ras-M APK Pathw ay IL-6 signalling is initiated by the binding of 
IL-6 to IL-6R a which can then recruit gpl30 to form the IL-6 signalling complex 
Gpl30 associated Jaks are activated by phosphorylation which then phosphorylate 
tyrosine residues in the gpl30 tail SHP2 is recruited to the tail o f gpl30, becomes 
phosphorylated and recruits the guanme nucleotide exchange factor SOS via the 
adaptor protein, Grb2 SOS activates the small GTP binding protein, Ras Ras proceeds 
to phosphorylate Raf-1 which once activated phophorylates MEK MEK 
phosphorylates ERK which then phosphorylates various transcription factors and 
kinases that regulate gene expression
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leukaemic cell line M l (Minami et a l , 1996, Nakajima et a l , 1996) The expression of 
a dominant negative form of STAT3 in these cells inhibits IL-6 induced STAT3 
activation and prevents growth inhibition and differentiation that is typically induced 
Furthermore, IL-6 stimulation of the dominant negative STAT3 expressing M l cells 
leads to growth enhancement Therefore IL-6 is simultaneously inducing growth 
enhancing signals as well as growth arrest and differentiation signals, but the former are 
only apparent when STAT3 activation is suppressed (Minami et a l , 1996, Nakajima et 
a l , 1996) Similarly, m IL-6 induced differentiation o f the PC 12 pheochromocytoma 
cell line, the balance of Ras-MAPK and Jak-STAT signalling determines the outcome 
(Ihara et a l , 1997) Interleukm-6 induces neunte outgrowth m PC12 cells that have 
been pre-treated with nerve growth factor (NGF) The activation o f the Ras-MAPK 
pathway promotes this cellular differentiation while STAT3 activity blocks 
differentiation Nerve growth factor acts as a negative regulator o f STAT3 activity in 
the differentiation process (Ihara et a l , 1997)
Studies on gpl30 mediated growth signals indicates that two distinct signals are
\
required (Fukada et a l , 1996) It was shown that in gpl30 stimulated growth 
enhancement o f pro-B cell lines both MAPK and STAT3 activation are necessary 
MAPK signalling stimulates cell cycle progression while STAT3 signalling prevents 
apoptosis via induction of anti-apoptotic proteins (Fukada et a l , 1996, Naka et a l ,
2002)
More recently the PI3K/Akt pathway has been implicated in IL-6 signalling 
The mechanisms through which IL-6 activates this pathway are poorly understood but 
most likely involves the adaptor protein Gab-1 (Takahashi-Tezuka et a l , 1998) PI3K 
is an enzyme that modifies specific phosphatidylmositides so that the senne threonine 
kinase B/Akt is recruited to the plasma membrane where it becomes activated by 
Phosphoinositide Kinase-1 Some of Akt’s substrates include the forkhead transcription
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factor FKHR and the pro-apoptotic factor Bad (Katso et a l , 2001) The activation of 
PI3K has been observed to be important m the IL-6 mediated prevention o f apoptosis in 
both basal cell carcinoma and hepatoma cells (Chen et a l , 1999, Jee et a l , 2002)
1 2 5 4 N egative R egulation o f IL -6 Signalling
In most cases the activation o f each IL-6 signalling pathway is transient 
indicating the presence of inherent negative regulatory mechanisms Many of these 
processes have now been established including receptor degradation and the expression 
of negative regulators
The removal o f cytokine receptors from the cell surface is an efficient 
mechanism to terminate signalling After binding IL-6, the IL-6Ra/IL-6 complex is 
internalised resulting in depletion o f IL-6 surface binding sites within 30 to 60 minutes 
Reappearance of these receptors can take up to 8 hours and is sensitive to 
cycloheximide treatment This indicates receptor degradation and de novo protein 
synthesis is required for replenishment (Zohlnhofer et a l , 1992) A di-leucine 
internalisation motif m the cytoplasmic domain of gpl30 has been established to be 
necessary for internalisation (Dittnch et a l , 1994) however, it is unclear whether gpl30 
is degraded or recycled during this event (Hemnch et a l , 1998)
The negative regulation of Jak-STAT signalling is also affected by a family of 
negative regulators called Protein Inhibitors of Activated STATs (PIAS) This family of 
constitutively expressed proteins comprises five mammalian members PIAS1, PIAS3, 
PIASxa, PIASx(3 and PIASy (Naka et a l , 2002) The exact mechanisms through which 
these inhibitors negatively regulate STATs is not completely clear (Naka et a l , 2002) 
PLAS1 and PIAS3 are the best understood members o f this family PIAS1 specifically 
inhibits STAT1 signalling by preventing DNA binding (Liu et a l , 1998) while PIAS3 
blocks STAT3-DNA binding (Chung et a l , 1997) The interaction between PIAS and
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STATs requires tyrosme phosphorylation of STATs suggesting that PIAS may act via 
inhibition of dimensation (Naka et a l , 2002, Imada and Leonard, 2000)
A family o f cytokine inducible inhibitors o f the Jak-STAT pathway has also 
been discovered (Starr et a l , 1997) Suppressors O f Cytokine Signalling (SOCS) are a 
family o f 8 proteins (CIS, SOCS 1-7) which negatively feedback on cytokine signalling 
induced through gpl30 (Naka et a l , 2002) They all contain a central SH2 domain and 
directly interact with the kinase domain of Jaks leading to reduced kinase activity 
(Endo et a l , 1997) Interleukm-6 signalling causes rapid upregulation of CIS, SOCS1, 
SOCS2 and SOCS3 expression (Starr et a l, 1997) The mechanism of inhibition by 
SOCS vanes between members SOCS-1 binds to Jaks thereby inhibiting 
phosphorylation of gpl30, STATs and the Jaks themselves (Starr et a l , 1997, Naka et 
a l , 1997) SOCS3, in addition to binding Jaks, also associates with specific phospho- 
tyrosine residues within activated gpl30 preventing signalling molecules, in particular 
SHP2, binding their target sites (Naka et a l , 2002)
1.2.6 Physiological and Pathophysiological Functions of IL-6
Interleukin-6 plays a role in many diverse physiological responses IL-6 is a key 
signalling cytokine m the immune system, the development o f inflammatory responses, 
the processes o f liver regeneration and bone metabolism and the development of 
various cancers Aberrant IL-6 signalling has also been associated with the progression 
of numerous diseases
1 2  6 1 Physiological Functions o f IL-6
Interleukin-6 is an important cytokine m the development o f immune responses 
IL-6 induces the differentiation of activated but not resting B cells to produce
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immunoglobulins (Muraguchi et a l , 1988, Takatsuki et a l , 1988) Normal resting B 
cells do not express the IL-6 receptor, expression only occurring on the surface o f the 
activated cell type (Taga et a l , 1987) Furthermore, IL-6 stimulates macrophage 
differentiation Treatment of the myeloid cell line, M l, with IL-6 results in the 
induction o f phagocytic activity and morphologic changes characteristic of mature 
macrophages (Chiu and Lee, 1989) Interleukm-6 also plays a role m the development 
of T cells IL-6 stimulates the proliferation of thymic and peripheral T cells (Lotz et a l , 
1988, Uyttenhove et a l , 1988) and, in co-operation with mterleukm-1, can induce T 
cell differentiation to cytolytic T cells (Renauld et a l , 1989) A role for IL-6 in the 
activation of natural killer cells has also been reported (Luger et a l , 1989)
Interleukm-6 has been identified as an important regulator of bone metabolism 
Interleukm-6 induces osteoclastogenesis and osteoclast activity (Kunhara et a l , 1990, 
Tamura et a l , 1993) Osteoclasts are the large multmucleate cells derived from 
differentiated macrophages which are responsible for breakdown and resorption of 
bone tissue Through these effects IL-6 can contribute to bone remodelling
Interleukm-6 also plays a role in the reproductive system Interleukin-6 levels 
increase m the endometrium during the menstrual cycle suggesting a role for IL-6 in the 
preparation for implantation and the process of menstrual shedding (Tabibzadeh et a l , 
1995) Furthermore, IL-6 appears to be a paracrine regulator o f the seminiferous 
epithelium, IL-6 exerting an inhibitory effect on meiotic DNA synthesis during 
spermatogenesis (Hakovirta et a l , 1995)
In addition to these processes IL-6 has effects in the skm, blood and neural 
systems Interleukm-6 induces the proliferation o f cultured human keratmocytes giving 
it a role m skm renewal (Grossman et a l , 1989) Interleukm-6 also stimulates the 
proliferation of megakaryocytes, the large bone marrow cells that give rise to blood 
platelets (Hill et a l , 1991, Navarro et a l , 1991) In the neural system it has been
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demonstrated that IL-6 is capable of inducing neural cell differentiation and 
proliferation (Ihara et a l , 1997)
1 2 6 2 IL-6 and the L iver
In order to maintain homeostasis, inflammatory cytokines such as IL-6 are 
rapidly removed from the circulation The liver is the mam site o f IL-6 degradation in 
the body 125I-IL6 injected into rats is cleared with a plasma half life o f approximately 
two minutes (Castell et a l , 1988, Castell et a l , 1990a) After 20 minutes, 
approximately 80% of the IL-6 is removed from the circulation and is located in the 
liver The IL-6 primarily accumulates around the hepatocytes and m particular around 
the bile canahculi Degradation products of this radiolabelled IL-6 eventually 
accumulate in the bile
In addition to the degradation process, IL-6 has other important functions in the 
liver The acute phase response is an inflammatory reaction which compnses fever, 
corticosteroid release and hepatic production o f acute phase proteins (Streetz et a l ,
2000) Interleukin-6 stimulates hepatocytes to produce acute phase proteins such as 
serum amyloid A, fibrinogen, C-reactive protein, a i-antitrypsin while simultaneously 
suppressing the production of albumin (Ramadon and Christ, 1999, Gauldie et a l , 
1987, Castell et a l , 1990b, Andus et a l , 1987) Interleukm-6 deficient mice are unable 
to mount an inflammatory response to localised tissue damage and the induction of 
acute phase proteins is dramatically reduced in these animals (Fatton et a l , 1994)
It was long considered that the induction of acute phase proteins was the mam 
function o f IL-6 m the liver, however, it later became apparent that IL-6 has a 
fundamental role in the process o f liver regeneration Partial hepatectomy (PHx) 
involves the removal o f specific liver lobes accounting for approximately two thirds of 
the organs mass The residual undamaged liver lobe increases in size in order to
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compensate for the deficiency in liver mass (Fausto, 2000) During this regeneration 
process hepatocytes divide in a process which takes 24-48 hours and the rest of the cell 
lineages follow during the next five days before returning to quiescence (Fausto, 2000) 
It has been observed that tumour necrosis factor-a (TNF-a) and then IL-6 serum levels 
become elevated during the first hours after PHx in rats (Cressman et a l , 1995) 
Furthermore, strong activation o f STAT3 has been described during this period 
(Cressman et a l , 1995) The proliferative response during liver regeneration in IL-6-/- 
mice is severely impaired (Cressman et a l , 1996) The G1 phase is abnormal in these 
mice resulting m a reduced rate of DNA synthesis This further correlates with a lack 
o f STAT3 activation and decreased expression of AP-1, Myc and cyclin D1 mRNA 
Injection o f IL-6 pnor to hepatectomy rescues this phenotype and prevents hepatic 
damage (Cressman et a l , 1996) In TNF Receptor-1 knockout mice there is no increase 
in IL-6 serum levels following PHx (Yamada et a l , 1997) In this instance mice show 
similar defects in liver regeneration to those observed m IL-6-/- mice and IL-6 injection 
again rescues this phenotype Collectively this has led to a model o f cytokine signalling 
in liver regeneration that involves activation of IL-6 expression by TNF-a followed by 
hepatocyte priming by IL-6 (Streetz et a l , 2000) Hepatocytes must be pnmed in this 
manner before they can respond to growth factors such as hepatocyte growth factor 
(HGF), transforming growth factor-a (TGFa) and epidermal growth factor (EGF) 
(Fausto, 2000)
IL-6 also has protective effects on the liver which are mediated m part by its 
ability to stimulate regeneration Following liver injury the levels o f gut denved 
endotoxins increase and stimulate Kuppfer and endothelial cells to produce acute 
reactant cytokines such as IL-6 and TNF-a (Clavien et a l , 1996) These cytokines 
stimulate the repair process including hepatocyte proliferation IL-6 also protects the 
liver from liver ischaemia and promotes post-reperfusion hepatocyte proliferation
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(Camargo et a l , 1997) Administration of recombinant IL-6 almost completely blocks 
Con-A dependent or T cell associated livéi iailure through multiple mechanisms 
(Mizuhara et a l , 1994) Protective effects of IL-6 have also been observed m liver 
injury induced by bile duct ligation, caecal ligation and puncture, sepsis and 
tetrachloride administration (Streetz et a l , 2000)
1 2 6 3 IL-6 and D isease
Aberrant IL-6 signalling is linked to many human diseases including 
autoimmune diseases, chronic proliferative diseases, viral infections and malignancies 
Increased levels o f IL-6 signalling are observed m many autoimmune diseases For 
example, rheumatoid arthritis (RA) is associated with elevated expression of IL-6 and 
sIL-6R m the synovial fluids (Kotake et a l , 1996) Rheumatoid Arthritis is a systemic 
inflammatory disease characterised by the destruction of cartilage and bones in the 
affected joints (Naka et a l , 2002) The observation that IL-6 and its soluble receptor are 
upregulated m this disorder gives a possible explanation for the increased osteoclastic 
activity observed and a mechanism for joint destruction (Kotake et a l , 1996) 
Humanised anti-IL-6R antibody treatment has been proposed as a possible therapy for 
RA and has entered clinical tnals (Naka et a l , 2002)
Osteoporosis is another bone wasting disease which is closely linked to IL-6 
signalling As previously described, IL-6 stimulates osteoclast activity and increases 
bone resorption The inhibition of IL-6 gene expression partially explains oestrogens 
ability to prevent osteoclast activation (Jilka et a l , 1992, Girasole et a l , 1992) In post­
menopausal osteoporosis, the absence o f oestrogens results m increased IL-6 levels 
demonstrating a possible mechanism for the increased bone breakdown associated with 
this disorder (Jilka et a l , 1992, Girasole et a l, 1992) Interleukm-6-/- mice are
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protected from bone loss associated with ovariectomy providing further evidence for 
IL-6 involvement in this disease (Poll et a l , 1994)
Many proliferative disorders are intrinsically linked to IL-6 signalling 
Overexpression of IL-6 in mice produces a syndrome resembling the systemic 
lymphoprohferatve disorder Castleman’s disease (Brandt et a l , 1990) Furthermore, the 
epidermal hyperplasia seen in the psonatic epithelium has been linked to IL-6 
signalling and its ability to stimulate keratinocyte proliferation (Grossman et a l , 1989)
The Human Immunodeficiency Virus-1 TAT protein induces the expression of 
IL-6 (Scala et a l , 1994) This infection is associated with severe psoriasis, B cell 
lymphoma and Kaposi’s sarcoma The over expression of IL-6 may, in part, account for 
these associated diseases (Scala et a l , 1994) In other infections, such as 
meningococcal septic shock, the median serum concentration o f IL-6 can reach levels 
as high as 189ng/mL demonstrating a potential role for IL-6 in sepsis (Waage et a l , 
1989)
1 2 6 4 IL-6 and Cancer
Interleukm-6 contributes to the progression of numerous malignancies, being 
recognised as both a growth promoter and inhibitor The immunomodulatory functions 
o f IL-6 can also affect the advancement of a multitude of tumours Dysregulated 
activation of IL-6 signalling pathways and signalling components has also been 
identified m the progression of several malignancies
The immunogenic effects of IL-6 have an impact on the progression of many 
cancers in vivo  For example, recombinant human IL-6 (rhIL-6) administration in mice 
results m the regression of pulmonary micromestastases from weakly immunogenic 
tumours but not from non immunogenic tumours (Mule et a l , 1992) In vivo generation 
of tumour specific cytotoxic T lymphocytes (CTLs) was observed m the responder
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animals This indicates a potential role for IL-6 in the treatment o f solid tumours that 
have the capacity to elicit T cell responses (Mule et a l , 1992) In vitro studies using a 
combination o f B7-1 (CD80), IL-6 and interleukin-12 (IL-12) demonstrated an ability 
to stimulate the development of tumour specific CTLs (Gajewski et a l , 1995) In this 
case B7-1 induced interleukm-2 production by CD8+ T cells, IL-6 stimulated their 
proliferation and IL-12 enhanced lytic ability (Gajewski et a l , 1995) Interleukin-6 may 
also affect cancer progression through tumour specific antigen expression It has been 
demonstrated that IL-6 can act directly on human colon carcinoma cells and selectively 
increase Carinoembryomc antigen and Histocompatibility Leukocyte Antigen class I 
antigen expression providing a possible mechanism by which IL-6 suppresses tumour 
growth in vivo (Ullmann et a l , 1992) The role o f IL-6 m the recruitment and/or 
proliferation of tumour-associated macrophages has also been proposed as a possible 
anti-tumour effect of IL-6 in vivo (Bonta and Ben-Efraim, 1993)
Interleukm-6 can also influence proliferation of many cancer cells directly 
Interleukm-6 has been identified as an autocrine growth factor for various malignancies 
including renal cell carcinoma (Miki et a l , 1989), plasmacytoma (Nordan et a l , 1987), 
human multiple myeloma (Kawano et a l , 1988, Jemberg et a l , 1991, Levy et a l , 1991, 
Okuno et a l , 1992) and Kaposi’s sarcoma (Miles et a l , 1990) Interleukm-6 is also an 
autocrine growth factor for several lymphomas (Yee et a l , 1989) including Hairy Cell 
Leukaemia m which it does not directly affect growth but rather mediates TNF-induced 
DNA synthesis via mtracytoplasmic mechanisms (Barut et a l , 1993) Interleukm-6 has 
additionally been reported to inhibit the growth of numerous other cancers Interleukin- 
6 inhibits the growth of human breast carcinoma cells, an effect that is further enhanced 
by the addition o f sIL-6R (Novick et a l , 1992, Chen et a l , 1988) At concentrations 
that stimulate growth m B cell hybndomas and plasmacytomas, IL-6 was also shown to 
strongly inhibit growth in a number of leukaemia/lymphoma cell lines (Chen et a l ,
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1988) Interestingly, IL-6 behaves as a paracrine growth inhibitor in early stage 
melanoma cells however it switches to an autocnne growth stimulator withm the same 
cell lineage during melanoma progression (Lu et a l , 1992, Lu and Kerbel, 1993) It 
appears the advanced stages o f melanoma become resistant to the inhibitory effects of 
IL-6 and, in some cases, can use it to support its own proliferation The IL-6 mediated 
inhibition o f melanoma cells is sensitive to STAT3 and is associated with the 
upregulation of the cell cycle dependent kmase inhibitors p2 l wafl/c,pl (Florenes et a l ,
1999) and p27k,pl (Kortylewski et a l , 1999) A STAT3 dependent growth inhibition in 
the prostate carcinoma cell line, LNCAP, has also been observed (Spiotto and Chung,
2000)
The dysregulated activation of STATs appears to be involved in both viral and 
oncogene-mediated cellular transformations STAT3 is constitutively activated in cells 
transformed by Src tyrosine kinase (Yu et a l , 1995) Disruption of STAT3 signalling 
blocks the transformation of mouse fibroblasts by this oncoprotein (Bromberg et a l ,
1998) Constitutively activated STATs have also been described in cells transformed by 
viruses including Epstein Barr Virus and the Human T-cell lymphotropic virus-1 
(Imada and Leonard, 2000) Furthermore, unremittingly active STATs are present in a 
vanety o f primary tumour cells including active STAT1 and/or STAT3 in multiple 
myeloma, leukaemia, lymphomas, melanoma, lung cancer and prostate cancer 
(Bowman et a l , 2000) Bromberg et al have demonstrated that STAT3 can act as an 
oncogene (Bromberg et a l , 1999) The expression of a constitutively activated form of 
STAT3, STAT3C, in immortalised fibroblasts leads to transformation as scored by 
colony formation m soft agar and tumour formation m nude mice (Bromberg et a l ,
1999) Dysregulated signalling is a possible reason for these constitutively activated 
forms of STAT3 An IL-6 autocrine or paracrine loop is responsible in the case of 
certain myeloma and prostate cancer cell lines (Lou et a l , 2000, Catlett-Falcone et a l ,
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1999) In human HCC the expression o f SOCS-1 is silenced by methylation resulting 
in uncontrolled STAT3 activation (Yoshikawa et a l , 2001a)
The role o f IL -6 m the advancement o f HCC remains unclear Stimulation o f the 
IL-6R a in the human HepG2 hepatoma cell line results m p27k]pl accumulation and 
growth arrest m the G 1 phase (Klausen et a l , 2000) Similarly, Kim et al have 
identified a growth inhibitory effect o f IL -6 in the H-35 rat hepatoma cell line however 
the underlying mechanisms o f this effect were not determined (Kim and Baumann,
1999) In contrast, IL -6 has been indicated as an autocrine growth factor in other 
hepatoma cells In the IL -6 producing HCC-M hepatoma cell line, proliferation is 
inhibited following IL -6 antisense treatment (Kumagai et a l , 2002) Interleukin-6 has 
also been implicated m the survival o f hepatoma cells as suggested by its ability to 
inhibit TGF-p-mduced apoptosis m human Hep3B cells (Chen et a l , 1999) The 
overexpression o f IL -6 m a rat hepatocellular carcinoma cell line is linked to increased 
metastatic potential in vivo  (Reichner et a l , 1998) while the transfection o f an IL-6 
expression vector m a munne tumour cell line was inhibitory to in vivo  tumour growth 
(Dougherty et a l , 1994) These reports, coupled with the observation that serum levels 
o f IL -6 are often increased in human HCC patients (Goydos et a l , 1998, Gianmtrapam 
et a l , 2002), suggests a potentially significant role for IL -6 in this malignancy
1.2.7 Summary
Interleukm-6 is a pleiotropic cytokine with diverse functions in many biological 
systems throughout the human body Interleukin-6 signalling, which is transduced 
through the gpl30 receptor, activates both the Jak-STAT and the Ras-M APK pathways 
The interplay and balance between these stimulated pathways determines the ultimate 
outcome o f IL -6 signalling m each cellular context Interleukin-6 has multiple effects m 
many physiological processes and is associated with the pathogenesis o f numerous
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autoimmune, hyperproliferative and infectious diseases This cytokine has important 
regulatory functions m liver protein production, liver regeneration and has a protective 
role m liver failure Interleukin-6 is also an important factor in the progression o f many 
malignancies Interleukm-6 has been identified as both a growth factor and in other 
cases a growth inhibitor o f several cancer types The effects o f IL -6 in HCC remain 
poorly defined Various reports have indicated possible functions for IL -6 m this cancer 
however no unified theory o f its effects has yet been established
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Interleukm-6 is inextricably linked to normal hepatocyte proliferation and liver 
function Several reports demonstrate growth regulatory effects o f IL -6 m cancer 
progression While previous studies have established an inhibitory effect o f IL-6 on 
HCC progression, others have identified growth promoting and survival effects after 
IL -6 treatment Past research on the effects o f IL -6 in HCC has primarily been 
performed in vitro  with only limited in vivo data currently available
The current studies proposed to establish the effects o f IL -6 in HCC using 
complimentary in vitro  and in vivo HCC models The initial aim o f these studies was to 
determine i f  HCC is associated with alterations in the tissue expression o f IL-6 
signalling components compared to normal liver The next aim was to establish the 
effects o f IL -6 signalling in cultured HCC cells and isolated hepatocytes primarily 
focusing on the activation o f the Jak-STAT and Ras-M APK pathways m addition to the 
expression and function o f cell cycle regulatory proteins These studies also aimed to 
establish the effect o f IL -6 on HCC proliferation in vitro  The aim o f the final section o f 
these studies was to establish an algmate based cell microencapsulation system for 
sustained IL -6 delivery in vivo
1.3 Aims of the Present Study
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Chapter 2: General Methods
2.1 Animals
Male ACI rats (Harlan In c , Indianapolis, IN, U SA , 175-225g) were used m 
these studies All experiments were approved by the University o f North Carolina at 
Charlotte Institutional Animal Care and Use Committee (IACUC) and conform to the 
Care and Use o f Laboratory Animal Guidelines
2.2 Cell Culture and Cell Lines
2 2 1 M aterials
Alpha’s Modification o f Minimum Essential Media (AMEM), Eagle’s 
Minimum Essential Media (EMEM) with glutamine, foetal bovine serum (FBS, pnme 
and dialysed), Fungizone (amphotericin B), 7 5%  (w/v) sodium bicarbonate solution 
and phosphate buffered salme (PBS) were all purchased from Biosource (Camarillo, 
Ca, USA) Glutamax, 0 25%  (v/v) trypsm-EDTA and Trypan Blue stain were purchased 
from Gibco/Invitrogen Life Sciences (Carlsbad, CA, USA) Methotrexate 
(amethoptenn) was purchased from Calbiochem/EMD Biosciences (San Diego, CA, 
USA) Molecular grade dimethyl sulphoxide (DMSO) and isoflurane were purchased 
from Fisher Scientific (Pittsburgh, PA, USA) Gentamycin was purchased from 
Mediatech (Hendon, V A, USA) Tissue culture treated sterile flasks and plates were
purchased from BD Biosciences (San Diego, Ca, USA) A  bright line counting
chamber/haemocytometer was purchased from Hausser Scientific (Horsham, PA, 
USA) Potassium chlonde, sodium chloride, magnesium sulphate, sodium bicarbonate,
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ethylenediaminetetraacetic acid (EDTA), lactic acid, pyruvic acid, glucose, potassium 
phosphate and collagenase were all purchased from Sigma-Aldnch (St Louis, MO, 
USA) Biocoat collagen coated plates were purchased from Becton Dickinson 
Laboratories (Bedford, MA, USA)
2 2 2 Cell L ines
The rat hepatoma cell line, H4IIE, was originally derived from the Reuber-35 
hepatoma (Pitot et a l , 1964) and was purchased from the American Type Culture 
Collection (ATCC, Manassas, VA, USA) A  CHO (Chinese hamster ovary) cell line 
stably expressing IL -6 (CHO-IL6) and a mock transfected CHO cell line (CHO-CTRL) 
were a kind gift from Dr Leonard G Komans and Dr Teresa Zimmers (University o f 
Miami School o f Medicine, Miami, FL, USA) These lines were generated by
introduction o f a plasmid vector containing human IL -6 complimentary DNA (CHO-
IL 6) or empty vector (CHO-CTRL) into DHFR-deficient CHO-DUXX cells by 
protoplast fusion followed by methotrexate selection Primary rat hepatocytes were 
isolated as descnbed m section 2  2  8
2 2 3 Cell C ulture M edia
H4IIE cells and primary isolated hepatocytes were cultured m high serum media 
composed o f EM EM  with glutamine (2mM) supplemented with Fungizone (2 5^g/mL), 
gentamycin (50|ig/mL), sodium bicarbonate (1 5mg/mL) and 10%  (v/v) prime FBS For 
preparing stocks o f H4IIE cells, a freezing media comprising EM EM , DMSO and 
prime FBS at a ratio o f 3 1 5 was used
CHO cells were cultured m high serum media composed o f AM EM  
supplemented with Fungizone (2 5jig/mL), gentamycin (50|ig/mL), sodium bicarbonate 
( 1 5mg/mL), Glutamax (2mM), methotrexate (0 2|iM) and 10%  (v/v) dialysed FBS
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CHO cells were frozen in a freezing media containing dialysed FBS supplemented with 
7% (v/v) DMSO
2 2 4 Cell Propagation
Both H4IIE and CHO cells were stored in cryo-vials submerged in liquid 
nitrogen These vials were thawed by immersion m a 37°C water bath Thawed cells 
were immediately placed in high serum media (HSM) and centrifuged at 300 x g for 3 
mins Media was aspirated and the cell pellet was resuspended m HSM Cells were 
placed m a tissue culture flask (150cm2) and were grown to 90% confluency at 37°C in 
a 5% CO2, humidified incubator
2 2 5 Cell Passaging and Splitting
H4IIE or CHO cells were washed twice m PBS (37°C) and then trypsmised 
using 0 25%  (v/v) trypsm-EDTA Cells were incubated at 37°C for 3-5 mins until cells 
had detached pnor to the addition o f HSM to stop trypsin digestion Cells were pelleted 
at 300 x g for 3 mins and resuspended m HSM Viable cells were counted on a 
haemocytomer using trypan blue exclusion Cells were then diluted appropnately for 
seeding m tissue culture flasks or plates and cultured at 37°C m a 5% CO2, humidified 
incubator A  split ratio o f 1 4 was used for further passaging o f cells in tissue culture 
flasks (150 cm2) while seeding density in tissue culture plates was dependent on the 
experimental conditions required
2 2 6 Cell Storage
H4IIE or CHO cells (150cm 2 flask) were washed twice in PBS and then 
trypsmised using 0 25% (v/v) trypsm-EDTA Cells were incubated at 37°C for 3-5 mins 
until cells had detached pnor to the addition o f HSM to stop trypsm digestion Cells
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were pelleted at 300 x g for 3 mins and resuspended in cell freezing media. Cells were 
aliquoted into cryo-vials and placed in a Nalgene Cryo 1°C  freezing container which 
allows a cooling rate o f PC/min. This was placed at -80°C overnight and then vials 
were transferred to liquid nitrogen for long term storage.
2.2.7 H 4IIE Cell Isolation
H4IIE cells were passaged alternatively between culture and animal. This 
prevents the complete adaptation o f these cells to either the in vitro  or in vivo  
environment and selects for optimal clonogenic characteristics as previously described 
(Evans and Kovacs, 1977). H4IIE cells were grown for three serial passages in vitro 
prior to their inoculation into the parenchyma o f the left hepatic lobe o f male ACI rats 
as described in section 2 .3 .1. The resulting tumour mass which developed after 14-16 
days was resected and minced with sterile scissors in HSM. The suspension was placed 
in tissue culture dishes and incubated for 4h at 37°C . Cells were washed twice with 
PBS (37°C) and then grown to confluency in HSM at 37°C  in a 5% CO2 humidified, 
incubator.
2.2.8 Ilepatocyte Isolation
Fresh hepatocytes were isolated from male adult ACI rats using a modification 
o f the two step perfusion technique as initially described by Seglen et al (Seglen, 1976).
Male ACI rats were anaesthetised using an isoflurane/oxygen mixture to a depth that
abolished the hind leg withdrawal reflex. A mid ventral laparotomy was then performed 
and the hepatic portal vein w'as canulated with tubing (polyethylene, 0.28mm i.d.) at a 
region proximal to bifurcation and attached by 3-0 (USP) nylon suture. Prewarmed 
(37°C) oxygenated Kreb’s buffer (119m M  NaCI, 1.2m M  M gS04, l.2mM KH2PO4, 
4.65mM KC1, 25mM NAHCO3. 0.1 mM EDTA, 5mM C 3H60 3, ImM C 3H30 3Na and
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5mM CoH|206; oxygenated with 95% O2 / 5% CO2) was pumped at trickle rate into 
liver. The descending aorta was severed and the speed o f pump delivering oxygenated 
Kreb’s buffer was briefly increased (allowing the liver to swell slightly) forcing red 
blood cells from the liver and then returned to initial rate. The liver was removed from 
the rat and suspended in a liver perfusion system (Figure 2 .1). Using this system the 
liver was initially perfused with oxygenated Kreb’s buffer (37°C) for 5 mins and then 
with a recirculating collagenase solution (lmg/mL in oxygenated Kreb’s buffer; 37°C) 
for 10 -12  mins. The uppermost layer o f the liver was disrupted and cells released 
through gentle agitation in Kreb’ s buffer under sterile conditions. Cells were washed 
three times in Kreb’s buffer and resuspended in high serum culture media. Cells were 
seeded in collagen coated six well plates at 2 x 10 '1 cells/well and were allowed to 
attach for 4h at 37°C in a 5%  CO2, humidified incubator. Cells were washed in PBS and 
were quicsccd using serum free cell culture media for 12h at 37°C in a 5% CO2, 
humidified incubator.
2.3 HCC Tum our Model
2.3.1 H4I1E Tum our Model
In vivo  studies were performed using a rat model o f HCC that was initially 
described by Evans and Kovacs (Evans and Kovacs, 1977; Kovacs et al., 1977). H4IIE 
cells were cultured as described in section 2.2. Cultured H41IE cells were washed twice 
in sterile PBS, trypsiniscd and then resuspendcd in sterile PBS at a concentration o f 
1x 10  cells/niL. Male ACI rats were anaesthetised using isoflurane/oxygen mixture and 
a mid ventral laporotomy was perfomied. 0.1 mL o f resuspended H4IIE cells were 
injected directly into the parenchyma o f the left hepatic lobe using a 30 gauge needle. 
Rats were sutured, allowed to recovered and then maintained for 14 -16  days on a 
12h/12h light dark schedule with water and chow pellet a d  libitum. This technique
40
Lwer Trap
Condenser
Figure 2.1 H epatocyte isolation perfusion system . Kreb’ s buffer/collagenase mix was 
loaded into a condenser and oxygenated with 95% 0 ^ 5 %  CO2 which was delivered via 
tube A. Kreb's bufTer/collagenase was pumped from the condenser via  tube B to the 
reservoir. From the reservoir the solution was delivered to the liver which was 
suspended in the liver trap or recirculated back to condenser. Line C recirculated the 
Kreb's buffer/collagenase solution through the water bath to the reservoir in order to 
maintain the solution at 37°C.
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resulted in reproducible HCC tumour formation Sham operated specimens were treated 
identically with the exception that the inoculation o f the left hepatic lobe was 
performed using 0 lm L PBS only
2.4 Preparation of Cell Lysates
2 4 1  M aterials
HEPES, sodium chloride (NaCl), magnesium chlonde (MgCh), Triton X-100, 
(3-glycerophosphate, sodium dodecyl sulphate (SDS), sodium deoxycholate, 
dithiothreitol (DTT), Tns-HCl, sodium vanadate were all purchased from Sigma 
Aldnch (St Louis, MO, USA) Cell scrapers were purchased from Coming (Coming, 
N Y, USA) Sonic Dismembrator model 100 ultrasomcator and Ultra Turrax T8 
homogemser were both purchased from Fisher Scientific (Pittsburgh, PA, USA) 
Complete protease inhibitor tablets (containing PMSF, aprotmin and leupeptin) were 
purchased from Roche Applied Science (Indianapolis, IN, USA)
2 4 2 Preparation o f C ultured Cell Lysates for Protein A nalysis
Primary hepatocytes and cell lines were cultured as descnbed in section 2 2 
Cells were nnsed with PBS (4°C) and lysed using ice cold mitogen activated protein 
kinase (MAPK) lysis buffer (25mM HEPES, 300mM NaCl, 1 5mM M gCl2, 200nM 
EDTA, 1%  (v/v) Triton X-100, 20mM P-glycerophosphate, 0 1%  (w/v) SDS, 0 5% 
(w/v) sodium deoxycholate, 0 5mM DTT, lOOmM sodium vanadate, 100|ig/mL PMSF, 
2|ig/mL leupeptm, 2|ig/mL aprotmin, pH 7 5) Plates were scraped and collected lysates 
were then sonicated and stored at -80°C pnor to analysis
2 4 3 Preparation o f T issue Cell Lysates for Protein A nalysis
HCC tumours were generated as descnbed in section 2 3 Tumour, normal and
42
sham liver tissues were resected and immediately snap frozen in liquid nitrogen To 
create whole cell tissue lysates, approximately 200-300mg o f tissue was placed in 
M A PK lysis buffer (Section 2 4 2) and homogenised on ice The preparation was then 
sonicated (4°C) and centrifuged at 500 x g for 5 mins (4°C) The resulting supernatant 
was collected, re-somcated, and stored at -80°C prior to analysis
To create cell membrane preparations approximately 200-300mg o f tissue was 
placed in 50mM Tns-HCl containing 100jag/mL PM SF, 2jig/mL leupeptin and 2jag/mL 
aprotimn The tissue was homogenised (4°C) until dispersed pnor to centrifugation at 
10,000 x g for 75 mins (4°C) The supernatant was discarded and the resulting pellet 
resuspended m 50mM Tns-HCl containing 100|ag/mL PM SF, 2jag/mL leupeptin and 
2^g/mL aprotimn Samples were sonicated prior to storage at -80°C
2.5 Immunoblotting
2 5 1  M aterials
B C A  Protein Assay Reagent Kit and CL-XPosure x-ray film were purchased 
from Pierce Biotechnology (Rockford, IL, USA) Disposable 96 well ELISA  plates 
were purchased from Coming (Coming, N Y, USA) Tns, acrylamide, N ,N ’-methylene- 
bisacrylamide, glycme, ammonium persulphate (APS), TEMED, Ponceau S solution, 
Tween-20, sodium chloride (NaCl), concentrated hydrochloric acid (HCL) and (3- 
mercaptoethanol were all purchased from Sigma-Aldnch (St Louis, MO, USA) 
Laemmli buffer, Mini-Protean 3 electrophoresis system, Mini Trans-Blot module and 
blotting grade non fat dry milk (NFDM) were purchased from Biorad Laboratones 
(Hercules, CA, USA) Nitrocellulose membranes and EC L detection reagents were 
purchased from Amersham Biosciences (Piscataway, N J, USA) See Blue Plus II 
prestamed protein size marker was purchased from Invitrogen Life Sciences (Carlsbad,
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CA, USA) X-ray film was developed using a S R X -10 1 Medical Film Developer 
(Komca, Mahwah, N J, USA) and densitometry performed using the Kodak EDAS290 
imaging software (Kodak, Rochester, N Y, USA)
2 5.2 BC A  Protein Assay
Protein concentrations were determined using a B C A  protein assay kit Protein 
standards ranging between 0-2000|ig/mL were prepared using bovme serum albumin 
(BCA kit) diluted m M APK lysis buffer (Section 2 4 2) Standards and lysates were 
loaded in duplicate in a 96 well ELISA  plate Working B C A  reagent was prepared by 
mixing 50 parts o f BC A  reagent A with 1 part B C A  reagent B and this was added to 
each well The plate was sealed and incubated at 37°C for 30 mins Absorbance at 
562nm was measured on a j^Quant microplate reader (Biotek instruments, Winooski, 
VT, USA) The mean absorbance for each standard was corrected for mean zero 
standard absorbance and plotted against protein concentration The resulting standard 
curve was used to determine protein concentration o f the unknowns
2 5 3 W estern B lotting
SDS-PAGE gels were prepared using the Mini-Protean 3 electrophoresis 
system The lower gel (resolving gel) contained 10 -15%  (v/v) acrylamide/NJNT- 
methylene-bisacrylamide solution (30% (w/v) acrylamide, 0 8% (w/v) N ,N ’-methylene- 
bisacrylamide), 25% (v/v) SDS PAGE lower buffer (1 5M Tns, 0 OHM SDS, pH 8 8), 
ultrapure water, APS (0 75mM) and TEMED (7mM) The upper gel (stacking gel) 
contained 13  5% (v/v) acrylamide/N,N’ -methylene-bisacrylamide solution (30% (w/v) 
acrylamide, 0 8% (w/v) N ,N ’-methylene-bisacrylamide), 30% (v/v) SDS PAGE lower 
buffer (0 5M Tns, 0 OHM SDS, pH 6 8), ultrapure water, APS (0 75mM) and TEMED 
(7mM) Wells for protein loading were created m the upper gel
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Sample protein concentrations were equalised using M APK lysis buffer 
(Section 2 4 2) and boiled with Laemmli working buffer (Laemmli buffer with 0 05% 
(v/v) P-mercaptoethanol) for 5 mins prior to loading on SDS-PAGE gels Prestained 
protein size marker was loaded on gel Proteins were electrophoresed using the Mim- 
Protean 3 electrophoresis system and electrophoresis running buffer containing 25mM 
Tns, 0 2M glycine and 3 5mM SDS Proteins were transferred to nitrocellulose 
membranes m the Mini Trans-Blot module using electrophoresis transfer buffer (25mM 
Tns, 0 2M glycme, 20% (v/v) methanol) Membranes were stained with Ponceau S 
solution to confirm equal loading Membranes were then blocked with blocking 
solution containing 5% (w/v) non fat dry milk (NFDM) m Tns buffered saline (TBS, 
50mM Tns, 4mM MgCl, 140mM NaCl, 0 34% (v/v) conc HC1) with 0 1%  (v/v) 
Tween-20 for lh  at room temperature (RT) Membranes were washed three times in 
TTBS (0 1%  (v/v) Tween-20 in TBS) Membranes were incubated overnight with 
pnmary antibody at the appropriate dilution m blocking solution at 4°C Membranes 
were washed 3 times in TTBS Membranes were then incubated for 2h with appropnate 
peroxidase conjugated secondary antibodies diluted 1 5000 in blocking solution at RT 
Membranes were washed 3 times in TTBS followed by 2 nnses in TBS Membranes 
were incubated with E C L  detection reagents and exposed to x-ray film Film was 
processed using a Komca Medical Film Developer Densitometnc analysis o f optical 
integrated volume was performed using Kodak EDAS290 imaging software
2.6 IL-6 ELISA (Enzyme-Linked Immunosorbent Assay)
2 6 1  M aterials
The BD Pharmingen TM B substrate reagent set was purchased from BD 
Biosciences (San Diego, CA, USA) Disposable 96 well E LISA  plates were purchased
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from Coming (Coming, NY, USA) Sodium carbonate (Na2C0 3 ) and phosphoric acid 
(H3PO4) were purchased from Sigma-Aldrich (St Louis, MO, USA)
2 6 2 R at IL-6 E L ISA
E LISA  for rat IL-6 was performed using a BD Opteia Rat IL-6 ELISA  kit (BD 
Biosciences, San Diego, CA, USA) ELISA  plates were coated with capture antibody 
(anti-rat IL-6) diluted 1 125 m Coating Buffer (0 1M  NaHC0 3 , 34mM Na2C 03  , pH 
9 5) overnight at 4°C All the following steps were performed at room temperature 
Wells were washed with wash buffer (WB, PBS with 0 05% (v/v) Tween-20) Plates 
were blocked with assay diluent (10%  (v/v) FB S m PBS) for lh  Wells were washed 
again with WB prior to the addition o f standards or samples to the plate in duplicate 
Standards were created using recombinant rat IL-6 Plates were incubated for 2h After 
washing with WB, the detection antibody (biotinylated anti-rat IL-6) was added to each 
well (1 250 m assay diluent) for 30 mins Plates were then washed with WB and 
incubated for 30 mins with enzyme reagent (avidm-horseradish peroxidase conjugate, 
1 250 in assay diluent) Plates were washed again in WB Equal parts o f TMB substrate 
components (tetramethylbenzidme and hydrogen peroxide) were combined and added 
to each well Plates were incubated for 30 mins m the dark prior to the addition o f the 
stopping solution (1M  H3PO4) Absorbance was measured at 450/570nm on a jiQuant 
microplate reader (Biotek Instruments, Winooski, VT, USA) The mean absorbance 
(450-570nm) for each standard was corrected for mean zero standard absorbance and 
plotted against rat IL-6 concentration The IL-6 concentrations o f unknown samples 
were determined from this standard curve
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ELISA  for human IL -6 was performed using the BD Opteia Human IL -6 ELISA  
kit (BD Biosciences, San Diego, CA, USA) E LISA  plates were coated with capture 
antibody (anti-human IL-6) diluted 1 250 m coating buffer (0 1M  NaHCC>3, 34mM 
Na2C 0 3  , pH 9 5) overnight at 4°C All the following steps were performed at room 
temperature Wells were washed with wash buffer (WB, PBS with 0 05% (v/v) Tween- 
20) Plates were blocked with assay diluent (10%  (v/v) FB S m PBS) for lh  Wells were 
washed again with WB pnor to the addition o f standards or samples to the plate in 
duplicate Standards were created using recombinant human IL -6 Plates were 
incubated for 2h After washing with WB the working detector was added to each well 
for lh The working detector was biotinylated anti-human IL -6 and avidin horseradish 
peroxidase both diluted 1 250 in assay diluent Plates were washed again in WB Equal 
parts o f TM B substrate components (tetramethylbenzidme and hydrogen peroxide) 
were combined and added to each well Plates were incubated for 30 mins in the dark 
prior to the addition o f the stopping solution (1M  H3PO4) Absorbance was measured at 
450/570nm on a jiQuant microplate reader (Biotek Instruments, Winooski, VT, USA) 
The mean absorbance (450-570nm) for each standard was corrected for mean zero 
standard absorbance and plotted against human IL -6 concentration The IL-6 
concentrations o f unknown samples were determined from this standard curve
2.7 Statistics
Experimental values were expressed as mean values ± the standard error o f the 
mean (SEM) Statistical significance was calculated using the student’ s t-test for 
comparison o f two groups and analysis o f variance (ANOVA) followed by the 
Bonferroni post-hoc test for multiple comparisons Probability values o f p<0 05 were 
considered significant
2 6 3 H um an IL-6 EL ISA
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Chapter 3: Altered Expression of IL-6 Signalling 
Components in HCC
3.1 Introduction
Interleukin-6 is a pleiotropic cytokine with diverse biological functions (Naka et 
a l , 2002) Liver specific functions o f IL-6 include the stimulation o f acute phase 
protein production (Ramadon and Christ, 1999, Gauldie et a l , 1987, Castell et a l , 
1990b, Andus et a l , 1987), protection against many forms o f liver injury (Clavien et 
a l , 1996, Camargo et a l , 1997, Mizuhara et a l , 1994) and stimulation o f liver 
regeneration (Fausto, 2000, Streetz et a l , 2000) Dunng liver regeneration IL-6 plays a 
pivotal role m priming hepatocytes for proliferation Increased IL-6 serum levels and 
STAT3 activation m the liver are observed immediately following partial hepatectomy 
(PHx) (Cressman et a l , 1995) Interleukin-6-/- mice are characterised by a severely 
impaired proliferative response due to abnormal G 1 phase progression after PHx 
(Cressman et a l , 1996) This defect can be corrected by pre-operative IL-6 
administration Interleukm-6 sensitises hepatocytes to growth factors such as 
hepatocyte growth factor (HGF), transforming growth factor-a (TGFa) and epidermal 
growth factor (EGF) (Yamada et a l , 1997, Fausto, 2000) Further corroborating 
evidence o f the importance o f IL-6 signalling m hepatocellular proliferation is 
demonstrated in studies involving double transgenic mice expressing human IL-6 and 
soluble IL-6R (sIL-6R) In these studies co-expression o f IL-6 and sIL-6R causes
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nodular regenerative hyperplasia and adenoma development in the liver (Maione et a l , 
1998, Schirmacher et a l , 1998)
Interleukin-6 is also involved with the progression o f many malignancies 
Interleukin-6 acts as an autocrine growth factor for many cancer types including renal 
cell carcinoma (Miki et a l , 1989), plasmacytoma (Nordan et a l , 1987), human multiple 
myeloma (Kawano et a l , 1988, Levy et a l , 199 1, Okuno et a l , 1992) and various 
lymphomas (Yee et a l , 1989) Interleukm-6 also inhibits proliferation in other 
malignant cell types including human breast carcinoma cells (Novick et a l , 1992, Chen 
et a l , 1988), a number o f leukaemia/lymphoma cell lines (Chen et a l , 1988) and 
human melanoma cells (Florenes et a l , 1999, Kortylewski et a l , 1999) Furthermore, 
many cancer cell types are characterised by dysregulated expression o f IL-6 signalling 
pathway components Most notably, constitutively activated STATs are observed in a 
variety o f primary tumour cells (Bowman et a l , 2000) Active STAT3 can act as an 
oncogene (Bromberg et a l , 1999) and is implicated in both viral and oncogene 
mediated cellular transformations (Bromberg et a l , 1998, Yu et a l , 1995) In the case 
o f certain myeloma and prostate cancer cell lines, an IL-6 autocnne or paracrine loop is 
responsible for the constitutive activation o f STAT3 (Catlett-Falcone et a l , 1999, Lou 
et a l , 2000) and, m some other cases, dysregulated SOCS expression is involved 
(Yoshikawa et a l , 2001a)
Hepatocellular carcinoma, like other cancers, is characterised by aberrant 
cellular proliferation The intrinsic link between IL-6 signalling and normal 
hepatocellular proliferation suggests a possible role for IL-6 m HCC progression The 
function o f IL-6 m HCC is unclear IL-6 has been shown to inhibit human HepG2 
(Klausen et a l , 2000) and rat H-35 (Kim and Baumann, 1999) hepatoma cell growth in 
vitro  On the other hand, IL-6 acts an autocrine growth factor for HCC-M hepatoma 
cells (Kumagai et a l , 2002) and a survival factor for human Hep3B hepatoma cells
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(Chen et a l , 1999) in vitro  The relationship between IL-6 signalling and HCC 
progression in vivo  remains poorly defined HCC cells transfected to overexpress IL-6 
have increased metastatic potential in vivo (Reichner et a l , 1998), while IL-6 
expression m transfected HCC cells inhibited proliferation in vivo  (Dougherty et a l ,
1994) In the clinical setting, serum levels of IL-6 are often elevated m human HCC 
patients (Gianmtrapam et a l , 2002, Goydos et a l , 1998) although whether this is part 
o f an autoimmune response m the cirrhotic liver or directly attnbutable to the tumour is 
unclear
The aim o f the current study was to examine the expression o f IL-6 signalling 
components m tumour and normal liver tissues from a rat model o f HCC
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3.2.1 Tumour Model
A  rat HCC tumour model was established by direct injection o f H4IIE cells into 
the left liver lobe o f male ACI rats as described in section 2 3 Tumours were 
photographed using a Fuji Finepix S602 zoom camera (Fujifllm U SA, Valhalla, NY, 
USA)
3.2.2 Preparation of Tissue Cell Lysates for Protein Analysis
Tissue cell membrane preparations and whole cell lysates were prepared from 
resected HCC, normal liver tissue (NL) from tumour burdened and NL from sham 
operated male A CI rats as described m section 2 4 3
3.2.3 Immunoblotting
Western blots were performed as descnbed m section 2 5 Antisera specific 
against gpl30 (M-20), IL-6Ra (M-20), p2 1 wafl/c,pl (F-5), SO CS-1 (C-20), SOCS-3 (H- 
103) and STAT3 (H-190) were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA) Antisera specific against p27Kipl and Phospho-STAT3 (Tyr705) were 
purchased from Cell Signaling Technology (Beverly, MA, USA) All primary 
antibodies were diluted 1 1000 m 5% (w/v) non fat dry milk (NFDM)/0 1%  (v/v) 
Tween/tns buffered salme (TBS) except for Phospho-STAT3 which was diluted 
1 2000 Horseradish peroxidase conjugated goat anti-rabbit Ig and goat anti-mouse Ig 
were purchased from Jackson Immunoresearch Laboratones (West Grove, PA, USA) 
and used at a dilution o f 1 5000 in 5% (w/v) NFDM/0 1%  (v/v) Tween/TBS
3.2 Methods
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3 2 4 1 M aterials
TRIzol reagent was purchased from Invitrogen Life Technologies (Carlsbad, 
CA, USA) Chloroform, isopropanol, ethanol, sodium chloride, Tns, bone acid, 
ethylenediaminetetraacetic acid (EDTA), ethidium bromide and disodium citrate were 
purchased from Sigma-Aldnch (St Louis, MO, USA) DEPC treated water was 
purchased from Ambion (Austin, TX, USA) RNAse free pestles and agarose were 
purchased from Fisher Scientific (Pittsburgh, PA, USA) Mini Sub Cell GT 
electrophoresis unit was purchased from Biorad Laboratones (Hercules, CA, USA) 
Kodak EDAS290 gel visualisation unit was purchased from Kodak (Rochester, NY, 
USA) Genesys 2 UV/Visible Spectrophotometer was purchased from Thermo 
Spectromc (Rochester, N Y , USA) DNA loading buffer was purchased from Eppendorf 
(Hamburg, Germany)
3 2 4 2 Total R N A  Isolation From  Tissue
Approximately lOOmg o f resected tissue from HCC tumour burdened or sham 
operated male ACI rats (section 2 3) were snap frozen in liquid nitrogen and stored at 
-80° C pnor to analysis To isolate RNA, liver tissue was placed in TRIzol and 
homogenised using an RNAse free pestle 20% (v/v) chloroform was added and the 
sample agitated Samples were then centrifuged at 10,000 x g for 15  mins (4°C) The 
aqueous phase was removed to a fresh tube and 0 25 vol o f isopropanol added followed 
by 0 25 vol o f RN A precipitation solution (1 2M NaCl, 0 8M disodium citrate) The 
sample was then incubated at room temperature for 10 mins and centnfuged at 10,000 x 
g for 10 mins (4°C) The pellet was next washed twice in 75%  ethanol, air dned and re- 
solubilised m DEPC water
3.2.4 RNA Isolation
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Cultured H4IIE cells (section 2 2) were washed twice with PBS and collected in 
TRIzol Samples were mixed and incubated at room temperature for 5 mins 20% (v/v) 
chloroform was added and the sample agitated The sample was centrifuged at 10,000 x 
g for 15 mins (4°C) The aqueous phase was removed to a fresh tube and 0 25 vol of 
isopropanol added followed by 0 25 vol o f RNA precipitation solution (1 2M NaCl, 
0 8M disodium citrate) The sample was then incubated at room temperature for 10 
mins and centrifuged at 10,000 x g for 10 mins (4°C) The pellet was next washed twice 
in 75%) ethanol, air dried and re-solubilised in DEPC water
3 2 4 4 Determination of Total RNA Concentration and Integrity
RNA concentration was calculated using the spectrophotometnc determination 
o f sample absorbance at 260nm and the following equation
RNA CONCENTRATION (jug/mL) =  4 0(ABSORBANCE2 60, J  x  DILUTION FACTOR 
Where
RNA CONCENTRATION = Concentration of RNA (jig/mL)
ABSORB ANCE260nm= Absorbance of sample at 260nm
In order to establish RNA integrity, RNA samples were combined with DNA 
loading buffer and run on a 2% (w/v) agarose gel made up m DEPC treated TBE buffer 
(45mM Tris-Borate, ImM EDTA) containing ethidium bromide (2(iL in 50mL 
agarose) Gels were placed m a gel electrophoresis unit containing DEPC treated TBE 
and run at 60V Gels were visualised using a Kodak EDAS290 visualisation unit, intact 
RNA appearing as sharp, clear 18s and 28s RNA bands m denaturing gels (Figure 3 1)
3 2 4 3 T o tal RN A  Isolation from  C u ltu red  Cells
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Figure 3 1 Sample RNA integrity gel Total RNA was isolated from normal liver 
resected from HCC burdened animals (NL) and HCC tissue RNA was electrophoresed 
on a 2% (w/v) agarose gel containing ethidium bromide and visualised under UV
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3 2 51 Materials
Superscript™ first strand cDNA synthesis kit and RNAseOUT RNAse inhibitor 
were purchased from Invitrogen Life Technologies (Carlsbad, CA, USA) ThermoPol 
lOx concentrate buffer, Taq polymerase and dNTPs were purchased from New England 
Biolabs (Beverly, MA, USA) PCR primers were synthesised by IDT (Coralville, IA, 
USA) Eppendorf Mastercycler Gradient Thermal Cycler was supplied by Eppendorf 
(Hamburg, Germany)
3 2 5 2 Method
First strand cDNA synthesis was performed on 5jig of total RNA using a 
Superscript™ first strand synthesis kit and Oligo(dT) as primers RNA was initially 
incubated at 65°C for 5 mins in the presence of 0 5|ig 01igo(dT)i2 is and lOnmol of 
dNTP mix and then placed on ice for 3 mms 9jjL of reaction mixture (2jxL 10X RT 
buffer, 4jnL 25mM MgCk, 2\jlL 0 1M DTT, \\iL  RNaseOUT) was added to each RNA 
sample/pnmer mix and samples incubated at 42°C for 2 mms 1 |xL of Superscript II RT 
was added to each tube Reverse transcription (RT) was earned out at 42°C for 50 mins 
The RT reaction was terminated at 70°C for 15 mms ljiL of RNAse H was then added 
to each tube and samples were incubated for 20 mms at 37°C l\i\ of this RT product 
was then used in a polymerase chain reaction (PCR) PCR was earned out in 20jil (total 
volume) o f reaction buffer (containing 2jal ThermoPol 10X buffer, 0 5|iM of each 
primer, 5 units of Taq polymerase and 250|iM dNTP’s) The oligonucleotides used for 
amplification of the cDNA for IL-6, S9, gpl30 and IL-6Ra were as desenbed in Table 
3 1
After an initial 5 mms denaturation at 95°C, PCR was performed for 32 cycles 
m the case o f IL-6, 25 cycles in the case o f S9 and 22 cycles for the amplification of
3.2 5 Reverse Transcriptase -  Polymerase Chain Reaction
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Gene Sense Primer Antisense Primer
IL-6 5 ’ ACAGTGCATCATCGCTGTTC3 ’ 5 ’CC GGAGAGGAG ACTTCACAG3 ’
S9 5 ’ GCTGAG ACG ACTTGTTCGAA TTG3 ’ 5 TG GC A TTC TTC C TC TTC A C TC G 3 ’
Gpl30 5 TCA A C TTG TG G A A C C A TG TG G 3 ’ 5 T C C A A C TG A C A C A G C A TG TTC 35
IL-6Ra 5 ’TCACAGAGCAGAG AATGG ACT3 ’ 5 ’GTATGGCTGA TACCACAAGGT3 ’
Table 3 1 Primers used for the PCR amplification of the cDNA for IL-6, S9, gpl30 
and IL-6Ra
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both gpl30 and IL-6Ra using an Eppendorf Mastercycler Gradient Thermal Cycler 
Each cycle for IL-6 amplification consisted o f 30 secs denaturation at 95°C, 30 secs 
annealing at 55°C followed by 45 secs polymerization at 72°C For S9 amplification a 
cycle consisted of 30 secs at 95°C followed by 30 secs at 60°C and then 45 sec at 72°C 
For the amplification of both gpl30 and IL-6Ra a cycle consisted of 30 secs at 95°C 
followed by 30 secs at 56°C and then 45 secs at 72°C
PCR products were combined with 2\iL of DNA loading buffer and run on a 2% 
(w/v) agarose gels made up in TBE (45mM Tns-Borate, ImM EDTA) containing 
ethidium bromide (2jiL in 50mL agarose gel) Gels were placed in a gel electrophoresis 
unit filled with TBE and run at 60 V Gel images were captured using a Kodak ED AS 
290 image capture system
3.2.6 H istochem istry
3 2 61 Materials
Citnsolv clearing agent, Permount mounting media, haematoxyhn, TissuePrep paraffin 
based embedding media, HistoPrep tissue capsules, xylene, microscope slides, glass 
coverslips and eosm were purchased from Fisher Scientific (Pittsburgh, PA, USA) 
Paraformaldehyde was purchased from Sigma-Aldnch (St Louis, MO, USA) GVA 
mounting solution and goat serum were purchased from Zymed Laboratones (San 
Francisco, CA, USA) HM 315 rotary microtome was purchased from Richard-Allan 
Scientific (Kalamazoo, MI, USA) ATP1 automatic tissue processor was purchased 
from Triangle Biomedical Sciences Inc (Durham, NC, USA) 1X51 fluorescence 
microscope, IP LAB version 3 55 scientific image processing software, Fluoview 
FV500 1X70 confocal laser scanning biological microscope and Fluoview FV500 
version 4 3 image processing software were all purchased from Olympus America 
(Melville, NY, USA) Phosphate buffered saline (PBS) was purchased from Biosource
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(Camarillo, Ca, USA) Donkey serum and Texas Red conjugated donkey anti rabbit 
IgG were purchased from Jackson Immunoresearch Laboratories (West Grove, PA, 
USA) Antisera specific against gpl30 (M-20) and IL-6Ra (M-20) were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA)
3 2 6 2 Tissue Processing
Liver tissues resected from HCC tumour burdened and sham operated ACI rats 
(section 2 3) were fixed for 24h in 4% (w/v) paraformaldehyde at 4°C Tissue was 
placed m 50% (v/v) ethanol for lh  at 4°C followed by lh  incubation in 70% (v/v) 
ethanol (4°C) Tissue was placed in tissue capsules, dehydrated and paraffimsed using 
an automatic tissue processor Tissue was embedded m paraffin blocks Tissue sections 
(5jnm thickness) were cut using a rotary microtome and attached to positively charged 
microscope slides Slides were dried overnight at 37°C
3 2 6 3 Haematoxylin and Eosin (H & E) Staining
Liver tissues were processed as described m section 3 2 6 2 Tissues were 
deparaffmised by dipping slides in xylene for 5 mms and rehydrated by dipping slides 
in descending grades o f ethanol (100%), 95%, 80%, 70%, 50% v/v) for 5 mms each 
Following incubation in PBS for 10 mms slides were dipped m haematoxylin for 15 
mins Slides were washed in 80% (v/v) ethanol and then stained with eosm for 1 mm 
Tissues were then dipped consecutively m 80% (v/v), 95% (v/v) and 100% (v/v) ethanol 
followed by xylene Coverslips were then mounted using Permount based mounting 
media and viewed on an Olympus 1X51 microscope, images being captured using IP 
LAB software
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yLiver tissues were processed as described m section 3 2 6 2 Tissues were 
deparaffmised by dipping slides m Citnsolv for 5 mins and rehydrated by dipping 
slides m descending grades of ethanol (100%, 95%, 80%, 70%, 50% v/v) for 5 mins 
each Tissues were then incubated in PBS for 20 mins Tissues were blocked with 5% 
(v/v) donkey serum (in PBS) Slides were washed in PBS and then incubated with 
appropriate primary antibody (1 100 in PBS) overnight in a humidified chamber (4°C) 
Slides were then washed m PBS and incubated with appropriate fluorophore conjugated 
secondary antibody (1 500 m PBS) for 2h at room temperature in a darkened, 
humidified chamber Slides were washed m PBS and covershps mounted using GVA 
mounting media Slides were allowed to dry at 4°C before viewing on an Olympus 
Fluoview FV500 1X70 confocal laser scanning microscope Images were captured 
using Fluoview FV500 software
3.2.7 IL -6  ELISA
3 2 7 1 Materials
Hepann was purchased from Fisher Scientific (Pittsburgh, PA, USA) Amicon 
Ultra-15 centrifugal filters were purchased from Milhpore (Billerica, MA, USA) 
Escherichia coh derived lipopolysacchande (LPS) was purchased from Sigma-Aldnch 
(St Louis, MO, USA)
3 2 7 2 Sample Preparation for ELISA
Blood (5-7mL) was collected from HCC tumour burdened and sham operated 
male ACI rats (section 2 3) two weeks after H4IIE cell injection by cardiac puncture 
using a 27 g needle and collected m a syringe containing 50 units hep arm Blood was 
centrifuged at 1000 x g for 10 mins The plasma was then removed and concentrated
3 2 6 4 Im m unofluorescence
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using an Amicon Ultra-15 centrifugal filter device (10 KDa cutoff) centrifuged at 3000 
x g for 75 mins (4°C)
H4IIE cells were grown m culture (section 2 2) in the absence or presence of 
LPS (lOOng/mL) Media samples were removed 24h later and concentrated using 
Amicon Ultra-15 centrifugal filter devices (lOKDa cutoff) centrifuged at 3000 x g for 
45 mins (4°C)
3 2 7 3 Rat IL-6 ELISA
Samples were collected and concentrated as descnbed m section 3 2 7 2 An 
ELISA specific for rat IL-6 was performed on concentrated samples as descnbed in 
section 2 6 2
60
3 3 1 Tumour Model
H4IIE cells inoculated directly into the left hepatic lobe of male ACI rats 
resulted in an encapsulated reproducible tumour mass forming after 14-16 days (Figure 
3 2) H&E histological analysis performed on adjacent non-tumour bearing liver lobes 
and HCC specimens (Figure 3 3) showed a typical hepatocyte trabecular arrangement 
running radiantly from central veins and separated by sinusoids (Figure 3 3a) This 
trabecular structure was diminished m HCC due to reduced connective tissue (Figure 
3 3b) HCC was further characterised by increased cellulanty or nuclear crowding and 
neo-vasculansation (Figure 3 3b and 3 3c)
3 3 2 IL-6 Receptor Expression in HCC In  Vivo
The expression of IL-6Ra and gpl30 components of the IL-6 receptor complex 
were measured m HCC, normal liver resected from tumour burdened animals (NL) and 
normal liver from sham operated animals (SH) by Western blot using antibodies 
specific against either IL-6Ra or gpl30 Using these antibodies single protein bands 
were detected at either 80KDa (IL-6Ra) or 130kDa (gpl30, Figures 3 4 and 3 5 
respectively) Following protein transfer, data were analyzed for optical integrated 
volume These data demonstrated no significant difference m IL-6Ra expression in NL 
versus SH (Figure 3 4) In contrast, IL-6Ra expression was significantly decreased in 
HCC versus normal liver from sham operated and HCC burdened animals (61 4±8 3% 
decrease m expression versus NL, n=4 per group, p<0 05 Figure 3 4) Analysis of 
gpl30 data demonstrated no significant differences between NL and SH while gpl30 
expression was significantly decreased in HCC as compared to both NL and SH 
(60 4±9 3% decrease m expression versus NL, n=4 per group, p<0 05, Figure 3 5) 
Decreased IL-6 receptor expression m HCC versus normal tissue was
3.3 Results
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(a)
H C C  T u m o u r
(b) Tum our
Figure 3.2 Photographs of HCC tumours. H 4 IIE  cells were injected directly into the 
parenchyma of the left hepatic lobe o f male A C I  rats. After 14 days the liver was 
removed and photographed, a) External view of liver demonstrating large H C C  tumour 
mass in the left hepatic lobe b) Cross section view o f H C C  tumour mass.
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(b) HCC(a )  NORMAL
Central Vein Sinusoid
Hepatocytes Blood Vessels
(c) TUMOUR BORDER
Figure 33  Histological sections of HCC and normal hepatic tissues stained with 
haematoxylin and eosin. H 4 IIE  cells were injected directly into the parenchyma o f the 
left hepatic lobe o f male A C I rats. Sham operated animals were injected with PBS  
alone. After two weeks, H C C  tumour tissue and normal liver tissue was resected, 
processed and stained with haematoxylin and eosin. Photomicrographs (20x) represent 
a) normal liver tissue from a sham operated rat, b) H C C  tumour tissue and c) the H C C  
tumour/normal border.
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Figure 3 4 HCC is characterised by decreased expression of IL-6Ra versus normal 
liver tissue in vivo Representative Western blot analysis performed on membrane 
lysates prepared from normal liver resected from sham operated animals (SH), normal 
liver resected from HCC burdened animals (NL) and HCC tissue using an antibody 
specific against IL-6Ra HCC tumours were established by direct injection of H4IIE 
cells into the left hepatic lobe of male ACI rats Sham operated animals were injected 
with PBS alone
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Figure 3 5 HCC is characterised by decreased expression of gpl30 versus normal 
liver tissue in vivo Representative Western blot analysis performed on membrane 
lysates prepared from normal liver resected from sham operated animals (SH), normal 
liver resected from HCC burdened animals (NL) and HCC tissue using an antibody 
specific against gpl30 HCC tumours were established by direct injection of H4IIE 
cells into the left hepatic lobe of male ACI rats Sham operated animals were injected 
with PBS alone
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confirmed by lmmunofluorescent staining of liver tissue resected from tumour 
burdened rats Tissue from the tumour/normal border was stained with antibodies 
specific for gpl30 and IL-6Ra (Figure 3 6, n=4) Specific staining for both gp 130 
(Figure 3 6a) and IL-6Ra (Figure 3 6b) was abundant in normal tissue while tumour 
tissue stained only minimally for both of these receptor components Further analysis 
indicated that both gpl30 and IL-6Ra were also downregulated at the RNA level in 
HCC Semi quantitative RT-PCR analysis for gpl30 (Figure 3 7a) and IL-6Ra (Figure 
3 7b) RNA expression in NL and HCC tissue detected single bands at -375 bp and 
-480 bp respectively Densitometnc analysis showed that IL-6Ra RNA expression in 
HCC tissue was 55 85±16 4% of that seen m NL (n=6 per group, p<0 05, Figure 3 7b) 
while gpl30 RNA expression was decreased to 58 88±10 38% versus NL (n=6 per 
group, p<0 05, Figure 3 7a) To ensure equal loading of samples, S9 nbosomal RNA 
was detected as an internal control (Figure 3 7c)
3 3 3 Expression and Activity of IL-6 Dependent Signalling Pathway 
Components in HCC InVivo
To assess IL-6 dependent signalling in HCC and NL specimens, the expression 
and activity o f STAT3 and downstream effectors (p21wafl/cipl and p27Kipl) m HCC, NL 
and SH specimens were assessed by Western blot analysis Using an antibody specific 
against STAT3, a single protein band was detected at ~82kDa Densitometnc analysis 
o f these data demonstrated no significant differences m total STAT3 expression 
between any of the samples analysed (Figure 3 8b, n=4 per group) In contrast, HCC 
was associated with increased STAT3 activity as assessed using an antibody specific 
against the tyrosine phosphorylated (Tyr705) isoform of STAT3 (pSTAT3) (n-4 per 
group, Figure 3 8a) Phospho-STAT3 expression was not detected in normal liver tissue
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Figure 3.6 Immunofluorescent staining of IL-6 receptor components at the normal 
liver/HCC interface. Representative immunofluorescent staining for a) gpl30 and b) 
IL-6Ra in normal and HCC tissue at the tumour/normal border. HCC tumours were 
established by direct injection o f H4IIE cells into the left hepatic lobe o f male ACI rats. 
Resected tissue was processed and stained with antibodies specific against gpl30 and 
IL-6Ra. Texas Red conjugated secondary antibodies were used for detection.
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Figure 3 7 Decreased IL-6 receptor mRNA expression in HCC versus normal liver 
tissue in vivo RT-PCR analysis of RNA isolated from normal liver resected from HCC 
burdened animals (NL) and HCC tissue using primers specific for a) gpl30, b) IL-6Ra 
and c) S9 nbosomal RNA (control for equal loading) HCC tumours were established 
by direct injection of H4IIE cells into the left hepatic lobe of male AC! rats
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Figure 3 8 HCC is characterised by increased STAT3 activity versus normal liver 
tissue in vivo a) Representative Western blot analysis performed on whole cell lysates 
prepared from normal liver resected from sham operated animals (SH), normal liver 
resected from HCC burdened animals (NL) and HCC tissue using an antibody specific 
against active (phospho-) STAT3 b) Representative Western blot analysis performed 
on whole cell lysates prepared from normal liver resected from sham operated animals 
(SH), normal liver resected from HCC burdened animals (NL) and HCC tissue using an 
antibody specific against STAT3 HCC tumours were established by direct injection of 
H4IIE cells into the left hepatic lobe of male ACI rats Sham operated animals were 
injected with PBS alone
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resected from tumour burdened animals or sham operated (Figure 3 8a) Analysis of 
downstream signalling pathways associated with STAT3 activation demonstrated 
similar expression patterns as those for STAT3 activity whereby increased amounts of 
p21wafl/c,pl and p27K,pl were detected in HCC samples as compared to either NL or SH 
samples (Figure 3 9 and 3 10) Expression of p21wafl/cipl was not detectable m normal or 
sham tissues while p27K,pl expression in normal tissues was 41 5±8 1% that seen in 
HCC (n=4 per group, p<0 05) No differences in p 2 lwafl/cipl or p27Klpl expression were 
detected between NL and SH samples (Figure 3 9 and 3 10)
Analysis o f Jak inhibitor expression demonstrated upregulated expression of 
SOCS-1 and downregulated expression of SOCS-3 in HCC (Fig 3 11 and 3 12 
respectively, n=4 per group) Western blot analysis using antibodies specific for SOCS- 
1 demonstrated increased SOCS-1 protein expression m HCC samples as compared to 
NL or SH samples SOCS-1 expression was not detected in NL or SH samples 
Immunoblotting with antibodies specific for SOCS-3 demonstrated significantly 
decreased SOCS-3 expression m HCC compared to NL or SH tissues (11 38±4 18% 
versus NL, p<0 05, n=4), no differences being detected between NL and SH
3 3 4 IL-6 Expression in HCC
To assess IL-6 production by HCC, IL-6 mRNA levels were determined by 
semi-quantitative RT-PCR These experiments detected a single RT-PCR product at 
~130bp’s (Figure 3 13a) In these experiments, HCC was associated with increased IL- 
6 mRNA expression as compared to NL and SH samples IL-6 mRNA expression was 
not detected m NL or SH (Figure 3 13a) To ensure equal loading of samples, S9 
nbosomal RNA was detected as an internal control (Figure 3 13b) Previous 
histological analysis of HCC tumours from these models demonstrated the presence of 
other cell types m HCC samples, most notably endothelial cells derived from tumour
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Figure 3 9 HCC is characterised by increased expression of p21wafl/cipl versus 
normal liver tissue in vivo Representative Western blot analysis performed on whole 
cell lysates prepared from normal liver resected from sham operated animals (SH), 
normal liver resected from HCC burdened animals (NL) and HCC tissue using an 
antibody specific against p 2 lwafl/cipl HCC tumours were established by direct injection 
of H4IIE cells into the left hepatic lobe of male ACI rats Sham operated animals were 
injected with PBS alone
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Figure 3 10 HCC is characterised by increased expression of p27Klpl versus normal 
liver tissue in vivo Representative Western blot analysis performed on whole cell 
lysates prepared from normal liver resected from sham operated animals (SH), normal 
liver resected from HCC burdened animals (NL) and HCC tissue using an antibody 
specific against p27Kipl HCC tumours were established by direct injection of H4IIE 
cells into the left hepatic lobe of male ACI rats Sham operated animals were injected 
with PBS alone
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Figure 3 11 HCC is characterised by increased expression of SOCS-1 versus 
normal liver tissue in vivo Representative Western blot analysis performed on whole 
cell lysates prepared from normal liver resected from sham operated animals (SH), 
normal liver resected from HCC burdened animals (NL) and HCC tissue using an 
antibody specific against SOCS-1 HCC tumours were established by direct injection of 
H4IIE cells into the left hepatic lobe of male ACI rats Sham operated animals were 
injected with PBS alone
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Figure 3 12 HCC is characterised by decreased expression of SOCS-3 versus 
normal liver tissue in vivo Representative Western blot analysis performed on whole 
cell lysates prepared from normal liver resected from sham operated animals (SH), 
normal liver resected from HCC burdened animals (NL) and HCC tissue using an 
antibody specific against SOCS-3 HCC tumours were established by direct injection of 
H4IIE cells into the left hepatic lobe of male ACI rats Sham operated animals were 
injected with PBS alone
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Figure 3 13 Increased IL-6 mRNA expression in HCC versus normal liver tissue in 
vivo RT-PCR analysis of RNA isolated from normal liver resected from sham operated 
animals (SH), normal liver resected from HCC burdened animals (NL) and HCC tissue 
using primers specific for a) IL-6 and b) S9 nbosomal RNA (control for equal loading) 
HCC tumours were established by direct injection of H4IIE cells into the left hepatic 
lobe o f male ACI rats Sham operated animals were injected with PBS alone
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*
neo-vasculansation and the possibility of increased blood derived cells in the tumours 
To determine if the increased IL-6 mRNA detected m HCC samples is from HCC cells, 
and not other cell populations, pure populations o f isolated H4IIE cells were analysed 
in culture m the absence or presence of lipopolysacchande (LPS) These data 
demonstrated detectable basal IL-6 mRNA expression in H4IIE cells which were 
significantly elevated following LPS stimulation (2 5 fold increase, p<0 05, n=4, Figure 
3 14a) S9 nbosomal RNA acted as an internal loading control (Figure 3 14b)
IL-6 protein expression from plasma of sham operated and HCC tumour 
burdened animals were next assessed using a rat IL-6 specific ELISA These 
failed to provide detectable levels of IL-6 m either sham operated or HCC burdened 
animals even following plasma concentration using Amicon Ultra-15 centrifugal filter 
devices (Figure 3 15) Plasma concentration was initially earned out in filters with 
10,000Da cutoff membranes Due to high albumin levels present m plasma, the 
retentate proved too viscous for use m ELISA and limited the achievable concentrating 
factor In an effort to alleviate this problem a pre-filtration step using a filter with a 
50,000Da cutoff was added to this procedure This step precleared the albumin from the 
plasma and allowed a higher achievable concentration factor However, plasma IL-6 
still remained undetectable (Figure 3 15) To determine whether HCC cells were 
capable o f producing IL-6, H4IIE cells were cultured m the presence or absence of LPS 
(lOOng/ml) These data demonstrated no detectable levels of IL-6 in the media without 
cells Following 24h of culture IL-6 was detected at a level o f 2 2 ± l  5 p g /m lin  media 
removed from untreated cells (Figure 3 15, n=6 separate expenments per group assayed 
m duplicate) Treatment with LPS for 24h led to significantly increased IL-6 levels in 
media 22 5±5 0 pg/ml as compared to media from untreated cells (n=6 separate 
experiments per group assayed m duplicate, p<0 05)
76
(a)
200 bp
100 bp
IL-6 
mRNA
(b)
300 bp
+
LPS
+
S9
Figure 3 14 IL-6 mRNA expression in HCC in vitro RT-PCR analysis of RNA 
isolated from cultured H4IIE cells grown in the presence (+) or absence (-) of LPS 
(lOOng/mL) over a 24h period using primers specific for a) IL-6 and b) S9 nbosomal 
RNA (control for equal loading)
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Figure 3 15 IL-6 protein expression in HCC in vivo and in vitro ELISA specific for 
rat IL-6 performed on plasma collected from sham operated (SH) and tumour burdened 
(HCC) male ACI rats HCC tumours were established by direct injection of H4IIE cells 
into the left hepatic lobe o f male ACI rats Sham operated animals were injected with 
PBS alone Plasma was collected two weeks after surgery Concentration of circulating 
IL-6 was not detectable (N/D) ELISA specific for rat IL-6 was also performed on 
media collected from cultured H4IIE cells grown m the presence (+) or absence (-) of 
LPS (lOOng/mL) over a 24h period LPS treatment significantly increased IL-6 
expression in H4IIE cells (* p<0 05, n=6 separate experiments per group assayed in 
duplicate)
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Previous reports demonstrate that IL-6 is critical in the process of normal 
hepatic growth and regeneration (Streetz et a l , 2000, Fausto, 2000) To date relatively 
little is known about the role of IL-6 in HCC The results presented in this study 
demonstrate altered expression and activity of components of IL-6 dependent signalling 
pathways in tumourigemc hepatic tissue as compared to histologically normal liver 
specimens Specifically, these data demonstrate decreased expression of IL-6Ra and 
gpl30 subunits of the IL-6 receptor in HCC tissue as compared to normal liver Despite 
these observations, HCC tissue is characterised by increased IL-6 production and 
STAT3 activity as compared to pair-matched and sham operated NL Analysis of 
proteins involved in cell cycle progression clearly demonstrate increased expression of 
both p 2 lwafl/c,pl and p27Kipl in HCC, both common downstream effectors o f IL-6 
signalling Finally, the inducible inhibitors o f cytokine signalling SOCS-1 was 
upregulated while SOCS-3 was downregulated in HCC tissue compared to pair 
matched NL tissue
Previous reports have identified IL-6 as a critical cytokine in the initiation phase 
of liver regeneration (Streetz et a l , 2000, Fausto, 2000) Reduced liver mass causes 
increased serum TNF-a levels followed by increased IL-6 and downstream STAT3 
activation STAT3 activation in collaboration with additional transcription factors, such 
as C/EBPp, enhance the expression of additional factors including NF-IL-6, c-myc, c- 
fos, IRF-1 enabling resting hepatocytes to progress into cell proliferation (Streetz et a l , 
2000, Fausto, 2000) More recently, Zimmers et al report the potential o f IL-6 to act as 
a complete mitogen in the liver In this model circulating IL-6 levels were elevated in 
nude mice using a transfected CHO cell lme, leading to dramatic hepatomegaly and 
hepatocyte hyperplasia in the absence of liver injury (Zimmers et a l , 2003) In support 
of this observation, previous research using double transgenic mice expressing human
3.4 Discussion
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IL-6 and human soluble IL-6R under liver specific promoters also report hepatomegaly, 
hepatic hyperplasia and the presence of hepatic adenomas (Maione et a l , 1998, 
Schumacher et a l , 1998)
The current studies demonstrate significantly decreased IL-6Ra expression in 
HCC specimens as compared to normal liver Normally the IL-6Ra is present on a 
comparatively small number o f cell types including hepatocytes, neutrophils, 
monocytes and some T- and B- cells (Kallen, 2002) In other tumour cells, a growth 
inhibitory effect o f IL-6 is enhanced through the addition of sIL-6Ra suggesting that 
IL-6Ra expression may be the rate-hmitmg factor in cellular response to IL-6 (Oh et 
a l , 1997, Ganapathi et a l , 1996, Bellido et a l , 1998) Evidence from these studies 
demonstrates that HCC tissue expresses higher IL-6 mRNA than normal liver IL-6, 
however, was not detectable in rat plasma of tumour burdened or sham operated 
animals One potential explanation of these observations may be the highly vascular 
nature o f HCC and the increased blood flow/infiltration of blood borne cells into the 
tumour However, following isolation and culture of pure HCC cell population, basal 
IL-6 mRNA and protein expression was clearly detectable and was further enhanced by 
treatment with LPS IL-6 expression is upregulated in many haematological 
malignancies and solid tumours (Miki et a l , 1989, Nordan et a l , 1987, Kawano et a l , 
1988, Jemberg et a l , 1991, Levy et a l , 1991, Okuno et a l , 1992, Miles et a l , 1990, 
Yee et a l , 1989) The tumour suppressors p53 and retinoblastoma protein have both 
demonstrated an ability to repress IL-6 expression while many mutated forms of these 
proteins lack this functionality (Santhanam et a l , 1991) The mutation status of both of 
these proteins is unknown in H4IIE cells however, these tumour suppressors have been 
reported to be frequently mutated in human HCC (Edamoto et a l , 2003) and may 
provide a possible mechanism for IL-6 upregulation In other cases, such as that of 
glioblastomas, the amplification of the IL-6 gene at its locus appears to be responsible
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for IL-6 overexpression (Tchirkov et a l , 2001) Given that the tumour itself can express 
IL-6, down regulation o f the IL-6Ra in HCC may act to “mask” the tumour from the 
effects of autocrine IL-6 stimulation Indeed, studies using human cervical carcinoma 
cells, in which the IL-6Ra subumt is down regulated at a transcriptional level, 
demonstrate decreased IL-6 responsiveness despite high IL-6 expression in these cells 
(Hess et a l , 2000) Similarly, in melanoma cells, transduction of an IL-6 cDNA leads 
to decreased IL-6Ra expression and confers IL-6 resistance to these cells (Silvani et a l ,
1995) IL-6 has also been shown to downregulate IL-6Ra mRNA expression in rat 
hepatocytes (Nesbitt and Fuller, 1992) In these studies, we also show significantly 
lower gpl30 expression in HCC as compared to normal liver Unlike IL-6Ra, gpl30 is 
ubiquitously expressed and is not normally subject to the same regulatory mechanisms 
as the IL-6Ra subunit However, hyper-stimulation with IL-6 has been shown to down 
regulate gpl30 expression in splenic T cells (Wang et a l , 1998) and receptor 
internalisation and degradation in hepatic cells (Zohlnhofer et a l , 1992)
As is the case with other tumours, HCC is characterised by dysregulated 
expression and abnormal activation of many cell signalling proteins In this study 
increased STAT3 activity was identified m HCC tissue compared to normal hepatic 
tissue Furthermore, increased p 2 lwafl/ctpl and p27K,pl expression was observed in these 
tumours in vivo STAT3 is constitutively activated in cells transformed by SRC 
tyrosine kmase (Yu et a l , 1995) and has been shown to have the ability to act as an 
oncogene (Bromberg et a l , 1999) Constitutively activated STAT3 has also been 
discovered m many primary tumours including multiple myeloma and squamous cell 
carcinomas (Bromberg, 2001) Explanations for the persistent activation of STAT3 are 
varied For example, aberrant EGF/EGFR signalling accounts for constitutive 
activation o f STAT3 in squamous cell carcinomas while in multiple myelomas 
overexpression and dysregulation of the IL-6Ra and production o f IL-6 stimulates
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STAT3 activity (Bromberg, 2001) In a HCC cell line, Yoshikawa et al, have identified 
methylation induced silencing of SOCS-1, a Jak inhibitor, leads to constitutive STAT3 
activation (Yoshikawa et a l , 2001b) Interestingly, constitutive activation of STAT3 in 
murine plasmacytomas and hybndomas is associated with the acquisition of an IL-6 
independent phenotype (Rawat et a l , 2000) This raises the question o f whether 
constitutive STAT3 activation in HCC tumours is directly related to increased tumour 
IL-6 production Alternatively, other cytokines and/or growth factors that have been 
demonstrated to utilise a STAT3 pathway (e g EOF) may be produced, either by the 
tumour or in response to the tumour, that regulate STAT3 activity However, data from 
these studies also identified increased expression of SOCS-1 and decreased expression 
of SOCS-3 in HCC compared to NL SOCS-1 and SOCS-3 inhibit phosphorylation of 
Jakl, Jak2 and Jak3 and are induced by STAT signalling (Starr et a l , 1997) While 
SOCS-1 and SOCS-3 genes are silenced in many malignancies, including certain 
human HCC (Watanabe et a l , 2004, Yoshikawa et a l , 2001a, He et a l , 2003), 
overexpression has been identified in other tumours and has been linked to cytokine 
resistance (Raccurt et a l , 2003, Sakai et a l , 2002, Tannapfel et a l , 2003) Indeed 
downregulated expression of SOCS-3 may be responsible for constitutively activated 
STAT3 in these HCC tumours due to the absence of adequate negative regulation of IL- 
6 signalling The absence of SOCS-3 expression has been demonstrated to prolong the 
activation of STAT3 during IL-6 signalling in the liver while IL-6 signalling remains 
normal in the absence of SOCS-1 expression (Croker et a l , 2003)
The functional significance of constitutively activated STAT3 in this tumour 
model remains to be determined Many STAT3 target genes have been identified in 
other malignant cells including those involved in cell survival, angiogenesis, immune 
evasion and proliferation The dysregulated expression of both p21wall/up! and p27K,pl 
observed m these studies may be in response to an unremittingly active form of
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STAT3 Both o f these genes contain STAT responsive elements and can be modulated 
by IL-6 type cytokines (Bellido et a l , 1998, Kortylewski et a l , 1999, de Komng et a l ,
2000) P 2 lwafl/cipl and p27K,pl are cyclin dependent kinase (cdk) inhibitors that can 
inhibit G1 associated cyclin complexes including CDK4/cychn D and CDK2/Cyclin E 
and, in doing so, inhibit cell cycle progression At low stoichiometric concentrations, 
P21wafl/Clpl and P27K,pl may serve as assembly factors for active cyclin/CDK complexes 
(LaBaer et a l , 1997) and have been implicated as regulators of hepatocyte proliferation 
in the liver after partial hepatectomy where they determine the rate of progression 
through the G1 phase o f the cell cycle (Albrecht et a l , 1998) Overexpression of both 
p21wafl/c,pl and p27K,pl has been previously observed in human HCC specimens and it is 
worth noting that genetic mutations in either of these genes are rare in human 
malignancies (Qin and Ng, 2001)
In conclusion, HCC is characterised by many aberrations in IL-6 signalling At 
present it is uncertain why HCC tumours produce significantly more IL-6 as compared 
to pair-matched normal liver although it is tempting to speculate that increased mtra- 
tumour IL-6 is responsible for decreased IL-6 receptor expression in HCC If this is 
indeed the case, decreased IL-6 receptor levels in HCC tumours may act as a 
potentially evasive technique utilised by these cells to mask themselves from IL-6 
Furthermore, overexpression of SOCS and constitutive activation o f STAT3 have each 
been linked to cytokine resistance and IL-6 independence in other tumours (Raccurt et 
a l , 2003, Sakai et a l , 2002, Tannapfel et a l , 2003, Rawat et a l , 2000) Overall, it is 
clear that determining the effects of IL-6 in isolated HCC cells should provide a greater 
understanding of the differences in IL-6 signalling in vivo
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Chapter 4: Interleukin-6 Signalling in HCC
4.1 Introduction
In chapter 3 HCC was demonstrated to be characterised by altered expression of 
IL-6 signalling components as compared to normal liver Specifically, HCC displays 
decreased expression of both components of the IL-6 receptor, increased IL-6 
production and constitutively activated STAT3 While the underlying reasons behind 
IL-6 upregulation in HCC tumours are unclear, it is possible that decreased IL-6 
receptor expression may render the cells less responsive to IL-6
Classically IL-6 binds to membrane-bound IL-6Ra leading to the recruitment of 
trans-membrane gpl30 receptor subunits into an active, hexamenc IL-6 receptor 
complex Homodimensation of the gpl30 proteins leads to phosphorylation of STATs 
via Jaks that are constitutive^ associated with gpl30 Phosphorylation of STATs leads 
to STAT-dimer formation and translocation to the nucleus where target gene 
modulation occurs (Heinrich et a l , 1998) In addition to this classical model of receptor 
activation and downstream signalling, IL-6 can also signal via a soluble IL-6 receptor 
(sIL-6R) In this instance, IL-6 binds a soluble form of the a-receptor and this complex 
activates signalling in cells expressing the gpl30 receptor that may not inherently 
express IL-6Rct, as well as potentiating IL-6 signalling in cells that do express IL-6Ra 
Importantly, many of the effects of the sIL-6Ra/IL6 complex can be inhibited by the 
presence of soluble gpl30 in the serum (Kallen, 2002)
Previous reports demonstrate that the majority o f the intracellular effects of IL-6 
are mediated via STAT3 activation although, involvement o f STAT1 and/or STAT5
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have also been reported in specific target cells (Heinrich et a l , 1998) In addition to the 
Jak-STAT pathway the Ras-mitogen activated protein kinase (MAPK) pathway can 
also be activated following IL-6 receptor activation (Fukada et a l , 1996) Following 
ligand binding, Src homology protem 2 tyrosine phosphatase-2 (SHP-2) interacts with 
gpl30 and activates a downstream Ras-MAPK cascade Interleukin-6 signalling 
through this pathway ultimately leads to the phosphorylation/activation of extracellular 
regulated kinases (ERKs) which in turn serve as important regulators of nuclear 
transcription activity and cytoplasmic function (Chang and Karin, 2001) Collectively, 
the balance between the Jak-STAT and Ras-MAPK pathways determines the outcome 
of IL-6 signalling withm each cellular context
Interleukin-6 is integrally linked to hepatic regeneration Following partial 
hepatectomy, IL-6 serum levels are elevated and this is accompanied by pronounced 
STAT3 activation in the liver (Streetz et a l , 2000) IL-6-/- mice show impaired liver 
regeneration, including abnormal G1 to S-phase progression and hepatocellular 
apoptosis The significance o f IL-6 m this process is farther confirmed as pre-operative 
IL-6 administration rescues the deficiency in hepatocyte proliferation (Cressman et a l ,
1996) Conversely hyperstimulation with IL-6 in human soluble IL-6Ra transgenic 
mice prior to partial hepatectomy results in delayed cell cycle progression and over 
expression of the cychn dependent kinase inhibitors p21wafl/cipl and p27Klpl (Wustefeld 
et a l , 2000) While apparently contradictory, these data may be explained by the 40 
fold induction o f suppressors of cytokine signalling (SOCS) that occurs within two 
hours of IL-6 administration where the timing of gpl30 stimulation is the rate limiting 
factor (Galun and Axelrod, 2002) In vitro, the role of IL-6 remains controversial, 
treatment of hepatocytes having been demonstrated to both stimulate and inhibit DNA 
synthesis (Kordula et a l , 1991, Kuma et a l , 1990, Satoh and Yamazaki, 1992)
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In tumour biology, IL-6 has been identified as a growth factor for several cancer 
cell types including renal cell carcinoma (Miki et a l , 1989), multiple myeloma 
(Kawano et a l , 1988) and plasmacytoma (Nordan et a l , 1987) In contrast, IL-6 has 
been reported to significantly inhibit the growth of other cancer cells Growth arrest and 
terminal differentiation is induced m M l myeloid leukaemia cells, an effect that is 
blocked by the expression of dominant negative forms of STAT3 (Minami et a l , 1996, 
Fukada et a l , 1996) Interleukin-6 also induces an anti-proliferative effect in early stage 
human melanoma cells associated with STAT-mediated transcriptional up-regulation of 
p27K,pl (Kortylewski et a l , 1999) and p21wafl/cipl (Florenes et a l , 1999) Similarly IL-6- 
induced growth inhibition has been reported in prostate cancer (LNCaP) (Spiotto and 
Chung, 2000) and osteosarcoma cells (MG63) (Bellido et a l , 1998) In hepatoma cells 
the effects of IL-6 on downstream effector pathways and cell proliferation remains 
uncertain Stimulation of the IL-6Ra in human HepG2 cells leads to the accumulation 
o f p27K,pl and growth arrest in the G1 phase (Klausen et a l , 2000) an inhibitory effect 
similar to that observed by Kim et al in the H-35 rat hepatoma cell line however, the 
underlying mechanism of this inhibition was not determined (Kim and Baumann, 
1999) In contrast, IL-6 has been indicated as an autocnne growth factor in other 
hepatoma cells IL-6 producing HCC-M hepatoma cell proliferation is inhibited 
following IL-6 antisense treatment (Kumagai et a l , 2002) IL-6 is also implicated in 
cell survival during hepatic injury and inhibits TGF-p-induced apoptosis in the human 
hepatoma derived Hep3B cell line (Chen et a l , 1999)
The aim of the current study was to examine IL-6 signalling and downstream 
cell cycle regulatory pathways in isolated HCC cells and hepatocytes in vitro
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Rat HCC tumour model was established by direct injection of H4IIE cells into 
the left liver lobe o f male ACI rats as described in section 2 3 H4IIE cells were isolated 
and cultured from the HCC tumour and passaged up to three times as descnbed m 
section 2 2 prior to use in experiments
4 2 2 Primary Hepatocyte Isolation
Fresh hepatocytes were isolated from male adult ACI rats using a modification 
of the two step perfusion technique as descnbed in section 2 2 8
4 2 3 Recombinant Human IL-6 Treatment
H4IIE cells and hepatocytes were quiesced for 16h (hepatocytes) or 24-48h 
(H4IIE) using serum free media prior to the addition of recombinant human IL-6 (rhlL- 
6, Biosource International, Camanllo, CA, USA) at varying concentrations (0- 
50ng/mL) Cell lysates for immunoblotting were prepared at varying time points (0- 
24h) after treatment as descnbed in section 2 4 2
4 2 4 Immunoblotting
4 2 41 Materials
Antisera specific against gpl30 (M-20), IL-6Ra (M-20), p21wan/c,pl (F-5), 
STAT3 (H-190), ERK2 (K-23), cdk4 (H-22), cdk2 (M-2), cdc2 p34 (C-19), cyclin A 
(C-19), Jakl (Q-19), Jak2 (C-20), Tyk2 (C-8), PCNA (PC-10) and KNRK nuclear
extract were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
Antisera specific against Retinoblastoma protein (Rb) was purchased from BD 
Biosciences (San Diego, CA, USA) Anti sera specific against p27Klpl, Phospho-STAT3
4.2 Methods
4 2 1  T um o u r M odel and  H4ILE Cell Isolation
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(Tyr705), Phospho-p44/42 MAPK (Thr202/Tyr204), Phospho-Jakl (Tyr1022/1023), 
Phospho-Jak2 (Tyrl007/1008), Phospho-Tyk2 (Tyrl054/1055), HA-Tag (262K), cyclin 
D3 (DCS22) and cyclin D1 (DCS6) were purchased from Cell Signaling Technology 
(Beverly, MA, USA) Horseradish peroxidase conjugated goat anti-rabbit Ig and goat 
anti mouse Ig were purchased from Jackson Immunoresearch Laboratories (West 
Grove, PA, USA) Horseradish peroxidase conjugated rabbit anti goat Ig was purchased 
from Sigma Immunochemicals (St Louis, MO, USA)
4 2 4 2 Western Blotting
Western blots were performed as described in section 2 5 10|iL of KNRK 
nuclear extract was loaded as a positive control for both p21wafl/cipl and p27lc,pl 
expression Cell lysates from H4IIE cells stimulated with rhIL-6 (50ng/mL, lh) or FBS 
(10% v/v, 10 mins) were used as positive controls for pSTAT3 and pERK 1/2 
expression respectively All primary antibodies were diluted 1 1000 with the exception 
of Phospho-STAT3 (1 2000) in 5% (w/v) non fat dry milk (NFDM)/0 1% (v/v) 
tween/tns buffered saline (TBS) Phospho-Jakl which was diluted 1 500 in 5% (w/v) 
BSA/0 1% (v/v) Tween/TBS All secondary antibodies were diluted 1 5000 in 5% (w/v) 
NFDM/0 1% (v/v) Tween/TBS
4 2 5 Pharmacological Inhibition of Jak-STAT and Ras-MAPK pathways
4 2 51 Materials
AG490 (a-Cyano-(3,4-dihydroxy)-N-benzylcinnamide Tyrphostin B42) was 
purchased from Calbiochem (San Diego, CA, USA) PD98059 (2-(2-ammo-3-
methoxyphenyl)-4H-1 -Benzopyran-4-one) was purchased from Cell Signaling 
Technology (Beverly, MA, USA) DM SO was purchased from Fisher Scientific 
(Pittsburgh, PA, USA)
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4.2 5 2 Pharmacological Inhibition of the RAS-MAPK pathway
Cultured H4IIE cells were quiesced for 48h m serum free media PD98059
(MEK-1 inhibitor, 20[iM) in serum free media was added to each well of quiesced 
H4IIE cells lh  prior to treatment with 50ng/mL rhIL-6 Control H4IIE cells were 
treated with DMSO (l^iL/mL) in serum free media lh  pnor to treatment with 50ng/mL 
rhIL-6 Cell protein lysates for immunoblottmg were prepared at varying time points 
(0-24h) after treatment as described m section 2 4 2
4 2*5 3 Pharmacological Inhibition of the Jak-STAT pathway
Cultured H4IIE cells were quiesced for 48h in serum free media AG490 (Jak
inhibitor) at varying concentrations (O-lSOjaM) in serum free media was added to each 
well of quiesced H4IIE cells lh  prior to treatment with 50ng/mL rhIL-6 Control H4IIE 
cells were treated with DMSO (0-0 6^iL/mL) m serum free media lh  prior to treatment 
with 50ng/mL rhIL-6 Cell lysates for immunoblottmg were prepared at varying time 
points (0-24h) after treatment as described in section 2 4 2
4 2.6 Transient Transfection of H4IIE Cells with Dominant Negative STAT3
4 2 61 Materials
pEFHASTAT3F (STAT3 dominant negative) and pEFHASTAT3 (STAT3 wild 
type) overexpression vectors (Figure 4 1a and 4 1b) were a kind gift from K Nakajima 
(Department o f Molecular Oncology, Osaka University Medical School, Japan) and 
have been previously descnbed (Nakajima et a l , 1996) Both vectors were originally 
constructed by cloning cDNA coding for either HASTAT3 or HASTAT3F mutant 
(Tyr705Phe) into a pEFBOS mammalian expression vector TE buffer, One Shot TOP 
10 chemically competent E co li, S O C  media, carbemcillin and ampicillm were
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(a) S ail STAT3F cDNA BamHI,Spelatimi, Not/RV
(b) Sail STAT3 cDNA Bell, EcoRV
Figure 4.1 Schematic representation of expression vectors pEFHASTAT3F and 
pEFHASTAT3 Vectors expressing a) dominant negative STAT3 (pEFHASTAT3F) 
and b) wild type STAT3 (pEFHASTAT3) are shown Both expression vectors were 
originally designed elsewhere through the cloning of cDNA for murine HA tagged 
STAT3 and STAT3F into the pEF-BOS plasmids Both plasmids contain ampicillin 
resistance genes as prokaryotic selection markers Restriction sites are labelled
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purchased from Invitrogen Life Technologies (Carlsbad, CA, USA) Glycerol, 
isopropanol, ethanol and agarose were purchased from Fisher Scientific (Pittsburgh, 
PA, USA) QIAprep spin miniprep kit and QIAfilter plasmid maxiprep kit were 
purchased from Qiagen (Valencia, CA, USA) BAMH1, Sail, EcoRV, BAMH1 
reaction buffer, Sail reaction buffer and 1Kb DNA ladder were purchased from New 
England Biolabs (Beverly, MA, USA) Tns, boric acid, ethylenediaminetetraacetic acid 
(EDTA) and ethidium bromide were purchased from Sigma-Aldrich (St Louis, MO, 
USA) Difco LB agar (Miller), Difco LB broth (Miller) and Difco Terrific Broth (TB) 
were purchased from BD Biosciences (San Diego, CA, USA) Mim Sub Cell GT 
electrophoresis unit was purchased from Biorad Laboratories (Hercules, CA, USA) 
Kodak EDAS290 gel visualisation unit was purchased from Kodak (Rochester, NY, 
USA) Genesys 2 UV/Visible Spectrophotometer was purchased from Thermo 
Spectronic (Rochester, NY, USA) DNA loading buffer was purchased from Eppendorf 
(Hamburg, Germany)
4 2 6 2 T ransform ation of E  coh
50ng of plasmid DNA (pEFHASTAT3F/pEFHASTAT3) was added to 50jiL 
TOP 10 E coh Cells were placed on ice for 30 mins and then heated to 42°C for 30 
secs Cells were replaced on ice for 2 mins 250|iL of S O C media (2% (w/v) tryptone, 
0 5% (w/v) yeast extract, lOmM sodium chloride, 2 5mM potassium chlonde, lOmM 
magnesium chlonde, lOmM magnesium sulphate, 20mM glucose) was added and 50jiL 
of this suspension was spread on LB agar plates (lOg/L tryptone, 5g/L yeast extract, 
lOg/L sodium chloride, 15g/L agar) containing ampicillin (70|ig/mL) and incubated 
overnight at 37°C One colony from the plate was used to inoculate 3mL of TB media 
(12g/L pancreatic digest o f casein, 24g/L yeast extract, 9 4g/L dipotassium phosphate,
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2 2g/L monopotassium phosphate) containing carbenicilhn (70jig/mL) This culture 
was incubated from 6h to overnight at 37°C with high agitation Transformed bacteria 
from these cultures were stored at -80°C in 40% (v/v) glycerol
4 2 6 3 Plasmid DNA Mmiprep
Plasmid DNA mimpreps were prepared using a QIAprep spin mmiprep kit All 
centrifugations were carried out at 17,500 x g and all buffers described were supplied 
as part of the QIAprep kit Overnight culture (3mL) of transformed E coh was 
prepared as described in section 4 2 6 2 Cells were pelleted, resuspended in 250}iL 
Buffer PI and transferred to a microcentrifuge tube 250(iL of Buffer P2 was added and 
mixed gently 350pL of Buffer N3 was then added and the sample centrifuged for 10 
mins Supernatant was added to a Qiaprep spin column and centrifuged for 60 secs The 
column was then washed using 0 75mL Buffer PE and centrifuged for 60 secs Finally 
the column was centrifuged for an extra 60 secs to remove residual buffer prior to 
elution of DNA by centrifuging with 50jxL of EB buffer for 60 secs
4.2.6.4 Restriction Digests
Restriction digests were performed to confirm the identity of each plasmid 
pEFHASTAT3F plasmid was cut with the restnction enzymes BAMH1 and Sail 
releasing the -2  3Kb cDNA coding for HASTAT3F (Figure 4 2) pEFHASTAT3 was 
cut with Sail and EcoRV releasing the ~2 5Kb cDNA coding for HASTAT3 (Figure 
4 3) Reaction mixtures were prepared as described m Table 4 1 and were 
mcubated at 37°C for lh  Products were combined with 2|iL of DNA loading buffer
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pEFHASTAT3F pEFHASTAT3
BAMH1 BUFFER 15*iL -
Sail BUFFER - 1 5|iL
BAMH1 0 5jiL -
Sail 0 5pL 0 5*iL
EcoRV - 0 5jiL
PLASMID DNA 4fiL 4*iL
Double Distilled Water 8.5jiL 8 5|iL
Table 4 1 Reaction mixtures for the restriction digest of pEFHASTAT3F and 
pEFHASTAT3. Restriction digests were prepared using 4[iL of miniprepped 
pEFHASTAT3F or pEFHASTAT3 plasmid DNA Reaction mixture comprising each 
component was incubated at 37°C for lh  Reaction products were electrophoresed on a 
0 8% (w/v) agarose gel containing ethidium bromide
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A B C D
4 0Kb 
3 0Kb
0 5Kb
pEF-Bos Vector
HASTAT3F
Figure 4 2 R estriction digestion of pE FH A ST A T 3F expression vector using  
B A M H l/S a ll Restriction digests were prepared using 4\iL o f miniprepped 
pEFHASTAT3F plasmid DNA Reaction mixture containing BAMH1 and Sail 
restriction enzymes was incubated at 37°C for lh  and products were electrophoresed on 
a 0 8% (w/v) agarose gel containing ethidium bromide Reaction was performed in the 
absence of restriction enzymes as control (A,B) HASTAT3F cDNA codmg region 
(-2  3Kb) was released from restriction digested pEFHASTAT3F (C,D)
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Figure 4.3 R estriction digestion o f  pE FH A STA T3 expression vector using  
E coR V /Sall Restriction digests were prepared using 4|iL of mmiprepped 
pEFHASTAT3 plasmid DNA Reaction mixture containing EcoRV and Sail restriction 
enzymes was incubated at 37°C for lh  and products were electrophoresed on a 0 8% 
(w/v) agarose gel containing ethidium bromide Reaction was performed in the absence 
o f restnction enzymes as control (A,B) HASTAT3 cDNA coding region (~2 5Kb) was 
released from restnction digested pEFHASTAT3 (C,D)
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and then electrophoresed on a 0 8% (w/v) agarose gel made with TBE buffer (45mM 
Tris-Borate, ImM EDTA) containing ethidium bromide (2p,L in 50mL) Gels were 
placed in a gel electrophoresis unit containing TBE and were run at 60V Gel images 
were captured using a Kodak EDAS 290 image capture system
4 2 6 5 Plasm id D N A  M axiprep
Plasmid DNA was prepared using the QIAfilter plasmid Maxiprep kit All 
buffers described were obtained as part o f this kit 10|iL o f the transformed E coh  
culture described in section 4 2 6 2 was used to inoculate 150mL of LB media (lOg/L 
pancreatic digest o f casein, 5g/L yeast extract and lOg/L NaCl) containing 70|ig/mL of 
carbemcillin and was grown overnight at 37°C Cells were harvested by centrifugation 
at 6000 x g for 15 nuns at 4°C The pellet was resuspended m lOmL PI buffer, lOmL of 
P2 buffer was added and the solution was incubated at room temperature for 5 mins 
lOmL of chilled P3 buffer was then added to the lysate and the sample was then rested 
for 10 mins on ice prior to centrifugation at 6,000 x g for 20 mins (4°C) The lysate was 
then added to the barrel o f a Qiafllter cartridge A QIAfilter tip 500 was equilibrated by 
passing lOmL of buffer QBT through it The cell lysate was then filtered through the 
equilibrated tip After the lysate had passed through the resin, the QIAgen tip was 
washed twice with 30mL of QC buffer DNA was then eluted in 15mL of buffer QF 
and precipitated by the addition o f 10 5mL of isopropanol at room temperature The 
solution was then mixed and centrifuged at 3,000 x g for 10 mins The DNA pellet was 
washed in 5mL of 70% (v/v) ethanol (room temperature) and then centrifuged at 6,000 
x g for 10 mins Finally the pellet was air dried and redissolved in 300|^L of TE buffer 
DNA yield was determined as described in section 4 2 6 6
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DNA was diluted 1 200 in nuclease free water Absorbance at 260nm was 
measured on a UV spectrophotometer DNA concentration was calculated using the 
following equation
DNA CONCENTRATION (mg/mL) = ABSORBANCE260mn (diluted 1 200) x 10 
Where
DNA CONCENTRATION = Concentration of DNA (mg/mL)
ABSORBANCE260nm = Absorbance of sample at 260nm
4.2.6.7 T ransient T ransfection o f H 4IIE  Cells
H4IIE cells were grown to approximately 80% confluency in 6 well tissue 
culture plates Transfection was earned out in serum free EMEM media in the absence 
o f antibiotics or buffering agents 36^ig of maxiprepped pEFHASTAT3F or 
pEFHASTAT3 plasmid DNA (section 4 2 6 5) was added to 600|iL of serum free 
EMEM media 60|iL o f Lipofectamme was also added to 600|iL of serum free EMEM 
media Both tubes were combined and were mcubated at room temperature for 35-40 
mins H4IIE cells were washed once with PBS followed by a second wash in serum 
free EMEM media 0 8mL of serum free EMEM media was added to each well 200|iL 
of Lipofectamine/plasmid DNA mix was gently added to each well Cells were 
incubated for 5-20h at 37°C in a 5% CO2 humidified incubator After incubation, lmL 
of 20% (v/v) FBS H4IIE cell media (section 2 2 3) was added to each well After 16h 
o f further incubation cells were quiesced in serum free media for a penod of 24h pnor 
to treatment with rhIL-6 as desenbed in section 4 2 3
4 2 6 6 DNA Quantification
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4 2 7.1 M aterials
HEPES, sodium chloride, magnesium chloride, [3-glycerophosphate, sodium 
dodecyl sulphate (SDS), dithiothreitol (DTT), adenosine triphosphate (ATP) solution 
(lOOmM), Tns-HCl, sodium vanadate, sodium fluoride, EDTA, EGTA and NP-40 were 
all purchased from Sigma Aldrich (St Louis, MO, USA) Cell scrapers were purchased 
from Coming (Coming, NY, USA) Complete protease inhibitor tablets (containing 
PMSF, aprotimn and leupeptin) were purchased from Roche Applied Science 
(Indianapolis, IN, USA) Protem A-agarose was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA) Histone HI (calf thymus) was purchased from 
Calbiochem (San Diego, CA, USA) Rb-C fusion protein was purchased from Cell 
Signaling Technology (Beverly, MA, USA) Redivue y-P32 labelled ATP and 
nitrocellulose membrane was purchased from Amersham Biosciences (Piscataway, NJ, 
USA) Laemmli buffer was purchased from Biorad (Hercules, CA, USA) A large 
SE600 electrophoresis unit and TE transfer unit were purchased from Hoefer (San 
Francisco, CA, USA) X-ray film was developed using a SRX-101 Medical Film
Developer (Konica, Mahwah, NJ, USA) and densitometry was performed using the
Kodak EDAS290 imaging software (Kodak, Rochester, NY, USA)
4 2 7 2 M ethod
H4IIE cells were grown to approximately 80% confluency and quiesced for 48h 
in serum free media Cells were then treated with rhIL-6 at a concentration of 50ng/mL 
Cells were washed twice in PBS (4°C) and collected at varying time points (0-24h) in 
ice cold kinase extraction buffer (50mM Tns-HCl, 1% (v/v) NP-40, 150mM NaCl, 
ImM EDTA, ImM Na3V04 , ImM NaF, lOOg/mL PMSF, 2 jig/mL leupeptin, 2 |ig/mL 
aprotimn) Cells were lysed in this buffer for 15 mms with agitation (4°C) Debns was
4 2 7 Cyclin Dependent Kinase Activity Assays
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cleared from lysates by centrifugation at 14,000 x g for 15 mins (4°C) Supernatants 
were then precleared with 20|iL of Protein A agarose beads for 10 mins with gentle 
agitation Beads were removed by centrifugation at (14,000 x g, 10 mins, 4°C) Protein 
concentration in each lysate was measured using the BCA protein assay as described in 
section 2 5 2 Protem concentration of each lysate was next adjusted to lmg/mL using 
ice cold PBS 500(iL of each cell lysate was then incubated with antibodies specific 
against either cdk2 or cdk4 at a dilution of 1 50 for 4h with gentle agitation 20|iL of 
Protem A agarose beads were then added to each sample and incubated overnight with 
gentle agitation (4°C) The beads were then collected by pulse centrifugation (10 secs, 
14,000 x g, 4°C) The supernatant was discarded The beads were washed once in ice 
cold kinase extraction buffer followed by two washes in ice cold PBS A final wash 
was carried out in ice cold 50mM Hepes/lmM DTT solution The beads were next 
resuspended in IO^iL of 50mM Hepes/lmM DTT 20^iL of 3x Kinase Reaction buffer 
(150mM Hepes, 3mM DTT, 30mM MgCl2> 7 5mM EGTA, 0 3mM Na3V 0 4, 30mM 13- 
glycerophosphate, 3mM NaF, 60|iM ATP, IOjiCi y-P32 labelled ATP per reaction) 
containing either 2mg/mL of Histone HI (cdk2) or Rb-C fusion protem (cdk4) as 
substrates was then added to the beads This reaction was earned out at 30°C for 30 
mins and terminated by the addition o f 15juL Laemmli buffer (100°C) Samples were 
loaded on a 12 5% SDS-PAGE gel, resolved by electrophoresis and transferred to a 
nitrocellulose membrane as desenbed in section 2 5 3 Once transferred, the membranes 
were exposed to x-ray film and developed using a Komca SRX-101 Medical Film 
Developer
4 2 8 C onfocal M icroscopy
H4IIE cells and freshly isolated hepatocytes were cultured for 24h in vitro in 
HSM pnor to fixation in methanol and visualisation using a Fluoview FV500 1X70
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confocal laser scanning biological microscope and Fluoview FV500 version 4 3 image
I
processing software (Olympus America, Melville, NY, USA)
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H4IIE cells were inoculated directly into the left hepatic lobe of male ACI rats 
An encapsulated, reproducible tumour mass formed 14-16 days post inoculation H4IIE 
cells were isolated from this tumour and grown in culture Confocal microscopy 
demonstrated that H4IIE cells have a distinctive structural phenotype compared to 
isolated cultured rat hepatocytes H4IIE cells were characterised by large nuclei, a low 
cytoplasm to nucleus ratio and an irregular shape with multiple cytoplasmic extensions 
(Figure 4 4a) Isolated cultured rat hepatocytes were larger, exhibited a regular 
polyhedral structure and were often binucleated (Figure 4 4b)
Immunoblotting using antibodies specific against IL-6Ra and gpl30 was 
performed on cell lysates from cultured H4IIE cells and isolated cultured hepatocytes in 
order to compare levels of IL-6 receptor complex expression To normalise conditions, 
both cell types were cultured on collagen coated plates Using these antibodies single 
protein bands were detected at ~80KDa (IL-6Ra) or ~130kDa (gpl30, Figures 4 5a and 
4 5b respectively) Following protein transfer, data were analyzed for optical integrated 
volume IL-6Ra expression was significantly decreased in cultured H4IIE cells (48 6%) 
versus cultured rat hepatocytes (Figure 4 5a, p<0 05, n=4 per group) Gpl30 expression 
was dramatically lower in H4IIE cells compared to cultured rat hepatocytes (Figure 
4 5b, upper panel, n=4 per group) During experimentation, differences in gpl30 
expression between hepatocytes and H4IIE cells in culture were so large that 
overexposure o f the film was required in order for comparison of gpl30 expression in 
H4IIE lysates and hepatocytes to be performed (Figure 4 5b, lower panel)
Having determined H4IIE cells retain the downregulated IL-6 receptor 
expression phenotype observed in vivo (section 3 3 2), the expression of the IL-6 
receptor complex with serial passaging in culture was next analysed Isolated H4IIE
4.3 Results
4 3.1 Characteristics of H4IIE Cells and Hepatocytes In Vitro
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Figure 4.4 C onfocal im ages o f isolated H 4IIE  (H C C ) cells and rat hepatocytes 
cultured in vitro Isolated H4IIE cells and primary rat hepatocytes were cultured in 
vitro for 24 hours in high serum media Confocal images (40x) represent a) H4IIE ceils 
and b) rat hepatocytes fixed in methanol
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Figure 4 5 H 4IIE  (H C C ) cells are characterised by decreased IL-6 receptor  
expression versus prim ary rat hepatocytes in vitro Representative Western blot 
analysis o f whole cell lysates from isolated primary cultured rat hepatocytes (Hep) and 
isolated H4IIE cells cultured on collagen plates using an antibody specific against a) 
IL-6Ra and b) gpl30 In figure (b), the lower panel represents a higher exposure time 
of the blot in the upper panel
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cells were cultured in vitro and passaged serially three times Immunoblotting using 
antibodies specific against IL-6Ra and gpl30 was performed on cell lysates from each 
passage Analysis o f optical integrated volume on Western blots probed with these 
antibodies demonstrated there was no significant difference in expression of IL-6Ra 
(Figure 4 6a, n=4 per group) or gpl30 (Figure 4 6b, n=4 per group) with passaging in 
vitro
4 3 2 Effect o f  IL-6 on STAT3 A ctivity in H 4IIE  Cells and H epatocytes  
In  Vitro
Previous studies demonstrated that STAT and ERK dependent pathways are 
activated following ligand binding to the IL-6Ra Dose and time course studies were 
next performed to determine appropriate dose and temporal parameters for H4IIE cells 
and isolated cultured rat hepatocytes in vitro Initially, cell lysates were prepared and 
total Jak (Jakl, Jak2 and Tyk2) and active Jak (pJakl, pJak2 and pTyk2) were detected 
by Western blot In H4IIE cells a dose of 50ng/mL rhIL-6 caused a time dependent 
increase m pJakl expression, an increase being detected 2 mins after addition and a 
maximal response occurring at 60 mrns (Figure 4 7a, upper panel, n=4 per group) 
Analysis of total Jakl expression demonstrated no change in expression throughout the 
time course o f the experiments (Figure 4 7a, lower panel, n=4 per group) In cultured 
hepatocytes, rhIL-6 again led to increases in Jakl activation in the absence of changes 
in total Jakl expression (Figure 4 7b, n=4 per group), activation again occurring within 
2 mins of addition and maximal activity was detected between 60-120 mins after 
addition (Figure 4 7b, upper panel, n=4 per group) Phospho-Jak2 expression was also 
increased in H4IIE cells after rhIL-6 treatment (50ng/mL) m a time dependent manner, 
an increase detected 10  mins after addition of rhIL-6 and a maximal response occurring 
between 40 and 60 mins (Figure 4 8a, upper panel, n=4 per group) No change in total
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gpl30
PI P2 P3
Figure 4 6 H 4IIE  (H C C ) cells retain a decreased IL-6 receptor expression  
phenotype during serial passaging in vitro Representative Western blot analysis of 
whole cell lysates from H4IIE cells serially passaged in culture (P1-P3) using an 
antibody specific against a) IL-6Ra and b) gpl30
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Figure 4 7 R hIL-6 stim ulates J a k l activity in H 4IIE  (H C C ) cells and isolated  
cultured rat hepatocytes m a tim e dependent m anner in the absence o f changes in 
total J a k l expression in vitro a) Representative Western blot analysis performed on 
cell lysate samples prepared from cultured H4IIE cells using an antibody specific 
against active (phospho-) Jakl (pJakl, upper panel) or total Jakl (lower panel) H4IIE 
cells were isolated and purified from in vivo HCC tissue and cultured prior to treatment 
with rhIL-6 (50ng/ml) in serum free media for varying time periods (0-120 mins) b) 
Representative Western blot analysis performed on cell lysate samples prepared from 
isolated cultured rat hepatocytes using an antibody specific against active (phospho-) 
Jakl (pJakl, upper panel) or total Jakl (lower panel) Hepatocyte cell populations were 
isolated from normal rat livers by perfusion Following attachment, hepatocytes were 
placed in serum free media prior to treatment with rhIL-6 (50ng/ml) for varying time 
periods (0-120  mins)
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Figure 4 8 RhIL-6 stim ulates Jak2 activity in H 4IIE  (H C C ) cells and isolated  
cultured rat hepatocytes in a tim e dependent m anner in the absence o f changes in 
total Jak2 expression in vitro a) Representative Western blot analysis performed on 
cell lysate samples prepared from cultured H4IIE cells using an antibody specific 
against active (phospho-) Jak2 (pJak2, upper panel) or total Jak2 (lower panel) H4IIE 
cells were isolated and purified from in vivo HCC tissue and cultured prior to treatment 
with rhIL-6 (50ng/ml) in serum free media for varying time penods (0-120 mins) b) 
Representative Western blot analysis performed on cell lysate samples prepared from 
isolated cultured rat hepatocytes using an antibody specific against active (phospho-) 
Jak2 (pJak2, upper panel) or total Jak2 (lower panel) Hepatocyte cell populations were 
isolated from normal rat livers by perfusion Following attachment, hepatocytes were 
placed in serum free media prior to treatment with rhIL-6 (50ng/ml) for varying time 
periods (0-120 mins)
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Jak2 expression was detected throughout the course o f the experiments (Figure 4 8a, 
lower panel, n=4 per group) In cultured hepatocytes, rhIL-6 (50ng/mL) also stimulated 
Jak2 activation in the absence o f changes in total Jak2 expression (Figure 4 8b, n=4 per 
group), increased pJak2 being detected at 2 mins and a maximal response observed at 
40-60 mins (Figure 4 8b, upper panel, n=4 per group) Stimulation o f H4IIE cells with 
rhIL-6 (50ng/mL) also activated Tyk2 in a time-dependent manner in the absence of 
changes o f total Tyk2 expression in these cells (Figure 4 9a, n=4 per group), increased 
pTyk2 expression being detected at 2 mins reaching a maximal response at 40 mins 
(Figure 4 9a, upper panel, n=4 per group) Recombinant human IL-6 (50ng/mL) also 
stimulated Tyk2 activation in cultured hepatocytes (Figure 4 9b, n=4 per group), 
increased pTyk2 expression being detected at 2 mins and a maximal response occurring 
between 60-120 mins (Figure 4 9b, upper panel, n=4 per group) Treatment of 
hepatocytes with rhIL-6 did not alter the expression of total Tyk2 (Figure 4 9b, lower 
panel, n=4 per group)
Cell lysates from H4IIE cells and cultured rat hepatocytes were next analysed 
for total STAT3 and active (pSTAT3) expression by Western blot In H4IIE cells 
50ng/mL rhIL-6 caused a time dependent increase in pSTAT3 expression, an increase 
being detected 5 mins after addition and a maximal response occurring between 40 and 
60 mins, followed by a decrease in expression at 2h (Figure 4 10a, upper panel, n=4 per 
group) Changes m pSTAT3 expression following rhIL-6 addition occurred in the 
absence of changes in total STAT3 expression throughout the time course (Figure 
4 10a, lower panel, n=4 per group) In cultured hepatocytes, treatment with rhIL-6 
again led to increases in STAT3 activation in the absence o f changes in total STAT3 
expression (Figure 4 10b, n=4 per group) As with H4IIE cells, STAT3 activation 
occurred within 5 mins of addition and a maximal change in activity was detected 
between 40 and 60 mins (Figure 4 10b, upper panel, n=4 per group) To assess optimal
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Figure 4 9 R hIL -6 stim ulates T yk2 activity in H 4IIE  (H C C ) cells and isolated  
cultured rat hepatocytes in a tim e dependent m anner in the absence o f changes m 
total Tyk2 expression in vitro a) Representative Western blot analysis performed on 
cell lysate samples prepared from cultured H4IIE cells using an antibody specific 
against active (phospho-) Tyk2 (pTyk2, upper panel) or total Tyk2 (lower panel) 
H4IIE cells were isolated and purified from in vivo HCC tissue and cultured pnor to 
treatment with rhIL-6 (50ng/ml) in serum free media for varying time periods (0-120 
mins) b) Representative Western blot analysis performed on cell lysate samples 
prepared from isolated cultured rat hepatocytes using an antibody specific against 
active (phospho-) Tyk2 (pTyk2, upper panel) or total Tyk2 (lower panel) Hepatocyte 
cell populations were isolated from normal rat livers by perfusion Following 
attachment, hepatocytes were placed in serum free media pnor to treatment with rhIL-6 
(50ng/ml) for varying time penods (0-120 mins)
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Figure 4.10 R h lL -6  stim ulates STA T3 activity in H 4IIE  (H C C ) cells and isolated  
cultured rat hepatocytes in a tim e dependent m anner in the absence o f changes in 
total STAT3 expression in vitro a) Representative Western blot analysis performed 
on cell lysate samples prepared from cultured H4IIE cells using an antibody specific 
against active (phospho-) STAT3 (pSTAT3, upper panel) or total STAT3 (lower panel) 
H4IIE cells were isolated and purified from in vivo HCC tissue and cultured prior to 
treatment with rhIL-6 (50ng/ml) in serum free media for varying time periods (0-120 
mins) b) Representative Western blot analysis performed on cell lysate samples 
prepared from isolated cultured rat hepatocytes usmg an antibody specific agamst 
active (phospho-) STAT3 (pSTAT3, upper panel) or total STAT3 (lower panel) 
Hepatocyte cell populations were isolated from normal rat livers by perfusion 
Following attachment, hepatocytes were placed in serum free media prior to treatment 
with rhIL-6 (50ng/ml) for varying time periods (0-120 mins)
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doses o f IL-6, H4IIE cells and cultured hepatocytes were next treated with rhIL-6 (0- 
50ng/mL) for 60 mins These data demonstrated dose dependent increases in pSTAT3 
expression in both cell types, increases in STAT3 activation occurring at l-5ng/ml and 
a maximal response being detected at 50ng/mL (Figure 4 11a and 4 11b, upper panel, 
n=4 per group) In both instances no differences m total STAT3 expression were 
detected at any of the doses employed (Figure 4 11a and 4 l ib , lower panel, n=4 per 
group)
4 3 3 Effect o f IL-6 on M E K  A ctivity in H 4IIE  Cells and H epatocytes In
Vitro
To investigate the involvement o f a MAPK pathway in intracellular IL-6 
signalling in H4IIE cells and hepatocytes, cells were treated with 50ng/mL rhIL-6 for 
different time penods and cell lysates prepared for Western blot analysis o f total and 
activated (phosphorylated) ERK 1/2 expression In both cell types total ERK expression 
did not change throughout the experimental period (Figure 4 12a and 4 12b, lower 
panel, n=4 per group) In H4IIE cells, rhIL-6 caused a biphasic change in ERK 1/2 
activity, an initial activation occurring between 2 and 5 mins before decreasing back to 
baseline, followed by a second period of stimulation between 40 and 60 mins (Figure 
4 12a, upper panel, n=4 per group) In contrast, in hepatocytes, while increases in 
pERK 1/2 detection occurred 5 mins after rhIL-6 addition, ERK 1/2 activity was 
maintained for 20-40 mins before returning towards basal levels at 60 and 120 mins 
(Figure 4 12b, upper panel, n=4 per group)
4 3.4 D ow nstream  Effects o f  IL-6 signalling in H 4IIE  Cells and H epatocytes
Having determined that IL-6 stimulates STAT3 and ERK 1/2 intracellular signalling 
pathways in normal and transformed hepatic cells, the effect o f IL-6 receptor activation
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Figure 411 RhIL-6 stimulates STAT3 activity in H4IIE (HCC) cells and isolated 
cultured rat hepatocytes in a dose dependent m anner in the absence o f changes in 
total STAT3 expression m  vitro a) Representative Western blot analysis performed 
on cell lysate samples prepared from cultured H4IIE cells using an antibody specific 
against active (phospho-) STAT3 (pSTAT3, upper panel) or total STAT3 (lower panel) 
H4IIE cells were isolated and purified from in vivo HCC tissue and cultured prior to 
treatment with rhIL-6 (0-50ng/ml) in serum free media for 60 mins b) Representative 
Western blot analysis performed on cell lysate samples prepared from isolated cultured 
rat hepatocytes using an antibody specific against active (phospho-) STAT3 (pSTAT3, 
upper panel) or total STAT3 (lower panel) Hepatocyte cell populations were isolated 
from normal rat livers by perfusion Following attachment, hepatocytes were placed in 
serum free media prior to treatment with rhIL-6 (0-50ng/ml) for 60 mins
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Figure 4 12 R hIL-6 stim ulates M EK  activity in H 4IIE  (H C C ) cells and isolated  
cultured rat hepatocytes in a tim e-dependent m anner in the absence o f changes in 
total ER K  expression in vitro. a) Representative Western blot analysis performed on 
cell lysates prepared from cultured H4IIE cells using an antibody specific against active 
ERK 1/2 (pERK 1/2, upper panel) or total ERK 1/2 (lower panel) H4IIE cells were 
isolated and purified from in vivo HCC tissue and cultured prior to treatment with rhlL- 
6 (50ng/ml) in serum free media for varying time periods (0-120 mins) b) 
Representative Western blot analysis performed on cell lysates prepared from isolated 
cultured rat hepatocytes using an antibody specific against active ERK 1/2 (pERK 1/2, 
upper panel) or total ERK 1/2 (lower panel) Hepatocyte cell populations were isolated 
from normal rat livers by perfusion Following attachment, hepatocytes were placed in 
serum free media prior to treatment with rhIL-6 (50ng/ml) in low serum media for 
varying time periods (0-120 mins)
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on nuclear signalling pathways involved in cell proliferation was assessed H4IIE cells 
and rat hepatocytes were cultured as previously and treated with 50ng/mL rhIL-6 over a 
24h time penod Cell lysates were prepared for both untreated and treated cells at 
varying time points
The expression of cyclins involved in the progression through the G1 restriction 
point was determined by Western blot analysis Immunoblottmg with antibodies 
specific against cyclin D l, D3 and A was earned out on cell lysates from H4IIE cells 
treated with rhIL-6 (50ng/mL) No differences in expression of cyclin A (Figure 4 13a, 
n=4), cyclin D l (Figure 4 13b, n=4) or cyclin D3 (Figure 4 13c, n=4) were detected in 
rhIL-6 treated H4IIE cells compared to untreated cells at any of the time points 
Furthermore, expression of each of these cyclins was not altered over the course o f this 
expenment in either treatment group Analysis o f hepatocyte cell lysates following 
rhIL-6 treatment demonstrated both cyclin A (Figure 4 14a, n=4) and cyclin D3 (Figure 
4 14c, n=4) were increased at 24h in both the untreated and rhIL-6 treated ceils There 
was however no difference in cyclin A or cyclin D3 expression between rhIL-6 treated 
and untreated hepatocytes at any of the time points assayed Western blot analysis for 
cyclin Dl expression in hepatocytes also indicated increased expression of this protein 
at 24h in untreated cells (Figure 4 14b, n=4) Treatment of hepatocytes with rhIL-6 
(50ng/mL) suppressed this increase in cyclin Dl expression at 24h (Figure 4 14b, 
n=4)
Having established cyclin expression in H4IIE cells and rat hepatocytes, the 
expression of cyclin dependent kinases (cdk) was next determined Cdk2 and cdk4 are 
key factors dunng transition through the G1 cell cycle restnction point while cdc2 p34 
is an important regulator o f passage through the G2/M stages o f the cell cycle (Morgan, 
1995) Immunoblottmg using antibodies specific against cdc2 p34, cdk2 and cdk4 was
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Figure 4 13 R hIL-6 treatm ent does not alter the expression o f cyclins A , D1 and  
D3 in H 4IIE  (H C C ) cells in vitro Representative Western blot analysis performed on 
cell lysates prepared from cultured H4IIE cells using an antibody specific against a) 
cyclin A, b) cyclin D1 and c) cyclin D3 H4IIE cells were isolated and purified from in 
vivo HCC tissue and cultured prior to treatment (+) with rhIL-6 (50ng/ml) in serum free 
media for varying time periods (0-24h) Cell lysates from untreated (-) H4IIE cells were 
used as controls
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Figure 4 14 R hIL-6 treatm ent does not a lter the expression o f cyclins A and D3 
but does suppress cyclin D1 expression in isolated cultured rat hepatocytes m 
vitro Representative Western blot analysis performed on cell lysates prepared from 
isolated cultured rat hepatocytes using an antibody specific against a) cyclin A, b) 
cyclin D1 and c) cyclm D3 Hepatocyte cell populations were isolated from normal rat 
livers by perfusion Following attachment, hepatocytes were placed in serum free 
media pnor to treatment (+) with rhIL-6 (50ng/ml) for varying time periods (0-24h) 
Cell lysates from untreated (-) hepatocytes were used as controls
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performed on lysates from rhIL-6 (50ng/mL) treated and untreated H4IIE cells and rat 
hepatocytes collected over a 24h time penod No changes m cdc2 p34 (Figure 4 15a, 
n=4), cdk2 (Figure 4 15b, n=4) or cdk4 (Figure 4 15c, n=4) expression between rhIL-6 
treated and control H4IIE cells was detected following 1L-6 treatment The treatment of 
hepatocytes with rhIL-6 did not alter the expression of either cdc2 p34 (Figure 4 16a, 
n=4), cdk2 (Figure 4 16b, n=4) or cdk4 (Figure 4 16c, n=4) when compared with 
untreated controls Expression of cdk4 was decreased at 8h and 24h in both rhIL-6 
treated and untreated hepatocytes (Figure 4 16c, n=4)
Expression of the cell cycle regulator proliferating cell nuclear antigen (PCNA) 
was next examined in rhIL-6 (50ng/mL) treated H4IIE cells and rat hepatocytes 
Immunoblotting with an antibody specific for PCNA demonstrated that rhIL-6 
treatment in H4IIE cells or hepatocytes had no effect on PCNA expression as compared 
to untreated controls over the experimental time penod (Figure 4 17, n=4) Expression 
of PCNA increased, though not significantly at 24h in both treated and untreated 
hepatocytes (Figure 4 17b, n=4)
H4IIE cells and rat hepatocytes were next analysed for p 2 lwafl/c,pl and p27K,pl 
expression following rhJL-6 (50ng/mL) treatment by Western blot analysis These data 
demonstrated time dependent increases in p 2 iwafl/cipl and p27Kipl expression in H4IIE 
cells Increased p21wafl/c,pl was detected 4h after rhIL-6 addition before peaking at 8h 
and returning to baseline levels after 24h (Figure 4 18a, n=4) In contrast, p27Kipl 
expression did not increase until 8h after treatment, elevated expression being 
maintained up to 24h after IL-6 treatment (Figure 4 19a, n=4) Expression levels of 
P21wafl/Cipl and P27K,pI in isolated hepatocytes did not change following rhIL-6 
treatment throughout the time course assayed (Figure 4 18b and 4 19b, n=4)
Having established that the expression of cdk inhibitors p 2 iwail/c,PI and p27^‘pl 
was elevated by rhIL-6 treatment in H4IIE cells, the expression of pRb/ppRb was
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Figure 4 15 R hIL -6 treatm ent does not alter the expression o f cyclin dependent 
kinases cdc2 p34, cdk2 and cdk4 in H 4IIE  (H C C ) cells in vitro Representative 
Western blot analysis performed on cell lysates prepared from cultured H4IIE cells 
using an antibody specific against a) cdc2 p34, b) cdk2 and c) cdk4 H4IIE cells were 
isolated and purified from in vivo HCC tissue and cultured prior to treatment (+) with 
rhIL-6 (50ng/ml) m serum free media for varying time periods (0-24h) Cell lysates 
from untreated (-) H4IIE cells were used as controls
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Figure 4.16 R hIL-6 treatm ent does not alter the expression o f cyclin dependent 
kinases cdc2 p34, cdk2 and cdk4 in isolated cultured rat hepatocytes in vitro
Representative Western blot analysis performed on cell lysates prepared from isolated 
cultured rat hepatocytes using an antibody specific against a) cdc2 p34, b) cdk2 and c) 
cdk4 Hepatocyte cell populations were isolated from normal rat livers by perfusion 
Following attachment, hepatocytes were placed in serum free media pnor to treatment 
(+) with rhIL-6 (50ng/ml) for varying time penods (0-24h) Cell lysates from untreated 
(-) hepatocytes were used as controls
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Figure 4.17 R hIL -6 treatm ent does not a lter the expression o f PC N A  in H 4IIE  
(H C C ) cells or isolated cultured rat hepatocytes in vitro a) Representative Western 
blot analysis performed on cell lysates prepared from cultured H4IIE cells using an 
antibody specific against PCNA H4IIE cells were isolated and purified from in vivo 
HCC tissue and cultured prior to treatment (+) with rhIL-6 (50ng/ml) in serum free 
media for varying time periods (0-24h) Cell lysates from untreated (-) H4IIE cells were 
used as controls b) Representative Western blot analysis performed on cell lysates 
prepared from isolated cultured rat hepatocytes using an antibody specific against 
PCNA Hepatocyte cell populations were isolated from normal rat livers by perfusion 
Following attachment, hepatocytes were placed m serum free media prior to treatment 
(+) with rhIL-6 (50ng/ml) for varying time periods (0-24h) Cell lysates from untreated 
(-) hepatocytes were used as controls
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Figure 4.18 R hIL -6 stim ulates expression o f the cyclm  dependent kinase inhibitor  
p21waf1/c,pl in H 4IIE  (H C C ) but does not alter its expression in isolated cultured rat 
hepatocytes in vitro. a) Representative Western blot analysis performed on cell lysates 
prepared from cultured H4IIE cells using an antibody specific against p21wafl/c,pl 
H4IIE cells were isolated and purified from in vivo HCC tissue and cultured prior to 
treatment with rhIL-6 (50ng/ml) in serum free media for varying time periods (0-24h) 
b) Representative Western blot analysis performed on cell lysates prepared from 
isolated cultured rat hepatocytes using an antibody specific against p21waf1/c,pl 
Hepatocyte cell populations were isolated from normal rat livers by perfusion 
Following attachment, hepatocytes were placed in serum free media prior to treatment 
with rhIL-6 (50ng/ml) for varying time periods (0-24h) KNRK nuclear extract was 
loaded as a positive control for p 2 iwafl/c,pl expression
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Figure 4 19 R hIL -6 stim ulates expression o f  the cyclm  dependent kinase inhibitor  
p2 7 K,P1 m  H 4IIE  (H CC) but does not alter its expression m  isolated cultured rat 
hepatocytes in vitro. a) Representative Western biot analysis performed on cell lysates 
prepared from cultured H4IIE cells using an antibody specific against p27Klpl H4IIE 
cells were isolated and purified from in vivo HCC tissue and cultured prior to treatment 
with rhIL-6 (50ng/ml) in serum free media for varying time periods (0-24h) b) 
Representative Western blot analysis performed on cell lysates prepared from isolated 
cultured rat hepatocytes using an antibody specific against p27Klpl Hepatocyte cell 
populations were isolated from normal rat livers by perfusion Following attachment, 
hepatocytes were placed in serum free media prior to treatment with rhIL-6 (50ng/ml) 
for varying time periods (0-24h) KNRK nuclear extract was loaded as a positive 
control for p27Kipl expression
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measured as a marker o f cdk activity at the G1 restriction point Hypophosphorylated 
Rb (pRb) acts as an inhibitor of premature entry of the cell into the S-phase of the cell 
cycle and is a target for cdk dependent phosphorylation These data demonstrated that 
4h after rhIL-6 treatment the levels of ppRB expression, the hyperphosphorylated form 
of Rb, were decreased as compared to untreated H4IIE cells (Figure 4 20, n=4) 
Throughout the remainder of the time course, ppRb expression remained significantly 
higher in untreated cells than cells treated with IL-6
Given that p21wafl/c,pl and p27Klpl expression was increased and Rb 
phosphorylation was decreased in IL-6 treated H4IIE cells, cdk activity was next 
determined m these cells Cultured H4IIE cells were treated with rhIL-6 (50ng/mL) 
over a 24h penod Cyclin dependent kmase 2 and cdk4 were immunoprecipitated from 
cell lysates collected at varying time points in IL-6 treated and untreated cells The 
activity of cdk2 was determined using a kinase reaction with Histone HI as a substrate 
IL-6 decreased the level of cdk2 activity as evidenced by decreased phosphorylation of 
the Histone HI substrate at 8h and 24h compared to untreated controls (Figure 4 21, 
n=4) Kmase reactions to measure cdk4 activity, usmg the Rb-C fusion protein as a 
substrate, also demonstrated decreased kmase activity at 8h after IL-6 treatment versus 
untreated cells (Figure 4 22, n=4)
4 3.5 Pharm acological Inhibition o f IL -6 Stim ulated E R K  A ctivation In  Vitro
To determine the intracellular signalling pathway responsible for rhIL-6 stimulated 
p2lWafi/c,pi and p27K.pi upreguiatlon ln H4IIE cells, PD98059, a selective MEK 
inhibitor, was used to abrogate IL-6 dependent ERK 1/2 activation H4IIE cells were 
cultured as previously and pretreated with PD98059 (20|xM) for lh  pnor to treatment 
with rhIL-6 (50ng/mL) Control cells were pretreated for lh  with DMSO (l^iL/mL) 
followed by rhIL-6 (50ng/mL) Cell lysates were then collected at varying time points
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Figure 4 20 R hIL -6 treatm ent in H 4IIE  (H C C ) cells is associated w ith  a decreased  
level o f phosphorylation o f the retinoblastom a protein in vitro Representative 
Western blot analysis performed on cell lysates prepared from cultured H4IIE cells 
using an antibody specific agamst the phosphorylated and hyperphosphorylated forms 
of Rb protein (pRb and ppRb respectively) H4IIE cells were isolated and purified from 
in vivo HCC tissue and cultured prior to treatment (+) with rhIL-6 (50ng/ml) in serum 
free media for varying time periods (0-24h) Cell lysates from untreated (-) H4IIE cells 
were used as controls Increased pRb versus ppRb represents increased ability to 
suppress entry of the cell into the S-phase of the cell cycle
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Figure 4.21 R hIL-6 treatm ent o f H411E (H C C ) cells is associated w ith a decreased  
level o f cdk2 activity in vitro Representative kinase assay analysis performed on cell 
lysates prepared from cultured H4IIE cells using Histone HI as substrate H4IIE cells 
were isolated and purified from in vivo HCC tissue and cultured prior to treatment (+) 
with rhIL-6 (50ng/ml) in serum free media for varying time periods (0-24h) Cell 
lysates from untreated (-) H4IIE cells were used as controls Cdk2 was 
immunoprecipitated from these lysates and used in an in vitro kinase reaction in the 
presence of radioactive y-P32 labelled ATP
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Figure 4 22 R hIL -6 treatm ent o f  H 4IIE  (H C C ) cells is associated w ith  a decreased  
level o f cdk4 activity in vitro Representative kinase assay analysis performed on cell 
lysates prepared from cultured H4IIE cells using Rb-C fusion protein as substrate 
H4IIE cells were isolated and purified from in vivo HCC tissue and cultured prior to 
treatment (+) with rhIL-6 (50ng/ml) in serum free media for varying time periods (0- 
24h) Cell lysates from untreated (-) H4IIE cells were used as controls Cdk4 was 
immunoprecipitated from these lysates and used in an in vitro kinase reaction in the 
presence of radioactivey-P32 labelled ATP
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up to 24h Previous data demonstrates rhIL-6 stimulates ERK 1/2 activity m a biphasic 
manner, an initial increase being detected 2-5 mins after addition followed by a second, 
sustained activation 40-60 mins later (Figure 4 12a) Treatment o f cells with DMSO 
abrogated initial, early ERK 1/2 activation but did not alter the second phase of the 
ERK activation profile (Figure 4 23b, n=4) Treatment with PD98059 abolished ERK 
1/2 activity at all time points assayed following rhIL-6 addition (Figure 4 23a, n=4) In 
contrast, treatment with either PD98059 or vehicle (DMSO) did not affect STAT3 
activation profiles in H4IIE cells following rhIL-6 stimulation (Figure 4 24, n=4) 
Having determined that PD98059 treatment abolishes ERK 1/2 activation in the 
absence o f changes in STAT3 activity, p 2 lwafl/c,pl and p27K,pl expression was next 
assayed following inhibition o f ERK 1/2 activity using PD98059 The addition of rhlL- 
6 in vehicle pretreated cells resulted in increased p 2 lwafl/c,pl and p27Kipl expression 4h 
and 8h respectively after addition (Figure 4 25b, n=4) The expression of both 
p2 ]wafi/cipi ^  p27K,pl was similar to that observed in the absence of DMSO (Figure 
4 18a and 4 19a, n=4) Immunoblotting for both p21wafl/c,pl and p27K,pl m cell lysates 
from PD98059 pretreated rhIL-6 stimulated H4IIE cells demonstrated both p2 l wafl/cipl 
and p27K,pl expression increased m response to rhIL-6 despite the absence o f ERK 1/2 
activation (Figure 4 25a, n=4) P 2 lwafl/cipl expression was increased 4h after rhIL-6 
addition reaching a maximal expression after 8h (Figure 4 25a, upper panel, n=4) and 
P27Klpl expression was increased at 8h and further increased up to 24h following rhIL-6 
treatment (Figure 4 25a, lower panel, n=4)
4 3 6 Inhibition o f IL-6 Stim ulated STA T3 A ctivation In Vitro
Having established that inhibition o f a MEK-ERK signalling pathway did not alter 
rhIL-6 stimulated p 2 lwafl/c,pl and p27ICipl expression in H4IIE cells, inhibition of 
STAT3 activation was next addressed In an initial attempt to inhibit STAT3, an
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Figure 4.23 PD98059 (M EK inhibitor) treatm ent of H 4IIE (HCC) cells abolishes 
rhIL-6 stimulation of M EK activity in vitro a) Representative Western blot analysis 
performed on cell lysates prepared from cultured H4IIE cells in the a) presence or b) 
absence o f  PD98059 using an antibody specific against active (phospho-) ERK 1/2 
(pERK 1/2, upper panel) or total ERK 1/2 (lower panel) H4IIE cells were isolated and 
punfied from in vivo HCC tissue and cultured prior to treatment with a) PD98059 
(20|aM) or b) DMSO (control, ljiL/mL) in serum free media for lh  Cells were then 
treated with rhIL-6 (50ng/mL) for varying time periods (0-120 mins) Cell lysate from 
quiesced H4IIE cells stimulated for 10 mins with serum was used as positive control 
(CTRL) forpERK 1/2
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Figure 4 24 R hIL -6 stim ulation o f STAT3 activity is not altered by PD 98059  
(M E K  inhibitor) treatm ent o f H 4IIE  (H C C ) cells in vitro. a) Representative Western 
blot analysis performed on cell lysates prepared from cultured H4IIE cells in the a) 
presence or b) absence of PD98059 using an antibody specific against active (phospho) 
STAT3 (pSTAT3, upper panel) or total STAT3 (lower panel) H4IIE cells were isolated 
and purified from in vivo HCC tissue and cultured prior to treatment with a) PD98059 
(20pM) or b) DMSO (control, l|iL/mL) in serum free media for lh  Cells were then 
treated with rhIL-6 (50ng/mL) for varying time periods (0-120 mins) Cell lysate from 
H4IIE cells stimulated for lh  with rhIL-6 was used as positive control (CTRL) for 
pSTAT3
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Figure 4 25 PD 98059 (M E K  inhibitor) treatm ent o f H 4IIE  (H C C ) cells does not 
inhibit the rhIL-6 stim ulated expression o f p 2 lwafl/cipI and p27 pI in vitro. a)
Representative Western blot analysis performed on cell lysates prepared from cultured 
H4IIE cells m the a) presence or b) absence o f PD98059 using an antibody specific 
against p21wafl/cipl (upper panel) or p27KlpI (lower panel) H4IIE cells were isolated and 
purified from in vivo HCC tissue and cultured prior to treatment with a) PD98059 
(20|iM) or b) DMSO (control, 1 jiL/mL) in serum free media for Ih Cells were then 
treated with rhIL-6 (50ng/mL) for varying time periods (0-24h)
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overexpression vector for dominant negative STAT3 was transiently transfected into 
H4IIE cells. pEFHASTAT3F expresses an HA tagged STAT3 (STAT3F) in which the 
tyrosine residue at position 705 has been replaced with a phenylalanine residue 
preventing its phosphorylation/activation. Control cells were transfected with the 
expression vector pEFHASTAT3 containing cDNA coding for HA tagged wild type 
STAT3. The optimum method for H41IE transfection had been previously determined 
in our laboratory using a series o f luciferase transfections and these parameters were 
used in these experiments. Highest levels o f transfection were previously obtained 
using 20jig lipofectamine/6ng of plasmid DNA/reaction in ImL o f media on an 80- 
90% confluent well in 6 well plates. In previous experiments, cells were incubated with 
this mixture for a period o f 20h prior to addition o f high serum media (HSM). 
Maximum luciferase activity was observed 48h post HSM addition. H4IIE cells were 
cultured as previously and transiently transfected with pEFHASTAT3F or 
pEFHASTAT3 expression vectors under these conditions. High levels o f cell death 
(-80-90%) occurred when II4IIE cells were incubated with transfection mixture for a 
period o f 20h. In all subsequent experiments an incubation of 5h with plasmid 
DNA/lipofectamine was used prior to addition o f HSM. This minimised cell death 
(—10-15% total cell death) in the H4IIE population. Once transfected, cells were 
maintained in HSM for 40h prior to quiescing for 24h in serum free media. Cells were 
then treated with rhIL-6 (50ng/mL) and cell lysates collected at varying time points. 
Immunoblotting specific against the HA-tag was then performed on cell lysates to 
determine if the cells were expressing the dominant negative or wild type STAT3. 
Despite continued efforts, the HA-Tag could not be detected in the H4IIE lysates from 
cells transfected with either pEFHASTAT3F (Figure 4.26a, n=5) or pEFHASTA'D 
(Figure 4.26b, n=5). Furthermore, Western blotting for active STAT3 in these lysates 
indicated that STAT3 was activated by rhIL-6 stimulation with no differences in
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Figure 4 26 H A -T ag w as not detectable in cell lysates o f H 4IIE  (H C C ) cells 
transfected w ith  H A -tagged w ild  type expressing or H A -tagged dom inant negative  
expressing STA T3 plasm ids in vitro Representative Western blot analysis performed 
on cell lysates prepared from a) pEFHASTAT3F transfected (STAT3 dominant 
negative expression vector) or b) pEFHASTAT3 transfected (STAT3 wild type 
expression vector) H4IIE cells using an antibody specific against active HA-Tag H4irE 
cells were isolated and purified from in vivo HCC tissue and cultured prior to 
transfection with pEFHASTAT3F or pEFHASTAT3 expression vectors After 40h in 
culture cells were quiesced in SFM for 24h and then treated with rhIL-6 (50ng/mL) for 
varying time periods (0-120 mins) Non transfected H4IIE cell lysates were loaded as 
control (CTRL)
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expression profile being observed between dominant negative and wild type 
transfcctants (Figure 4.27, n=4). Due to the low efficiency and the inherent difficulties 
associated with the transfection o f this cell type, other means to STAT3 inhibition were 
sought.
To counter the problems associated with transfection AG490, a specific 
inhibitor o f Jak activity, was next used to inhibit rhIL-6 stimulation o f STAT3 in H4IIE 
cells in vitro. To establish the parameters for optimum STAT3 inhibition. H4I1E cells 
were pretreated with AG490 (0-150nM) for lh  prior to stimulation o f cells with rhIL-6 
(50ng/mL). Cell lysates were collected lh post-rhIL-6 treatment, equalised for protein 
content and then analysed for pSTAT3 expression by Western blot. AG490 abrogated 
rhIL-6 dependent STAT3 activation, decreases in pSTAT3 detection being observed at 
a concentration o f 50^M AG490 and decreasing further to 19.20±9.57% o f untreated at 
IOOjiM (Figure 4.28, n=4). Pretreatment o f H4IIE cells with the highest dose o f AG490 
(150fLiM) altered cell morphology and was not used. 114IIE cells were cultured as 
previously and pretreated with AG490 or DMSO (0.6jiL/mL; vehicle) for lh followed 
by rhIL-6 over a 24h period. Cell lysates were collected at varying time points and 
analysed for STAT3 and ERK activation and p21wafl cipI and p27klpl expression by 
Western blot analysis. Treatment with rhIL-6 in the presence of DMSO increased 
STAT3 activation at 5 mins, reaching a maximal response at 40 to 60 mins in the 
absence of changes in total STAT3 expression (Figure 4.29b, n=4). In contrast, rhIL-6 
treatment in AG490 pretreated II4IIE cells led to an ablated phosphorylation o f STAT3 
following the same activation profile (Figure 4 .29a upper panel, n=4). AG490 
treatment did not alter total STAT3 expression (Figure 4 .29a lower panel).
Immunoblotting for pERK 1/2 was next performed to establish the effects o f 
AG490 on its activation profile following rhIL-6 treatment. Recombinant human 1L-6 
stimulated ERK 1/2 activation in the presence o f DMSO (0.6nL/mL; Figure 4.30b,
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Figure 4 27 T ransfection o f H 4IIE  (H C C ) cells w ith  a plasm id expressing  
dom inant negative STAT3 failed to inhibit rhIL-6 stim ulation o f STAT3 activity  
in vitro a) Representative Western blot analysis performed on cell lysates prepared 
from cultured pEFHASTAT3F transfected (STAT3 dominant negative expression 
vector) H4IIE cells using an antibody specific against active (phospho-) STAT3 
(pSTAT3) H4IIE cells were isolated and purified from in vivo HCC tissue and cultured 
prior to transfection with pEFHASTAT3F After 40h in culture cells were quiesced in 
SFM for 24h and then treated with rhIL-6 (50ng/mL) for varying time periods (0-120 
mins) b) Representative Western blot analysis performed on cell lysate samples 
prepared from cultured pEFHASTAT3 transfected (STAT3 wild type expression 
vector) H4IIE cells using an antibody specific against active (phospho-) STAT3 
(pSTAT3) H4IIE cells were isolated and purified from in vivo HCC tissue and cultured 
prior to transfection with pEFHASTAT3 After 60h in culture cells were treated with 
rhIL-6 (50ng/mL) for vaiying time periods (0-120 mins) Cell lysate from H4IIE cells 
stimulated for lh  with rhIL-6 was used as positive control (CTRL) for pSTAT3
134
0 5 10 50 100 CTRL
AG490 Concentration QiM)
Figure 4 28 A G 490 inhibits rhIL-6 stim ulation o f STA T3 activity in a dose  
dependent m anner in vitro. Representative Western blot analysis performed on cell 
lysates prepared from cultured H4IIE cells in the presence of varying concentrations of 
AG490 using an antibody specific against active (phospho-) STAT3 (pSTAT3) H4IIE 
cells were isolated and purified from in vivo HCC tissue and cultured prior to treatment 
with varying concentrations o f AG490 (0-100(jlM) in serum free media for lh  Cells 
were then treated with rhIL-6 (50ng/mL) for lh  Cell lysate from H4IIE cells stimulated 
for lh  with rhIL-6 was used as positive control (CTRL) for pSTAT3
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Figure 4.29 R hIL-6 stim ulation o f STAT3 activity is ablated by AG 490 (Jak  
inhibitor) treatm ent o f H 4IIE  (H C C ) cells in vitro. a) Representative Western blot 
analysis performed on cell lysates prepared from cultured H4IIE cells in the a) presence 
or b) absence of AG490 using an antibody specific against active (phospho-) STAT3 
(pSTAT3, upper panel) or total STAT3 (lower panel) H4IIE cells were isolated and 
purified from in vivo HCC tissue and cultured pnor to treatment with a) AG490 
(lOOj^M) or b) DMSO (control, 0 6|iL/mL) in serum free media for lh  Cells were then 
treated with rhIL-6 (50ng/mL) for varying time periods (0-120 mins) Cell lysate from 
H4IIE cells stimulated for lh  with rhIL-6 was used as positive control (CTRL) for 
pSTAT3
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Figure 4 30 R hIL -6 ability to stim ulate M E K  activity is not altered by A G 490 (Jak  
inhibitor) treatm ent o f H 4IIE  (H C C ) cells in vitro, a) Representative Western blot 
analysis performed on cell lysates prepared from cultured H4IIE cells in the a) presence 
or b) absence of AG490 using an antibody specific against active (phospho-) ERK 1/2 
(pERK 1/2, upper panel) or total ERK 1/2 (lower panel) H4IIE cells were isolated and 
purified from in vivo HCC tissue and cultured prior to treatment with a) AG490 
(100|iM) or b) DMSO (control, 0 6fi.L/mL) in serum free media for lh  Cells were then 
treated with rhIL-6 (50ng/mL) for varying time periods (0-120 mins) Cell lysate from 
quiesced H4IIE cells stimulated for 10 mins with serum was used as positive control 
(CTRL) for pERK 1/2
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n=4) was similar to that previously established in DMSO pretreated H4IIE cells 
(1 jil/mL, Figure 4 24b) The early phase o f ERK 1/2 activation (2-5 mins) was agam 
abolished in the presence o f DMSO while pERK 1/2 expression was increased at 40 
mins returning towards baseline expression by 60 mins post IL-6 treatment (Figure 
4 30b, upper panel, n=4) DMSO did not alter the expression of total ERK 1/2 (Figure 
4 30b, lower panel, n=4) Recombinant human IL-6 stimulation of AG490 pretreated 
H4IIE cells also resulted m increased levels of pERK 1/2 at 40 mins However, in these 
cells the increased ERK activity was sustained and remained upregulated up to 2h after 
rhIL-6 treatment (Figure 4 30a, upper panel, n=4) Total ERK 1/2 expression remained 
unchanged throughout this time period (Figure 4 30a, lower panel, n=4)
Expression of p21wafI/cipl and p27K,pl was next compared in AG490 pretreated 
and control (DMSO pretreated) H4IIE cells Immunoblotting of cell lysates using 
antibodies specific against p 2 lwafi/cipl m control H4IIE cells demonstrated that DMSO 
did not affect rhIL-6 stimulated p21wafl/c,pl expression (Figure 4 31b, upper panel, n=4) 
As observed m cells treated in the absence o f DMSO (Figure 4 18a), rhIL-6 caused an 
upregulation of p21wafl/cipl at 4h which was further increased at 8h before returning to 
baseline expression at 24h (Figure 4 31b, upper panel, n=4) Similarly, the upregulation 
o f p27Kipl expression in response to rhIL-6 stimulation was maintained in DMSO 
pretreated cells, increased levels being detected at 8h and 24h after rhIL-6 stimulation 
(Figure 4 31b, lower panel, n=4) Treatment of H4IIE cells with AG490 pnor to rhIL-6 
stimulation blocked the upregulation in p 2 lwafi/cipt observed in control cells (Figure 
4 31a, upper panel, n=4) In contrast, AG490 treatment did not alter rhIL-6 stimulated 
p27Klpl expression induced by rhIL-6 stimulation as compared to control cells (Figure 
4 31a, lower panel, n=4)
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Figure 4 31 A G 490 (Jak inhibitor) treatm ent o f H 4IIE  (H C C ) cells inhibits the 
rhIL-6 stim ulated expression o f p 2 lwafI/cipI but does not affect the expression o f  
p27K,pl in vitro a) Representative Western blot analysis performed on cell lysates 
prepared from cultured H4IIE cells in the a) presence or b) absence of AG490 using an 
antibody specific against p 2 lwaf,/c,pi (upper panel) or p27KtpI (lower panel) H4IIE cells 
were isolated and purified from in vivo HCC tissue and cultured prior to treatment with 
a) AG490 (IOOjjM) or b) DMSO (control, 0 6jiL/mL) in serum free media for lh  Cells 
were then treated with rhIL-6 (50ng/mL) for varying time periods (0-24h) KNRK 
nuclear extract was used as a positive control for both p 2 lwafl/cipl
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Previous studies have established a critical role for IL-6 signalling during 
hepatocyte proliferation (Streetz et a l , 2000, Fausto, 2000) In contrast, the role of IL-6 
in HCC remains controversial and poorly defined Data included in these studies 
establishes clear differences between IL-6 signalling pathways m HCC cells as 
compared to isolated cultured hepatocytes IL-6 signalling initiates Jak-STAT and Ras- 
MAPK signalling cascades in both normal and transformed liver cells While the Jak- 
STAT pathway was similarly activated in both cell types, IL-6 had a distinctive 
biphasic effect on ERK activity m HCC cells versus normal hepatocytes Furthermore, 
IL-6 treatment suppressed Cyclin D1 expression in hepatocytes but did not effect the 
expression of any of the other cell cycle regulatory proteins examined (cyclins, cdks 
and PCNA) In HCC cells, cyclin, cdk and PCNA expression was not affected by IL-6 
stimulation however IL-6 treatment did result m the upregulation o f the cdk inhibitors, 
P21wafl/C,pl and p27Kipl, an effect unseen in hepatocytes This increase in cdk inhibitor 
expression was associated with decreased cdk2 and cdk4 activity and reduced 
phosphorylation of their primary substrate, the retinoblastoma protein (Rb) IL-6 
stimulated p21wafl/cipl expression was abrogated by inhibition o f STAT3 activity, while 
p27Klpl expression was not affected by inhibition of the MAPK pathway or partial 
inhibition o f the Jak-STAT signalling cascade
Normally hepatocytes are long lived and rarely divide in vivo yet retain the 
ability to proliferate in response to infection and toxic injury (Taub, 2004, Fausto, 
2000) Two-thirds partial hepatectomy (the removal of approximately 70% of the liver) 
induces synchronised cell cycle entry o f approximately 95% of hepatic cells resulting in 
the complete replacement of the resected organ mass (Taub, 2004) Unlike cells of 
proliferative tissues, hepatocytes are generally quiescent and rest in the GO phase o f the 
cell cycle (Fausto, 2000) In liver regeneration, hepatocytes are primed to exit GO and
4.4 Discussion
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enter the G1 phase o f the cell cycle in preparation for DNA synthesis and mitosis The 
primed hepatocytes then respond to a variety of growth factors including transforming 
growth factor-a (TGF-a), hepatocyte growth factor (HGF) and epidermal growth factor 
(EGF) which stimulate the hepatocytes to overcome the G1 restnction point and 
commit to DNA replication (Fausto, 2000, Streetz et a l , 2000, Taub, 2004) IL-6 is a 
key cytokine in this priming process Reduced liver mass causes increased serum TNF- 
a levels which stimulate IL-6 expression and downstream STAT3 activation STAT3 
activation, in collaboration with additional transcription factors such as C/BBPp, 
enhance the expression of other factors such as NF-IL-6, c-myc, c-fos, Jun-B, IRF-1, 
and others, enabling the resting hepatocytes to progress into cell proliferation (Streetz 
et a l , 2000, Fausto, 2000) Activation of STAT3 and early gene expression is absent in 
IL-6-/- mice in which defective regeneration is reported following partial hepatectomy 
(Cressman et a l , 1996) Further reports demonstrate that the MAPK pathway activated 
during liver regeneration is stimulated by IL-6 signalling and is linked to G1 
progression (Li et a l , 2001, Talarmin et a l , 1999) More recently, Zimmers et al report 
that IL-6 can act as a complete mitogen in the liver In this model circulating IL-6 
levels were mcreased in nude mice using a transfected CHO cell line, leading to 
dramatic hepatomegaly and hepatocyte hyperplasia in the absence of liver injury 
(Zimmers et al 5 2003) In support o f this observation, previous research using double 
transgenic mice expressing human IL-6 and human soluble IL-6R under liver specific 
promoters also demonstrate hepatomegaly, hepatic hyperplasia and the presence of 
hepatic adenomas (Maione et a l , 1998, Schirmacher et a l , 1998)
Previous studies have demonstrated that the process of hepatocyte isolation 
(collagenase digestion) primes hepatocytes for replication as evidenced by expression 
of immediate early genes such as the proto-oncogenes, c-fos and c-jun, resulting in the 
entry o f these cells into the G1 phase of the cell cycle The presence o f growth factors
is required to stimulate the hepatocytes into DNA replication (S phase entry) in vitro 
reflecting the in vivo model o f liver regeneration (Albrecht and Hansen, 1999, Loyer et 
a l , 1996) Growth factors such as EGF-a and TGF-a lead to the orderly activation of 
key cell cycle regulatory proteins that control the transition through the G1 restriction 
point after which hepatocytes are fully committed to mitogen independent DNA 
synthesis and mitosis (Fausto, 2000, Streetz et a l , 2000, Loyer et a l , 1996) The 
expression of hepatocyte cyclm D1 mRNA increases at the G1 restriction point while 
cyclin A, cdk2, cdc2 p34 and cyclm D3 mRNA becomes detectable, or increase, in late 
G1/early S phase following mitogen stimulation In the absence of growth factors, 
expression of these proteins (except cyclm D3 and cdk4) does not occur (Loyer et a l , 
1996, Albrecht and Hansen, 1999) Surprisingly, in the current study, expression of 
cyclm D l, cyclm A and cyclin D3 were all increased at 44h after plating in hepatocyte 
cultures in the absence o f growth factors While these all serve as markers of cell cycle 
entry, the expression of cyclm D l alone has been shown to be sufficient for passage 
through the G1 restriction point in hepatocytes (Albrecht and Hansen, 1999) If indeed 
these hepatocytes are proliferating, the source of growth stimuli is unclear The 
presence o f FBS during the first four hours o f culture has previously been shown not to 
stimulate DNA synthesis in hepatocytes (Loyer et a l , 1996) Furthermore collagenase 
treatment, cell washing or cell seeding in culture medium do not induce cyclm Dl 
expression (Loyer et a l , 1996) It is worth noting that much of the previous research 
has been performed on hepatocyte populations which have been isolated by collagenase 
digestion and then further purified using a Percoll gradient (Loyer et a l , 1996, Albrecht 
and Hansen, 1999) In the current set o f experiments the hepatocyte population from 
collagenase digestion without further purification was used The population of non 
parenchymal cells such as stellate and Kupffer cells can reach up to 20% of these 
cultures Further enrichment of hepatocyte cultures with non parenchymal cells and
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incubation of hepatocytes with media from non parenchymal cell cultures have been 
shown to mcrease hepatocyte DNA synthesis (Hasmall et a l , 2000) In vivo, non 
parenchymal cells act as the mam source of hepatic cytokines and growth factors such 
as HGF and TNF-a (Taub, 2004) It is possible that secretion of growth factors by other 
cell populations in these cultures gave rise to the increased cell cycle activity observed 
Furthermore, it is worth noting that IL-6 treatment was capable of suppressing cyclin 
D1 expression in vitro in the absence o f effects on other cell cycle regulatory proteins 
studied While previous studies indicate a stimulatory role for IL-6 in the proliferation 
of cultured hepatocytes (Kuma et a l , 1990), several others report an inhibitory effect of 
IL-6 on DNA synthesis, even after growth factor stimulation in vitro (Satoh and 
Yamazaki, 1992, Kordula et a l , 1991) The exact mechanisms behind the inhibition of 
cyclin D1 expression by IL-6 in this study is unclear however, it may be associated 
with an inhibitory effect on hepatocyte proliferation in this culture system
Progression through the cell cycle is tightly controlled by cyclin dependent 
kinases (cdks) (Morgan, 1995) Cyclins associate with cdks and are the primary 
regulators of cdk activity (Sherr and Roberts, 1999, Morgan, 1995) The activation of 
cdk4 plays an important role m the passage through the G1 restriction point when the 
cell becomes committed to proceed through the cell cycle, while cdk2 activation plays 
an essential role in the transition into S phase and DNA synthesis Cyclin D1 
expression, which is induced during G1 phase in response to various mitogens, 
complexes with and activates cdk4 Cyclin dependent kinase 2 is regulated primarily by 
cyclin E and cyclin A during G l/S transition and S phase respectively (Sherr and 
Roberts, 1999, Morgan, 1995, Sherr and Roberts, 1995) Retmoblastoma protein (Rb) 
is the major target for cyclin dependent kinase activity and is phosphorylated by both 
cyclin D dependent kinases and by cdk2 Hyperphosphorylation of the Rb protein 
disrupts it association with E2F transcription factors which, once released, stimulates
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the expression of a series of genes required for DNA synthesis (Sherr and Roberts, 
1999, Morgan, 1995, Sherr and Roberts, 1995) In the present study IL-6 stimulation 
resulted in decreased phosphorylation o f Rb protein when compared to untreated HCC 
cells 4h after treatment which was maintained for up to 24h following addition 
Analysis of G l/S phase cyclin and cdk expression demonstrated no significant change 
in these regulatory proteins following IL-6 addition Increased levels o f the cyclin 
dependent kinase inhibitor p21wafl/c,pl were detected at 4h before peaking at 8h 
following IL-6 treatment corresponding with the decreases in hyperphosphorylated Rb 
protein detection Increased p27Kipl expression was detected at both 8h and 24h after IL- 
6 addition P27Kipl and p21wafl/cipl are members o f the Cip/Kip family of cdk inhibitors 
that can affect the activity of cyclin D-, E- and A-dependent kinases through binding o f 
both the cyclin and cdk subunits (Sherr and Roberts, 1999) Further analysis o f cdk 
activity in the current model demonstrates that IL-6 in HCC cells reduces the activity of 
both cdk2 and cdk4 in vitro Collectively this data suggests an inhibitory effect of IL-6 
treatment on cell cycle progression in these HCC cells Indeed, several other reports 
have identified a similar inhibitory effect of IL-6 in other cancer cells which have been 
further associated with the upregulation of p27K,pl and p21wafl/cipl (Kortylewski et a l , 
1999, Klausen et a l , 2000, Florenes et a l , 1999, Bellido et a l , 1998)
The addition of exogenous IL-6 activates identical intracellular signalling 
pathways (JAK-STAT and Ras-MAPK) m both transformed H4IIE cells and primary 
hepatocytes in culture Despite these apparent similarities in signalling pathways, 
treatment of cells with IL-6 only results m increased expression of the cdk inhibitors 
P21wafl/C,pl and p27Kipl in transformed hepatic cells In this study ERK 1/2 activation in 
H4IIE cells and cultured primary rat hepatocytes was observed following IL-6 
stimulation However, the temporal patterns o f ERK phosphorylation differed greatly 
between these two cell types A distinctive transient biphasic phosphorylation of ERK
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1/2 was observed in H4I1E cells as compared to the monophasic 
phosphorylation/activation in primary hepatocytes. Several reports have now identified 
the critical temporal profile o f ERK activation in mediating cell differentiation versus 
cellular proliferation (Weber et al., 1997; Meloche et ah, 1992; Cook and McCormick, 
1996; Tamemoto et al., 1992) whereby sustained ERK activation is implicated in ERK 
regulated cellular proliferation (Cook and McCormick, 1996; Meloche et al., 1992).
Both the Jak-STAT and MAPK pathways have been implicated in upregulating 
p2 paii c.pl p27k'r ‘ in response to IL-6 in other cell types (Kortylewski et al., 1999; 
Klausen et al., 2000; Florenes et al., 1999; Bellido et al., 1998). Furthermore, 
expression of p21"d" apl and p27k'rl has been linked to STAT3 activation (Bellido et 
al., 1998; Johannessen et al., 1999; de Koning et al., 2000; Kortylewski et al., 1999) 
and ERK 1/2 activity (Bottazzi et al., 1999; Dixon et al., 2002; Klausen et al., 2000) 
stimulated by other ligands. In II4IIE cells inhibition o f IL-6 stimulated ERK 1/2 
activity using PD98059 had no effect on p 2 P ‘’fl c,pl or p27kipl expression. Initially, in 
an effort to elucidate the involvement o f the STAT3 pathway in this model, H4IIE cells 
were transiently transfected with a dominant negative STAT3 (HASTAT3F) expression 
vector. In this mutant STAT3, the tyrosine residue at position 705 has been mutated to 
phenylalanine (Nakajima et al., 1996). Phosphorylation o f Tyr705 is required for 
dimerisation and nuclear translocation. Despite continued efforts this mutant form of 
STAT3 was not detectable in H4IIE cell lysates and IL-6 continued to stimulate STAT3 
activity in the transfected cells. Further work carried out in our research laboratory has 
demonstrated through the use o f LacZ detection systems that maximum achievable 
transient transfection efficiency could not be increased past 1% of the total cell 
population in this cell type. This would explain the lack o f HASTAT3F expression in 
the current study. Ideally stable transfections would prove more useful in this work
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however this expression vector, in its current state, lacks selection markers for animal 
cell culture and hence could not be used in this way
AG490, an inhibitor of Jak activity, was used as an alternative method to inhibit 
the IL-6 induced STAT3 pathway While complete abolishment of STAT3 activity was 
not possible m these cells, AG490 did allow a partial inhibition of STAT3 activity 
Phosphorylated STAT3 levels in AG490 pretreated cells decreased by approximately 
80% versus untreated cells following IL-6 treatment It is worth nothing that AG490 
mediated inhibition of STAT3 phosphorylation was accompanied by altered pERK 1/2 
expression Phosphorylation of ERK 1/2 was sustained up to 2h after stimulation m 
AG490 pretreated cells compared to a peak in phosphorylation at 40-60 mins observed 
m untreated cells after IL-6 addition Similar changes in ERK 1/2 activation have been 
reported when STAT3 activity is inhibited by AG490 or genetic means in other 
models, this effect being potentially linked to both decreased SOCS expression and 
decreased expression of phosphatases such as mitogen activated protein kinase 
phosphatase 1 (Ernst et a l , 2001, Sandberg et a l , 2004) The AG490 mediated 
reduction in STAT3 activation was sufficient to ablate p21wafl/upl expression indicating 
that the IL-6 stimulated activation of STAT3 is responsible for its upregulation in 
H4IIE cells Interestingly, IL-6 stimulated increases in p27K,pl expression in H4IIE 
cells were maintained despite decreased pSTAT3 The underlying mechanism by which 
P27Klpl expression is modulated in this cell type after IL-6 addition remains unclear 
Potentially, lower levels of active STAT3 are sufficient for p27Klpl upregulation, 
however, this could only be proved by complete inhibition of STAT3 activity which 
was not possible in the current studies Furthermore, other pathways may be regulated 
by IL-6 addition in this cell type STAT3 and MAPK are the primary targets after IL-6 
stimulation however STAT5 (Klausen et a l , 2000), PI3K (Chen et a l , 1999) and 
ST ATI (Kortylewski et a l , 1999) have been shown to be activated in other models
146
Furthermore, both PI3K and STATS have the ability to alter p27K,pl expression 
(Klausen et a l , 2000, Banerji et a l , 2001, Zhu et a l , 2003, Barata et a l , 2004) Overall, 
a more efficient system for STAT3 inhibition, in addition to further research on other 
potential activation targets for IL-6 within these cells, is required to fully establish the 
mechanism mvolved m the upregulation o f p27Kipl
H4IIE cells grown in culture do retain characteristics observed in vivo even with 
continual passaging H4IIE cells express decreased levels of both components of the 
IL-6 receptor in vitro The observed alterations in expression of IL-6 signalling 
components in resected tumours (chapter 3) led to the current study in which IL-6 
signalling in H4IIE cells and hepatocytes in vitro was compared and contrasted It has 
been established that IL-6 can activate similar pathways in both cell types however 
with different activation profiles Furthermore, it has been observed that IL-6 
upregulated the expression of the cdk inhibitors p 2 lwafl/cipl and p27Kipl in H4IIE cells, 
an effect that was unseen in hepatocytes This increase in cdk inhibitors also correlated 
with decreased cdk activity and reduced levels o f phosphorylation of their target, Rb 
Taken together, these data are suggestive of an inhibitory effect of IL-6 on cell cycle 
progression in H4IIE cells
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Chapter 5: Growth Regulatory Effects of IL-6 in HCC
5.1 Introduction
HCC is characterised by altered expression of components o f the IL-6 signalling 
cascade in vivo and in vitro (chapters 3 & 4) This includes downregulated expression 
of IL-6 receptor components and upregulated IL-6 production and secretion 
Nevertheless, IL-6 treatment o f HCC cells in vitro activates Jak-STAT and Ras-MAPK 
pathways leading to increased expression of the cdk inhibitors, p21wafl/c,pl and p27K,pl 
(chapter 4) Decreased phosphorylation of the Rb protein and attenuated cdk activity 
were observed concomitant with this upregulation Collectively, these events are 
potentially inhibitory on cell cycle progression in H4IIE cells, however, the 
consequences for cell proliferation remain to be determined
Interleukin-6 has been identified as a growth factor for several cancer cell types 
including renal cell carcinoma (Miki et a l , 1989), multiple myeloma (Kawano et a l , 
1988) and plasmacytoma (Nordan et a l , 1987) In contrast, IL-6 is reported to inhibit 
the growth of other cancer cells Growth arrest and terminal differentiation is induced 
in M l myeloid leukaemia cells, an effect that is blocked by the expression of dominant 
negative forms of STAT3 (Minami et a l , 1996, Fukada et a l , 1996) In addition, IL-6 
induces an anti-proliferative effect in early stage human melanoma cells associated 
with STAT-mediated transcriptional up-regulation of p27Klpl (Kortylewski et a l , 1999) 
and p 2 lwati/cipl (Florenes et a l , 1999) Similarly, IL-6-induced growth inhibition has 
been reported in prostate cancer (LNCaP) (Spiotto and Chung, 2000), human breast 
carcinoma cells (Novick et a l , 1992, Chen et a l , 1988) and a number of 
leukaemia/lymphoma cell lines (Chen et a l , 1988) In hepatoma cells the effects o f IL-
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6 on downstream effector pathways and cell proliferation remains uncertain 
Stimulation o f the IL-6Ra in human HepG2 cells results in the accumulation o f p27K,pl 
and growth arrest in the Gl phase (Klausen et a l , 2000) an inhibitory effect similar to 
that observed by Kim et al in the H-35 rat hepatoma cell line however the underlying 
mechanism of this inhibition was not determined (Kim and Baumann, 1999) In 
contrast IL-6 has been indicated as an autocrine growth factor in hepatoma cells where 
IL-6 producing HCC-M hepatoma cell proliferation is inhibited following IL-6 
antisense treatment (Kumagai et a l , 2002) Interleukin-6 is also implicated in cell 
survival during hepatic injury and inhibits TGF-p-induced apoptosis in the human 
hepatoma derived Hep3B cell line (Chen et a l , 1999)
The elucidation of IL-6 signalling pathways and their downstream effects in 
H4IIE cells has established an upregulation of cdk inhibitors p21wafl/c,pl and p27Kipl and 
a downregulation of cdk activity (chapter 4) The expression of both p 2 iwafl/c,pl and 
p27K,pl has been linked to IL-6 induced cell cycle arrest in other tumour cells (Klausen 
et a l , 2000, Kortylewski et a l , 1999, Florenes et a l , 1999) In the current studies, the 
effects of IL-6 treatment on cell proliferation were examined
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5.2 Methods
5 2 1 1  M aterials
Recombinant human IL-6 (rhIL-6), phosphate buffered saline (PBS) and pnme 
foetal bovine serum (FBS) were purchased from Biosource International (Camarillo, 
CA, USA) Thymidine methyl-[3H] was purchased from Perkin Elmer Life Sciences 
(Boston, MA, USA) Scintisafe Econo-1 scintillation fluid and scintillation vials were 
purchased from Fisher Scientific (Pittsburgh, PA, USA) Ether, ethanol, trichloroacetic 
acid and sodium hydroxide were purchased from Sigma-Aldnch (St Louis, MO, USA)
5 2.1 2 M ethod
H4IIE cells were isolated and cultured as described in section 2 2 Cells were 
seeded in 24 well plates and grown to approximately 80% confluency in high serum 
media (HSM) Cells were washed twice with PBS (37°C, pH 7 4) and then quiesced for 
24h in serum free media (SFM) SFM was then removed and replaced with media 
containing incremental increases in FBS levels (0 1-10% (v/v) FBS) for 20h At this 
point [3H] thymidine (l|iCi/m l) was added to each well for a further 4h For the IL-6 
treated group, parallel expenments were performed with the exception that cells were 
pretreated with rhlL-6 (20ng/ml) for 4h pnor to replacement o f SFM with media 
containing incremental increases in FBS levels (0 1-10% (v/v) FBS) and rhIL-6 
(20ng/ml) After incubation with [3H] thymidine, cells were washed three times in 10% 
(v/v) tncholoroactetic acid followed by 3 washes m ether ethanol (2 1) and allowed to 
dry Cells were then solubilised in 500^L 1M NaOH 100|iL of this solution was added 
to 5mL of scintillation fluid Counts per minute (cpm) for all samples were determined 
using a Beckman LS6000SC scintillation counter (Fullerton, CA, USA)
5.2.1 Nuclear Thymidine Incorporation
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5.2.2 A lam ar Blue Proliferation Assay 
5 2 2 1  M aterials
Alamar Blue was purchased from Biosource International (Camarillo, CA, 
USA) Microplate reader (jiQuant) was purchased from Biotek Instruments (Winooski, 
VT, USA)
5 2 2 2 M ethod
H4IIE cells were isolated and cultured as described in section 2 2 Cells were 
seeded in 96 well plates at 5 x 103 cells/well and grown overnight in HSM Cells were 
washed twice with PBS (37°C, pH 7 4) and then quiesced in SFM for 24h Cells were 
next pretreated with rhIL-6 (50ng/ml) for a period o f 4h prior to FBS stimulation (1% 
(v/v) FBS) Media (with or without IL-6) was refreshed daily After 48h, 10% of cell 
culture media in each well was replaced with Alamar Blue and 2h later the absorbance 
at 570nm and 600nm was measured using a jiQuant microplate reader Negative control 
wells were established in the absence of cells (media with Alamar Blue alone) 
Percentage reduction of Alamar Blue was calculated using the following equation 
where ^i=570nm and ^2~600nm
% Re duced = ^ ^  ~ ^  ^  , 0Q/0IN.C UUCta -  , w v , w V xiuo
V reA  AA ¿2 ) “  KA 4  )
Where
(s r e A )= 155,677 (Molar extinction coefficient o f reduced Alamar Blue at 570nm) 
{£red^i)~ 14,652 (Molar extinction coefficient o f reduced Alamar Blue at 600nm)
(£oxK ) = 80,586 (Molar extinction coefficient o f oxidised Alamar Blue at 570nm)
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E^ox^i)~ 117,216 (Molar extinction coefficient of oxidised Alamar Blue at 600nm)
)= Absorbance of test wells at 570nm 
{A ^ )=  Absorbance of test wells at 600nm 
(.Af^ ) =  Absorbance o f negative control wells at 570nm 
(/i'yl2)= Absorbance of negative control wells at 600nm
5.2.3 Cell Counting
5 2.3 1 M aterials
Haemocytometer was purchased from Hausser Scientific (Horsham, PA, USA) 
Trypsin-EDTA was purchased from Sigma-Aldnch (St Louis, MO, USA)
5 2 3 2 M ethod
H4IIE cells were isolated and cultured as described m section 2 2 Cells were 
plated in 12 well plates in HSM and allowed to attach and proliferate until 30-35% 
confluency was achieved At this point HSM was removed, the cells were washed twice 
with PBS (37°C, pH 7 4) and SFM was added for 24h At the end of this period, plates 
were separated into two groups and left either untreated or were treated with rhlL-6 
(50ng/ml) for 4h SFM was then removed from all wells and 1% (v/v) FBS media or
1% (v/v) FBS media containing 50ng/ml rhIL-6 was added to each well daily At 24h
intervals, media was removed from three wells and the cells were detached using 
trypsm-EDTA Cell suspensions from each of the three wells were then combined and 
manually counted using a haemocytometer This procedure was repeated over a three
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day period and was repeated a minimum of four separate times per experimental 
condition
5.2.4 FACS Cell Cycle Analysis
5 2 41  M aterials
Bovine Serum Albumin (BSA) was purchased from Fisher Scientific 
(Pittsburgh, PA, USA) RNAse A, propidium iodide and sodium citrate were purchased 
from Sigma-Aldnch (St Louis, MO, USA) BD FACSCalibur flow cytometer and 
Modfit LT version 3 0 software was purchased from BD Biosciences (San Jose, CA, 
USA)
5 2 4 2 M ethod
H4IIE cells were isolated and cultured as described in section 2 2 Cells were 
seeded in 6 well plates and grown to approximately 80% confluency in high serum 
media (HSM) Cells were washed twice with PBS (37°C, pH 7 4) and then 
synchronised in SFM (media refreshed every 2 days) for 7 days At the end of this 
penod, plates were separated into two groups and left either untreated or were treated 
with rhIL-6 (50ng/ml) for 2h SFM was then removed from all wells and 2 5% (v/v) 
FBS media or 2 5% (v/v) FBS media containing 50ng/ml rhIL-6 was added to each 
well Samples for cell cycle analysis were collected at varying time points (0-46h) At 
each time point cells were trypsimsed, pelleted at 2500 x g and then resuspended m 
PBS containing 0 1% (v/v) BSA Cells were washed twice in PBS/0 1% (v/v) BSA and 
then cell concentration was adjusted to 1 5 x 106 cells/mL Cells were fixed with ice 
cold absolute ethanol (3mL ethanol added to lmL of cells) and rested on ice for 15 
mms prior to storage at 4°C Cells were centrifuged at 1000 x g and ethanol was 
removed Cell pellet was next resuspended in 250jiL of RNase A (0 7mg/mL) and then
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incubated at 37°C for 15 mins Cells were then treated with 250|iL of propidium iodide 
(50^ig/mL) and incubated at room temperature in darkness for lh  PBS (500jiL) was 
added to each sample prior to FACS analysis Cells were passed through a BD 
FACScalibur flow cytometer and gated based on side light scatter (particle density) vs 
forward light scatter (particle size) plots in addition to further gating based on FL2-A 
(total fluorescence) vs FL2-W (transit time) plots to discriminate single cell viable 
populations from aggregates and debris FL2-A data was modelled using Modfit LT 
version 3 0 cell cycle analysis software
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5 3 1  Effect of rhIL-6 on HCC Cell Proliferation In Vitro
To determine the effects o f rhIL-6 on HCC cell proliferation H4IIE cells were 
isolated, grown m culture and treated with rhIL-6 (20-50ng/ml) Nuclear [3H] 
thymidine incorporation, Alamar Blue reduction and cell numbers were then assayed as 
indices of cellular proliferation Treatment of quiescent H4IIE cells with FBS led to a 
dose dependent increase in nuclear [3H] thymidine incorporation, a significant mcrease 
being detected following treatment with 1% (v/v) FBS rising to a maximal effect with 
the use of 5-10% (v/v) FBS media (345±17% versus 0 1% (v/v) FBS media, n=4 per 
group, p<0 05, Figure 5 1a) In parallel experiments, cells were pretreated with 20ng/ml 
rhIL-6 for 4h At the end of this period, media FBS concentrations were adjusted to 
those used previously Under these conditions, 20ng/ml rhIL-6 significantly inhibited 
FBS stimulated nuclear [3H] thymidine incorporation at all doses (0 1-10% v/v) of FBS 
employed (Figure 5 lb, p<0 05, n=4 per group)
To confirm these data an Alamar Blue assay was next used to determine the 
metabolic rate o f cells as an index of proliferation The Alamar Blue assay is a 
colourimetric assay in which oxidised Alamar Blue (blue) is converted to its reduced 
form (red) in the presence of proliferating cells In this set o f experiments 1% (v/v) FBS 
was used to stimulate proliferation of H4IIE cells Higher concentrations o f FBS caused 
greater levels o f proliferation which resulted in an inversion of the colour change in this 
assay, the underlying cause of this effect was not determined These data demonstrated 
a significantly reduced level of proliferation of H4IIE cells in the presence of rhIL-6 as 
assessed by the decreased presence o f the reduced (red) form of Alamar Blue These 
data demonstrated decreased Alamar Blue reduction in HCC cells pretreated with rhlL-
6 followed by 1% (v/v) FBS as compared to 1% (v/v) FBS treated alone (94 28±0 9%
5.3 Results
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Figure 5 1 RhIL-6 inhibits DNA synthesis in H4IIE (HCC) cells in vitro Nuclear 
[3H] thymidine incorporation was determined as a measure of de novo DNA synthesis 
in H4IIE HCC cells in culture as a marker of cellular proliferation a) H4IIE cells were 
isolated from in vivo HCC tissue, cultured and quiesced for 24h (SFM) prior to 
treatment with culture media containing varying amounts o f FBS (0-10% v/v) for 24h 
(n=4 per group, *p<0 05) b) H4IIE cells were isolated from in vivo HCC tissue, 
cultured and quiesced for 24h (SFM) prior to treatment with rhIL-6 (20ng/ml) for 4h 
At this point media was replaced with culture media containing varying amounts of 
FBS (0-10% v/v) and rhIL-6 (20ng/ml) for 24h (n=4 per group)
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versus 105 37±0 21% respectively, values are given as percentage reduction versus 
control cells (untreated), p<0 05, n=4 per group, Figure 5 2)
Finally, sequential cell count experiments were performed m which cells were 
treated with either 1% (v/v) FBS or 1% (v/v) FBS and 50ng/ml rhIL-6 These data 
demonstrated significantly increasing cell numbers 1-3 days after addition of 1% (v/v) 
FBS as compared to day 0 (Figure 5 3, n=4 per group, p<0 05) Furthermore, 
throughout the three day experimental period, cell numbers were significantly higher in 
FBS alone as compared to FBS and rhIL-6 (Figure 5 3, n=4 per group, p<0 05)
5 3 2 Effect of rhIL-6 on HCC Cell Cycle Progression In Vitro
To determine the effects o f rhIL-6 on HCC cell cycle progression H4IIE cells were 
isolated, grown in culture and treated with rhIL-6 (50ng/ml) These cells were stained 
with propidium iodide and DNA content was measured by flow cytometry In order to 
acquire an accurate analysis of cell cycle events the cells were first synchronised by 
serum deprivation as initially described by Pardee (Pardee, 1974) This procedure 
synchronises cells in the G0/G1 phase o f the cell cycle In order to examine the effect 
of serum deprivation on H4IIE cell cycle progression and to establish the ideal length 
of time required to sufficiently synchronise these cells, H4IIE cells were cultured in 
SFM for varying time periods (2-8 days) The percentage population of H4IIE cells in 
the G0/G1 phase of the cell cycle was analysed at each time point After cultunng for 2 
days in SFM, 48 01±1 0% of the H4IIE cells were in the G0/G1 phase o f the cell cycle 
(Table 5 1, n=4) Extended serum depnvation significantly increased the cell 
population in the G0/G1 phase reaching 64 78±2 0% (n=4, p<0 05 versus 2 days) and 
78 12±0 98% (n=7, p<0 05 versus 2 days) after 6 and 7 days culture in SFM 
respectively While further culturing of H4IIE cells in SFM did significantly enhance 
the G0/G1 cell population (80 1±0 23% at 8 days, n=4, p<0 05 versus 7 days) the
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Figure 5.2 RhlL-6 inhibits II4IIE (IICC) cell proliferation as evidenced by Alamar 
Blue reduction in vitro. The ability o f H4IIE cells to reduce Alamar Blue was 
determined using a colourimetric assay as a marker of cellular proliferation. H41IE cells 
were isolated from in vivo HCC tissue, cultured in 96-well plates and quiesced for 24h 
(SFM) prior to treatment with culture media that was either serum free or contained 1% 
(v/v) FBS in the absence (-) or presence (+) o f rhIL-6 (50ng/ml) for 48h (n=4 per group. 
*p<0.05).
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Figure 5 3 RhIL-6 inhibits H4IIE (HCC) cell proliferation as evidenced by cell 
counting in vitro To determine the net effect o f rhIL-6 on H4IIE HCC cell 
proliferation, H4IIE cells were isolated from in vivo HCC tumours, seeded on 12-well 
plates and allowed to grow to 35% confluence At this point media was removed and 
cells quiesced for 24h (SFM) At the end of this penod, media was removed and 
replaced with fresh media containing either 1% (v/v) FBS ( • )  or 1% (v/v) FBS + rhIL-6 
(50ng/ml) (♦) Cells were then cultured for a further 3 days and cell counts performed at 
days 0,1,2 & 3 (n=4 separate experiments per group, *p<0 05 versus day 0, #p<0 05 
FBS versus FBS+rhIL-6 for corresponding time pomts)
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Days
Quiesced
G0/G1 S G2/M
2 48 01±1 00 46 80±0 25 5 20±0 77
6 64 78±2 00 22 47±0 65 12 75±1 37
7 78 12±0 98 15 40±0 74 6 48±0 29
8 80 1±0 23 16 37±0 77 3 53±0 54
Table 5 1 Effect of serum deprivation on cell cycle progression in H4IIE (HCC) 
cells. Serum deprivation retards H4IIE cells in the G0/G1 phase o f the cell cycle H4IIE 
cells were isolated and cultured prior to quiescing for varying time (2-8 days) in SFM 
Cells were stained with propidium iodide and analysed for DNA content by flow 
cytometry Data represents the mean±SEM of n=4 expenments for 2 days, 6 days and 8 
days and n=7 expenments for 7 days
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differences were not pronounced, as a result, 7 days o f serum deprivation was 
considered sufficient for H4IIE cell cycle analysis Synchronised H4IIE cells were next 
treated with 2 5% (v/v) FBS to release the cells from this G0/G1 arrest and initiate 
DNA synthesis Analysis o f DNA content demonstrated that FBS treatment induced the 
exit o f H4IIE cells from the G0/G1 phase of the cell cycle with a significant decrease in 
the G0/G1 cell population being observed at 20h (15 09±0 35% decrease in G0/G1 
population, n=4, p<0 05 versus time 0, Figure 5 4 & 5 5) after FBS stimulation 
reaching a maximal decrease at 28h (19 72±0 02% decrease in G0/G1 population, n=4, 
p<0 05 versus time 0, Figure 5 4 & 5 5) This occurred concomitant with increases in 
the S phase population (Figure 5 4, n=4) Similar treatment o f H4IIE cells with FBS in 
the presence o f rhIL-6 (50ng/mL) resulted in significantly reduced exit o f cells from the 
G0/G1 phase of the cell cycle compared to untreated controls At 20h, treatment with 
FBS m the presence of rhIL-6 resulted in the exit of 9 86±0 16% of H4IIE cells from 
the G0/G1 phase of the cell cycle (Figure 5 5, n=4, p<0 05 versus untreated control at 
20h) At 28h after FBS stimulation in the presence o f rhlL-6 (50ng/mL) the population 
of cells exited from the G0/G1 phase of the cell cycle was increased further but not 
significantly (11 53±0 23%, n=4, Figure 5 5) After 46h, G0/G1 population of rhIL-6 
treated and untreated H4IIE cells increased to levels above those observed at Oh (Figure 
5 4, n=4)
161
2 0 h  
G(VG1: 60 .74%  
S: 36.92%  
G2/M: 2.34%
2 0 h  IL-6 
G<VG1: 67.38%  
S: 26 07%  
G2/M: 4.66%
2 4 h  
G0#G1: 66.6%  
S: 32.66%  
G2/M: 10.65%
2 4 h  IL-6 
G0*GV. 64.26%  
S: 24.68%  
G2/M: 11.07%
28h 
G0/G1: 67.06%  
S: 26 39% 
G2/M: 14.56%
</>
32h  
G0/G1: 63.61%  
S: 24.93%  
G2!U: 11.66%
4 6 h  
G0/G1: 79.16%  
S: 10.97%  
G2/M: 9.66%
D.NA CONTENT
28 h  IL-6 
G0#G1: 66.01%  
S . 23.6%  
G2/M: 11.6%
3 2 h  IL-6 
G0JG1: 66.41%  
3: 22.96%  
G2/M: 10.63%
4 6 h  IL-6
G0fG1: 82.62%
S: 8.18%
G2/M: 9.2%
DNA CONTENT
DNA C CONTENT ON A CONTENT
Figure 5.4 KhlL-6 induces a (¡0/G1 growth arrest in H4IIE cells in vitro.
Representative flow cytometric histograms of DNA content in H4IIE cells at varying 
lime points after treatment with IL-6. H4IIE cells were isolated and cultured prior to 
quiescing for 7 days in SFM. At the end o f this period, media was removed and 
replaced with fresh media containing either 2.5% (v/v) FBS or 2.5% (v/v) FBS + rhIL-6 
(50ng/ml). Cells were stained with propidium iodide and analysed for DNA content by 
flow cytometry at varying time points.
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Figure 5.5 KhlL-6 inhibits exit from («O/C.l phase of the II41IE cell cycle in vitro.
H4IIE cells were isolated and cultured prior to quiescing for 7 days in SFM. At the end 
of this period, m9edia was removed and replaced with fresh media containing either 
2.5% (v/v) FBS (black) or 2.5% (v/v) FBS + rhlL-6 (50ng/ml) (shaded). Cells were 
stained with propidium iodide and analysed for DNA content by flow cytometry at 
varying time points (*p<0.05% versus Oh, n=4 per group; #p<0.05 FBS versus 
FBS+rhlL-6 for corresponding time points, n=4 per group).
Interleukin-6 treatment in H4IIE (HCC) cells leads to increased expression of 
the cdk inhibitors p 2 lwatI/c,pl and p27Kipl and an associated decreased activity o f both 
cdk2 and cdk4 This is further correlated with a decreased level o f phosphorylation of 
the cdk target, Rb (chapter 4) The current study established that IL-6 treatment inhibits 
the proliferation of H4IIE cells in vitro Further analysis demonstrated that IL-6 induces 
a G0/G1 growth arrest in these cells
Previous reports identify IL-6 as a critical cytokine in the initiation phase of 
liver regeneration (Streetz et a l , 2000, Fausto, 2000) Reduced liver mass causes 
increased serum TNF-a levels followed by increased IL-6 and STAT3 activation 
STAT3 activation, in collaboration with additional transcription factors such as 
C/EBPp, enhance the expression of additional factors, such as NF-IL-6, c-myc, c-fos, 
IRF-1 and others, enabling the resting hepatocytes to progress into cell proliferation 
(Streetz et a l , 2000, Fausto, 2000) More recently, Zimmers et al report the potential of 
IL-6 to act as a complete mitogen in the liver In this model circulating IL-6 levels were 
elevated in nude mice using a transfected CHO cell line leading to dramatic 
hepatomegaly and hepatocyte hyperplasia in the absence of liver injury (Zimmers et a l , 
2003) In support o f this observation, double transgenic mice expressing human IL-6 
and human soluble IL-6R under liver specific promoters demonstrate hepatomegaly, 
hepatic hyperplasia and the presence of hepatic adenomas (Maione et a l , 1998, 
Schirmacher et a l , 1998) IL-6 treatment of hepatocytes in vitro however has resulted 
in both stimulation and inhibition of DNA synthesis (Kordula et a l , 1991, Kuma et a l , 
1990, Satoh and Yamazaki, 1992)
In contrast to its role in normal hepatocyte proliferation, the current study 
identifies a growth inhibitory effect o f IL-6 treatment in HCC cells in vitro This 
correlates with previous research which demonstrates decreased proliferation in both
5.4 Discussion
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human (Klausen et a l , 2000) and rat (Kim and Baumann, 1999, Lai et a l , 1999) 
hepatoma cell lines in response to IL-6 The reduced proliferation of human HepG2 
cells in response to IL-6 is linked to a MAPK dependent increase of p27Kipl in addition 
to mildly enhanced p 2lwafl/cipl levels (Klausen et a l , 2000) Conversely, IL-6 induced 
growth inhibition of H-35 rat HCC cells did not involve altered expression of either of 
these cdk inhibitors (Kim and Baumann, 1999, Lai et a l , 1999) In the current model an 
over expression of both p21wafl/cipl and p27Kipl, which is at least partially STAT3 
dependent, was correlated with IL-6 mediated inhibition of HCC cell proliferation 
Collectively these data suggest that the mechanisms of IL-6 induced growth inhibition 
in HCC are varied and cell type specific Furthermore, roles for IL-6 as an autocrine 
growth factor (Kumagai et a l , 2002) and survival factor (Chen et a l , 1999) have been 
demonstrated in human HCC cell lines, HCC-M and Hep3B, respectively This 
highlights distinct biological outcomes of IL-6 signalling m different HCC cell types 
Similarly, IL-6 has been shown to act as a paracrine growth inhibitor in certain prostate 
cancer cell lines and an autocrine growth stimulator in others (Spiotto and Chung, 
2000) Moreover, studies show that IL-6 can also switch from acting as a paracrine 
growth inhibitor to an autocrine growth stimulator during the progression of human 
melanoma (Lu and Kerbel, 1993, Florenes et a l , 1999) Taking into consideration that 
IL-6 is produced and secreted by H4IIE cells (chapter 3), these data suggest a role for 
IL-6 as an autocrine negative growth regulator m the current HCC model Indeed IL-6 
has been established to have similar autocrine growth inhibitory effects m human 
meningioma (Todo et a l , 1994) and lung cancer cells (Takizawa et a l , 1993) In the 
latter case, the cells have a relatively low IL-6 sensitivity when compared with 
noncarcinogemc human bronchial epithelial cells suggesting that escape from growth 
regulation of this inhibitory factor may be involved m lung oncogenesis Similarly, 
H4IIE cells are characterised by decreased expression of IL-6 receptor components
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(chapters 3 & 4) supporting potentially evasive cell mechanisms from IL-6 growth 
inhibition Autocrine negative growth regulation by other cytokines such as TGF-(3 in 
other cancer models has been established while the development of multicytokine 
resistance during the process of oncogenesis has been linked to clonal dominance of 
primary tumours by metastatically competent cells (Lu et a l , 1992, Kerbel, 1992, Wu 
et a l , 1992) Overall the proliferation of neoplastic cells is dependent on the interaction 
and balance between both stimulatory and inhibitory factors
Interleukin-6 treatment of H4IIE (HCC) cells blocked cell cycle progression in 
the G0/G1 phase H4IIE cells were synchronised by serum depnvation for 7 days pnor 
to the determination of the effects o f IL-6 on cell cycle progression This resulted in 
accumulation of H4IIE cells in the G0/G1 phase of the cell cycle While this was an 
extended period of serum starvation, past research confirms that H4IIE cells enter a 
quiescent state and can remain viable for up to 7 days in the absence of serum (Squinto 
et a l , 1989) The cells promptly re-enter the cell cycle once serum stimulated The 
current study demonstrates that IL-6 inhibits the entry of H4IIE cells into the S phase of 
the cell cycle Interleukin-6 stimulation in H4IIE cells results in an upregulation of the 
cdk inhibitors p 2 lwafl/c,pl and p27K,pl which occurs concomitant with a decreased 
activity of cdk2 and cdk4 in addition to decreased levels of Rb phosphorylation 
(chapter 4) Progression through the cell cycle is tightly controlled by cdks (Morgan,
1995) Cychns associate with cdks and are the primary regulators of cdk activity (Sherr 
and Roberts, 1999, Morgan, 1995) The activation of cdk4 plays an important role in 
the passage through the G1 restriction point when the cell becomes committed to 
proceed through the cell cycle, while cdk2 activation plays an essential role m the 
transition into S phase and DNA synthesis Cyclin D1 expression is induced during G1 
phase m response to various mitogens, complexes with and activates cdk4 Cyclin 
dependent kinase 2 is regulated primarily by cyclin E and cyclin A during Gl/S
<1
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transition and S phase respectively (Sherr and Roberts, 1999, Morgan, 1995, Sherr and 
Roberts, 1995) Retinoblastoma protein is the major target for cyclin dependent kinase 
activity and is phosphorylated by both cyclin D dependent kinases and by cdk2 
Hyperphosphorylation of the Rb protein disrupts it’s association with E2F transcription 
factors which once released can stimulate the expression of a series of genes required 
for DNA synthesis (Sherr and Roberts, 1999, Morgan, 1995, Sherr and Roberts, 1995) 
Cyclin dependent kinase inhibitors further regulate the activity of these cyclin/cdk 
complexes p27IClpl and p21wan/c,pl are members of the Cip/Kip family of cdk inhibitors 
that can affect the activity of cyclin D-, E- and A- dependent kinases through binding of 
both the cyclin and cdk subunits (Sherr and Roberts, 1999) Overall, increased cdk 
inhibitor expression leading to decreased cdk activity and a resulting reduction m Rb 
phosphorylation in response to IL-6 treatment gives a direct mechanism for the 
observed G0/G1 growth arrest m H4IIE cells
In conclusion, exogenous addition of IL-6 inhibits the proliferation of H4IIE 
HCC cells in vitro through the induction of an arrest in the G0/G1 phase of the cell 
cycle Interleukm-6 treatment increases both p21wafl/c,pl and p27Kipl in H4IIE cells, 
leading to decreased cdk2 and cdk4 activity and a subsequent decrease in Rb 
phosphorylation Ultimately this sequence of events results m reduced entry of H4IIE 
cells into the S phase o f the cell cycle and as a result decreased cell proliferation in 
vitro This may suggest an autocrine negative growth regulatory function for IL-6 when 
considered in light of results demonstrating that H4IIE cells produce both IL-6 and the 
IL-6 receptor However, dysregulated expression of various IL-6 signalling components 
and in particular decreased levels o f IL-6 receptor expression may suggest that 
mechanisms are present in H4IIE cells to evade the growth inhibitory effects o f IL-6
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Chapter 6: Microencapsulation of Engineered CHO 
Ceils for IL-6 Delivery In Vivo
6.1 In troduction
HCC is characterised by dysregulated expression of components o f the IL-6 
signalling cascade both in vivo and in vitro (chapters 3 & 4) This includes 
downregulated expression of the IL-6 receptor in addition to upregulated IL-6 
production and secretion Nevertheless, IL-6 treatment of HCC cells in vitro leads to 
the activation of Jak-STAT and Ras-MAPK pathways resulting in increased expression 
of the cdk inhibitors, p21wafl/cipl and p27Kipl (chapter 4) Decreased phosphorylation of 
the Rb protem and attenuated cdk activity were observed concomitant with this 
upregulation Collectively, these events induce a G0/G1 growth arrest in H4IIE HCC 
cells in vitro (chapter 5) However, the effects o f IL-6 administration on HCC 
progression in vivo remain to be determined
A growth inhibitory effect of IL-6 treatment has been demonstrated m H4IIE 
HCC cells in vitro (chapter 5) This correlates with previous research which has 
demonstrated decreased proliferation in both human (Klausen et a l , 2000) and rat (Kim 
and Baumann, 1999, Lai et a l , 1999) hepatoma cell lines in response to IL-6 However, 
roles for IL-6 as an autocrine growth factor (Kumagai et a l , 2002) and survival factor 
(Chen et a l , 1999) have also been demonstrated in the human HCC cell lines, HCC-M 
and Hep3B, respectively The effects of IL-6 on HCC progression in vivo remain
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poorly defined The overexpression of IL-6 in a rat hepatocellular carcinoma cell line 
was linked to an increase in metastatic potential (Reichner et a l , 1998) while the 
transfection of an IL-6 expression vector in a murine liver tumour cell line was 
inhibitory on tumour growth in vivo (Kang et a l , 1999) Previous reports demonstrate 
the potential of systemic IL-6 administration to decrease tumour burden of other 
cancers in vivo Human IL-6 administered to mice with transplantable acute myeloid 
leukaemia (AML) and irradiation/dexamethasone induced AML results in reduced 
leukaemia development and increased animal survival (Givon et a l , 1992) This may 
be due to direct effects on tumour cells and/or through an enhancement of the host 
immune system Recombinant IL-6 administration also reduces the number of 
established metastases from colon adeonocarcinoma and fibrosarcoma tumours in vivo, 
an effect mediated via the enhancement o f tumour specific CD8+ cytotoxic T 
lymphocyte (CTL) activity (Eisenthal et a l , 1993, Mule et a l , 1992) Furthermore, IL-6 
administration in combination with cyclophosphamide, a chemotherapeutic agent, 
ameliorates the majority o f C57BL/6 mice with advanced, 10 day subcutaneous or 
pulmonary sarcoma tumour nodules (Mule et a l , 1992) Similarly other cytokines have 
been administered as potential cancer therapeutics Interferon-a (IFN-a) has been the 
most successfully administered cytokine demonstrating anti-tumour effects in several 
haematological malignancies and solid tumours and also reducing the risk of malignant 
melanoma recurrence after surgical resection of localized lymph node metastases 
(Group , 1997, Kirkwood et a l , 1996) Interleukin-2 (IL-2) administered systemically 
at high doses can mediate renal carcinoma and melanoma tumour regression in some 
patients (Fyfe et a l , 1995, Rosenberg et a l , 1993) However, the infusion of defined 
cytokines is often associated with severe side effects and dose limiting toxicities (Fyfe 
et a l , 1995, Rosenberg et a l , 1993, Lienard et a l , 1992, Atkins et a l , 1997) Despite 
its involvement with several inflammatory disease states and systemic
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lymphoproliferative disorders, administration of high doses of IL-6 in mice does not 
result \n discernible side effects or toxicity (Eisenthal et a l , 1993, Givon et a l , 1992, 
Mule e ta l, 1992)
Systemically administered cytokines have a short half life in vivo 125I-IL6 
injected into rats is cleared with a plasma half life of approximately two minutes 
(Castell et a l , 1988, Castell et a l , 1990a) As a result it is difficult and expensive to 
maintain sustained high cytokine levels in vzvo The microencapsulation of cells 
engineered to secrete cytokines and their subsequent implantation in animals offers a 
more economical and sustainable method of cytokine delivery in vivo The principle of 
microencapsulation is to create a physical semi-permeable barrier between the 
encapsulated cells and the host immune system This membrane allows diffusion of 
oxygen and nutrients to the encapsulated cells while preventing contact with host 
immune cells or large molecules such as immunoglobulins (Uludag et a l , 2000) 
Alginate, an unbranched polysaccharide mainly extracted from brown algae, is used 
extensively for the encapsulation of many cell types Alginate is composed of 1,4- 
linked a-L guluromc acids (G) and (3-D mannuromc acids (M) which crosslink on 
contact with divalent cations (Ba2+ and Ca2+) to form a gel matnx (Uludag et a l , 2000) 
Cells are suspended m an iso-osmolar sodium algmate solution and are forced by a 
synnge through a nozzle forming droplets o f algmate containing cells which then fall 
into an iso-osmolar solution of Ba2+ or Ca2+ The divalent cations cause gelation of the 
algmate resultmg m spherical beads containing live encapsulated cells (Smidsrod and 
Skjak-Braek, 1990) In many cases the beads are next suspended in a poly-L-lysine 
(PLL) solution to enhance the perm-selective properties and strength of the algmate 
encapsulated structures Poly-L-lysine coated calcium crosslinked algmate beads can 
then be further modified by liquefication of the algmate core usmg calcium chelators 
such as citrate (Uludag et a l , 2000) Encapsulated cells have been successfully used to
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deliver biotherapeutic substances in vivo such as Factor IX for haemophilia therapy 
(Hortelano et a l , 1996), parathyroid hormone for the treatment of hypoparathyroidism 
(Hasse et a l , 1997) and dopamine in experimental models of Parkinson’s disease
(Aebischer et a l , 1994) Furthermore, encapsulated allogeneic and xenogeneic
I
pancreatic islets have been successfully used to establish normoglycaemia in diabetic 
rodents (O'Shea and Sun, 1986), dogs (Soon-Shiong et a l , 1992), monkeys (Sun et a l ,
1996) and in a human diabetic patient (Soon-Shiong et a l , 1994) In regard to cancer 
therapy, alginate encapsulation has been utilised as a method of delivery for many 
potentially therapeutic substances Anti-angiogemc factors such as endostatin and 
angiostatin delivered using encapsulated genetically modified cells result in decreased 
tumour volume and mcreased survival in the treatment o f rat glioma and murine 
melanoma respectively (Read et a l , 2001, Cirone et a l , 2003) Microencapsulated 
iNOS expressing cells have also been used to suppress tumour growth of colon and 
ovarian carcinomas in vivo (Xu et a l , 2002) Another group has developed a system 
using microencapsulated genetically engineered myoblasts expressmg IL-2 linked to 
the Fv region of a humanized antibody with affinity to tumours over-expressing the 
oncogene ERB2/HER2/NEU to specifically suppress tumour growth (Cirone et a l , 
2002)
The aim of the current study was to microencapsulate rhIL-6 expressmg CHO 
cells for rhIL-6 delivery in vivo and determine its effect on HCC progression
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6.2.1 Tumour Model
The rat HCC tumour model was established by direct injection of H4IIE cells 
into the left liver lobe of male ACI rats (200-25Og) as described in section 2 3 Tumour 
volumes (mm3) were calculated (Y zL  x W x H) from measurements of length (L), width 
(W) and height (H) o f tumour cross section
6.2.2 CHO Cell Culture
CHO-IL6, a CHO cell line stably expressing IL-6 and a mock transfected CHO 
cell line (CHO-CTRL) were used in these experiments These lines were generated by 
introduction of a plasmid vector containing the human IL-6 complimentary DNA 
(CHO-IL6) or empty vector (CHO-CTRL) into DHFR-deficient CHO-DUXX cells by 
protoplast fusion followed by methotrexate selection Cells were cultured as described 
in section 2 2
6.2.3 Alginate Microencapsulation of CHO Cells
6.2 3 1 Materials
Pronova ultrapure sodium alginate LVG was purchased from Pronova 
(Drammen, Norway) CaCh, hepes, NaCl and glucose were purchased from Sigma 
Aldrich (St Louis, MO, USA) R3603 Tygon autoclavable tubing, Nalgene filter 
holders, Coming suspension culture dishes (150mm x 25mm), Cytostir stirrer culture 
flasks, Stereomaster Zoom stereo microscope and sterile 5mL syringes were purchased 
from Fisher Scientific (Pittsburgh, PA, USA) Polypropylene mesh filters were 
purchased from Spectrum Laboratories (Rancho Dominguez, CA, USA) PHD 2000
6.2 Methods
172
syringe pump was purchased from Harvard Apparatus (Holliston, MA, USA) Air 
pressure meter was purchased from Cole Parmer (Vernon Hills, IL, USA) Millex
0 2jam vent air filter units were purchased from Milhpore (Bedford, MA, USA) 
Coaxial spray atomiser was purchased from Spraying Systems (Wheaton, IL, USA) 
AMEM was purchased from Biosource (Camanllo, CA, USA)
6 2 3 2 Cell Encapsulation
The apparatus was assembled as illustrated in figure 6 1 and 6 2 Briefly, a 5ml 
synnge mounted on a syringe pump was connected via tubing (1/8” inner diameter 
Tygon) to the liquid inlet on a coaxial spray atomiser The gas inlet on the atomiser was 
connected to an air line (1/4” inner diameter Tygon) Air was pumped at a rate of 
6L/min through a Millex (0 2|o,m) in line filter to the atomiser The atomiser was 
mounted 20cm above the surface level o f 150mL of a 1 5% (w/v) CaCb solution (1 5% 
(w/v) CaCU, 13mM hepes, 0 2^M sterile filtered) contained in a stenle 150mm cell 
culture suspension dish This solution was placed on a magnetic stirrer plate and 
agitated gently using a stenle magnetic stirrer
CHO cells were cultured, trypsimsed and then resuspended in PBS Cells were 
seeded at a concentration of lx l0 6 cells/mL in a 1 7% (w/v) sodium alginate solution 
(1 7% (w/v) ultrapure sodium alginate LVG, 0 9% (w/v) NaCl, 2 2mM hepes, 150mg/L 
glucose, pH 7 4, stirred overnight and then 0 2pm stenle filtered) Alginate/cell 
suspension (IxlO6 cells/mL) was placed in a syringe and fed to the atomiser at a rate of
1 OmL/min Alginate beads formed on contact with CaCl2 solution and were agitated 
gently for 5 mins Beads were initially filtered through a 500|xm polypropylene mesh 
filter and then the filtrate was passed through a 297pm polypropylene mesh filter 
Alginate beads were washed in place on the 297^m mesh filter using AMEM cell 
culture media (no antibiotics or buffers added) Algmate beads on the mesh filter were
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Stenle A ir
Figure 6.1 Illustrated representation of the apparatus used for alginate cell 
encapsulation CHO cells suspended in a 1 7% (w/v) sodium alginate solution were fed 
to a spray atomiser at a rate o f 1 OmL/min using a syringe mounted on a syringe pump 
Air was pumped through a sterile filter to the spray atomiser at a rate of 6L/min which 
was controlled using an air flow regulator Alginate/cell mix was sprayed into a CaCk 
solution which was agitated using a magnetic stirrer Alginate polymerised on contact 
with the CaCb solution resulting m beads contaimng encapsulated cells Beads were 
cultured in high serum media at 37°C in a humidified incubator in the presence of 5% 
C 02
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Figure 6.2 Photograph of the apparatus used for alginate cell encapsulation. CHO
cells suspended in a 1.7% (w/v) sodium alginate solution were fed to a spray atomiser at 
a rate o f l.OmL/min using a syringe mounted on a syringe pump. Air was pumped 
through a sterile filter to the spray atomiser at a rate o f 6L/min which was controlled 
using an air flow regulator. Alginate/cell mix was sprayed into a 1.5% (w/v) CaCfe 
solution which was agitated using a magnetic stirrer. Alginate polymerised on contact 
with the CaCl2 solution resulting in beads containing encapsulated cells. Beads were 
washed and cultured in high serum media in stirrer culture flasks at 37°C in a 
humidified incubator in the presence o f 5% COi.
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then placed in lOOmL CHO high serum media (HSM, section 2 2) in a Cytostir stirrer 
culture flask (lOOmL) and incubated with gentle agitation in a 37°C humidified 
incubator in the presence of 5% CO2 80mL of media was replaced every 2 days with 
fresh HSM Agitation was ceased and beads were allowed to settle for at least 15 mins 
prior to changing the media Bead size and shape was estimated by visualisation of 
beads using a stereo microscope
6.2.3 3 Poly-L-lysine Coating of Alginate Beads
CHO-IL6 encapsulated beads were removed from culture and washed twice in 
buffered saline (0 9% (w/v) NaCl, 2 2mM hepes, pH 7 4) Beads were then suspended 
in 0 05% (v/v) poly-L-lysine (PLL) for 6 mins with stirring Beads were collected and 
washed twice in buffered salme and next suspended in 0 06% (w/v) sodium alginate 
(0 06% (w/v) sodium alginate, 0 9% (w/v) NaCl) for 4 mins with stirring Beads were 
washed twice in buffered saline followed by two successive treatments with 15% (w/v) 
sodium citrate for 7 mins each Beads were then washed 3 times in buffered saline, 
resuspended m HSM and then incubated m stirrer culture at 37°C m a humidified 
incubator in the presence of 5% CO2
6.2.4 IL-6 ELISA
6 2 41  Plasma Preparation for IL-6 ELISA
Blood (5-7mL) was collected from male ACI rats via cardiac puncture using a 
27 gauge needle and syringe containing 50 umts heparin (Fisher Scientific, Pittsburgh, 
PA, USA) Blood was centrifuged at 1000 x g for 10 mms (4°C) Plasma was separated 
and stored at -20°C prior to analysis
176
CHO cells were grown in culture as described in section 2 2 Media samples 
(300jaL) were removed daily and stored at -20°C prior to analysis Cell number was 
calculated at each sample time point by direct cell counting using a haemocytometer
Encapsulated CHO cells were placed in culture in 6 well plates (6mL media per 
well) Media samples (300|oL) were removed daily and stored at -20°C prior to 
analysis Bead number in each well was determined by direct microscopic counting
6 2 4.3 IL-6 ELISA
ELISA for human IL-6 was performed on cell culture media and rat plasma 
using a BD OPTeia ELISA set as described in section 2 6
6.2.5 Live/Dead Cell Viability Assay
6 2 5 1  Materials
Live/Dead Viability /Cytotoxicity Kit containing Calcein AM and ethidium 
homodimer (EthD-1) was purchased from Molecular Probes (Eugene, OR, USA) 
Phosphate buffered saline (PBS) was purchased from Biosource (Camarillo, CA, USA) 
Nunc 4 well tissue culture plates were purchased from Fisher Scientific (Pittsburgh, 
PA, USA)
6 2 5 2 Method
Sample (lmL) of alginate beads was removed from stirrer culture and allowed 
to settle in an eppendorf tube for 5 mins Excess media was discarded and beads (in 
approximately 50|iL media) were placed in a 4 well tissue culture plate 250jwL of 
Live/Dead working reagent (2jiM Calcein AM, 4jliM EthD-1, PBS) was added and 
beads were incubated in darkness for 45 mins Beads were visualised using a Fluoview
6 2 4 2 C u ltu re  M edia P rep a ra tio n  fo r IL -6 E L ISA
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FV500 1X70 confocal laser scanning biological microscope and Fluoview FV500 
version 4 3 image processing software (Olympus America, Melville, NY, USA) 
Calcein AM is enzymatically converted to green fluorescent calcein by the ubiquitous 
intracellular esterase activity in living cells Dead cells appear red due to the binding of 
EthD-1 to nucleic acids in cells which have damaged membranes
6.2.6 Alginate Bead Implantation
Alginate Beads were removed from stirrer culture and allowed to settle in 50mL 
sterile tubes for 10 mins Excess media was discarded and alginate beads were placed 
in 15mL stenle centrifuge tubes Beads were washed 3 times in AMEM media (no 
antibiotics/buffers) and allowed to settle Excess AMEM was removed
Beads were implanted mtrapentoneally in tumour burdened male ACI rats (200- 
250g) under anaesthesia (isoflurane gas/oxygen mix) Rats were allowed to recover and 
were maintained with food and water ad libitum and exposure to a light-dark (12h/12h) 
cycle Rats were weighed daily At the end of the experimental period ammals were 
sacrificed and a peritoneal lavage was performed using AMEM to retrieve transplanted 
beads The liver was removed and weighed and resected liver tissue was snap frozen in 
liquid nitrogen prior to storage at -80°C
6.2.7 Preparation of Tissue Lysates
Tumour and normal liver tissue lysates for protein analysis were prepared as 
described in section 2 4 3
6.2.8 Immunoblotting
Western blots were performed as described in section 2 5 Antisera specific 
against gpl30 (M-20), IL-6Ra (M-20), IL-6 (M-19), PCNA (PC-10), ERK2 (K-23) and
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STAT3 (H-190) were all purchased from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA) Antisera specific against Phospho-STAT3 (Tyr705) and Phospho-p42/44 MAPK 
were purchased from Cell Signaling Technology (Beverly, MA, USA) All primary 
antibodies were diluted 1 1000 in 5% (w/v) non fat dry milk (NFDM)/0 1% (v/v) 
Tween/tns buffered saline (TBS) except for Phospho-STAT3 (1 2000) Horseradish 
peroxidase conjugated goat anti-rabbit Ig and goat anti-mouse Ig were supplied by 
Jackson Immunoresearch Laboratories (West Grove, PA, USA) and were used as 
secondary detection antibodies at a dilution of 1 5000 in 5% (w/v) NFDM/0 1% (v/v) 
Tween/TBS
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CHO-IL6 and CHO-CTRL cells were grown in culture Microscopic analysis 
demonstrated that these cell lines differed morphologically (Figure 6 3a and 6 3b) 
CHO-CTRL cells appear more elongated and larger than the rhIL-6 expressing CHO 
cells Both cell types proliferated rapidly in culture ELISA for human IL-6 performed 
on media from CHO-IL6 and CHO-CTRL cells removed at 3 and 4 days after seeding 
m culture demonstrated that CHO-IL6 media but not CHO-CTRL media was positive 
for human IL-6 (Table 6 1) The average production of IL-6 per CHO-IL6 cell over a 
24h period was determined as 35 16 +/- 5 79pg/mL (n=4 per group) and 31 26 +/- 
4 07pg/mL (n=4 per group) at 3 and 4 days after cell seeding respectively IL-6 
production rate per cell on successive days was not significantly different (n=4 per 
group)
Trial and error experiments involving the alteration of three factors (air flow 
rate, height of the atomiser from the CaCh solution and alginate flow rate) were next 
performed to establish optimal parameters for alginate encapsulation The apparatus 
was assembled as illustrated in Figure 6 1 and 6 2 The air flow rate was adjusted using 
an air flow regulator and the rate o f alginate delivery to the atomiser was altered using a 
syringe pump The atomiser was clamped on a biuret stand and height adjusted 
accordingly Experiments were performed using a 1 7% (w/v) sodium alginate solution 
in the absence of cells which was sprayed into a 1 5% (w/v) Ca.Ch solution Size, 
sphericity and uniformity o f alginate beads produced were estimated by visualisation 
using a stereo microscope Parameters were altered in order to obtain ~500|im diameter 
spherical beads Increasing the distance between the atomiser and the CaCb surface 
decreased the bead size and resulted in a more spherical bead (Table 6 2) At 5cm from 
the liquid surface the atomiser produced irregularly shaped beads which were typically
6.3 Results
6 3 1  E ncapsu lation  of C H O -IL 6 and  C H O -C T R L  Cells
(a)
(b)
Figure 6.3 Photomicrographs of cultured CHO-IL6 and CHO-CTRL cells, a)
CHO-IL6 and b) CHO-CTRL cells were grown overnight m high serum media in 
adherent tissue culture flasks Cells were fixed with methanol and viewed 
microscopically (40x) using an inverted light microscope
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Days After Seeding in 
Culture
CHO-IL6 cells 
Average IL-6 produced 
(pg/cell/day)
CHO-CTRL cells 
Average IL-6 produced 
(pg/cell/day)
3 35.16 +/- 5 79 ND
4 31 26 +/- 4 07 ND
Table 6 1 Human IL-6 production by CHO-IL6 and CHO-CTRL cells m vitro
ELISA for human IL-6 was performed on media removed from CHO-CTRL and CHO- 
IL6 cells at 3 and 4 days after initial seeding m culture Cells were counted using a 
haemocytometer and average rate o f IL-6 production per cell over 24h was established 
(n=4 per group) Concentrations below detectable level o f this ELISA were denoted not 
detectable (ND)
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Height (cm) Air Flow Fluid Flow Read Diameter/
Rate Rate Bead Shape (Sphericity)
(L/min) (mL/min)
5 2 0 1 »1mm/irregular
4 0 1 ~ I mm/irregular
5 0 1 ~ 1 mm/irregular
5 5 0 1 ~1 mm/irregular
5 5 0 25 > 1 mm/irregular
55 0 5 >lmm/irregular
6 1 0 >lmm/irregular
6 5 0 1 > 1 mm/irregular
15 5 5 1 0 ~500^m/irregular
6 1 0 ~500|im/irregular
20 5 5 1 0 ~700fim/regular
6 1 0 ~500|xm/regular
6 1 5 -500jim/regular
6 5 1 0 <500jjm/regular
75 0 5 <<500|im/regular
7 5 1 0 <<500(im/regular
25 6 1 0 <500^im/regular
Table 6 2 Effects of physical parameters on alginate bead size and sphericity. A
1 7% (w/v) sodium alginate solution was sprayed into a 1 5% (w/v) CaCl2 solution 
using a spray atomiser resulting in bead formation The height o f the atomiser from the 
CaCla solution surface, the gas and alginate flow rates were adjusted in a series of trial 
and error experiments to determine the optimum parameters for bead production Bead 
size and shape were estimated visually by stereo microscopy after alteration of each 
parameter
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above 1mm diameter despite the use o f different air and/or alginate flow rates When 
the atomiser was moved to 15cm from the liquid surface the bead diameter was on 
average approximately 500pin however the beads were still irregularly shaped 
Sphericity o f the beads was improved when the atomiser was moved to 20cm from the 
liquid surface At 20cm from the liquid surface, increasing the air flow rate above 
6L/min decreased the size of the alginate beads to below 500pm while increasing the 
alginate flow rate past lmL/min had no noticeable effect on either bead diameter or 
bead shape At 20cm, an air flow rate of 6L/mm and an algmate flow rate of lmL/min 
the beads were spherical with a diameter of -5 0 0pm These parameters were 
determined to be optimal for the encapsulation process
Despite this optimisation procedure a large proportion of the algmate beads 
produced were determined to deviate considerably from the average diameter of 
~500|im In an effort to obtain a more uniformly sized population of beads, 
polypropylene mesh filters were used in a two step filtration process to limit the bead 
size to between 297^m to 500jLim diameter The alginate beads were initially passed 
through a 500pm mesh filter to remove all beads greater than 500|im diameter (Figure 
6 4a) The filtrate was then passed through a 297pm filter to remove all beads below 
297pm diameter (Figure 6 4b) The retentate from the 297pm filter was used in all 
subsequent experiments (Figure 6 4c)
CHO-IL6 and CHO-CTRL cells were next encapsulated in alginate beads 
(297itm-500jim diameter) and cultured for over two weeks Live/Dead assays were 
performed to determine cell viability in these beads at varying times during culture 
CHO-CTRL and CHO-IL6 cell viability was high in alginate beads at 1 day after 
encapsulation and remained high up to 17 days in culture as demonstrated by the 
presence o f predominantly green staining cells in these beads (Figure 6 5) When 
observed 1 day after encapsulation both CHO-CTRL and CHO-IL6 cells were
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Figure 6 4 Two step nitration of beads results in a uniform sized bead population.
In order to obtain a uniformly sized bead population, beads (CHO-CTRL beads shown) 
were a) filtered through a 500|im polypropylene filter to remove beads greater than 
500|im diameter Retained beads were photomicrographed (4x) b) Filtrate from the 
500pm filtration step was passed through a 297pm polypropylene filter to remove 
beads smaller than 297|im diameter Filtrate was photomicrographed (4x) c) Beads 
retained on the 297jmi filter were dispersed in culture media and photomicrographed 
(4x)
Day 1 CHO-IL6
(C)
Day 8 CHO-CTRL
Day 4 CHO-CTRL
Day 8 CHO-CTRL
(e)
Day 17 CHO-IL6 Day 17 CHO-IL6
Figure 6.5 Encapsulated CHO-IL6 and CHO-CTRL cell viability and colony 
morphology in vitro, (a-e) Representative composite confocal images o f  alginate 
encapsulated CHO-IL6 (a,f,e) and CHO-CTRL (b,c,d) beads after live-dead staining at 
varying times throughout culture in vitro. Live cells fluoresce green and dead cells 
appear red. All images captured at lOx magnification except c & d which were captured 
at 40x to display colony morphology, f) Composite confocal image of a representative 
CHO-IL6 bead removed from culture 17 days after culture in vitro. Image represents an 
extended focus view (1 Ox) o f 1800 individual slices.
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dispersed throughout the alginate beads and typically appeared as single cells (Figure 
6 4a) As the culture progressed the CHO-CTRL and CHO-IL6 cells grew in colonies 
within the alginate beads (Figure 6 4b~f) After approximately 7 days o f culture both 
CHO-IL6 and CHO-CTRL cells were capable o f escaping the beads Beads were 
viewed microscopically and demonstrated escaping cells from colomes adjacent to the 
bead wall (Figure 6 6a-d) When 7 day old beads were placed in tissue culture plates in 
the presence o f HSM, the escaping cells attached to the plate surface and continued to 
grow normally (Figure 6 6e)
In order to reduce CHO cell escape alginate beads were next PLL coated and 
the bead core was liquefied using sodium citrate in order to allow more centralised cell 
growth within the beads While this procedure did cause the CHO cell colonies to 
disperse (Figure 6 7a-d) and did not alter cell viability, the process considerably altered 
bead sphericity (Figure 6 7b) Furthermore, the PLL coating procedure caused bead 
aggregation (Figure 6 7a) and in some cases bead rupture resulting in cell release 
(Figure 6 7b) Beads were not PLL coated for subsequent experiments due to these 
effects
ELISA for human IL-6 was performed on media from beads removed from 
culture at varying time points throughout the course o f the experiment to determine if 
the encapsulated CHO-IL6 cells could still produce and release rhIL-6 CHO-IL6 and 
CHO-CTRL beads were removed from stirrer culture and placed in tissue culture plates 
in the presence of HSM IL-6 production over a 24h penod was determined and related 
to bead number CHO-IL6 cells successfully produced and released human IL-6 into 
the culture media Rate o f IL-6 production by encapsulated CHO-IL6 cells significantly 
increased with time from 431 7±148 2pg/bead/day on Day 1 to 
3622 5±273 4pg/bead/day and 5494 8±777 8pg/bead/day at 7 and 12 days in culture 
respectively (Table 6 3 & Figure 6 8, n=4 per group, p<0 05, Day 7 versus Day 1,
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Figure 6.6 CHO cells escape from  alginate beads after 7 days culture in vitro. 
Representative phase contrast micrographs o f C H O -IL 6  beads 7 days after culture in 
vitro, a) Alginate encapsulated C H O -IL 6  cells were grown in culture for 7 days and 
then viewed microscopically (4x). b-d) Representative Alginate encapsulated CHO-1L6 
cell bead was viewed at b) lOx, c) 20x and d) 40x magnification demonstrating cell 
escape through the bead wall, e) Escaped C H O -IL 6  cells grew adherently on the plate 
surface as demonstrated by microscopy (20x).
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Figure 6.7 Poly-L-lysine (PLL) coating of encapsulated CHO cell beads diminishes 
bead integrity. Representative images o f PLL coated CHO-IL6 alginate beads, a-c) 
CHO-IL6 cell alginate beads were coated with PLL, the alginate core was then 
liquefied using citrate and beads were finally recoated with an outer layer o f alginate. 
Live/Dead staining was performed and confocal images were captured (lOx). Live cells 
fluoresce green and dead cells appear red. d) Confocal image o f PLL coated alginate 
bead demonstrating dispersal o f CHO-1L6 colony.
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Days m Culture CHO-IL6 cells 
Average IL-6 produced 
(pg/bead/day)
CHO-CTRL cells 
Average IL-6 produced 
(pg/bead/day)
1 431 7 +/- 148.2 ND
7 3622.5 +/- 273 4 ND
12 5494 8 +/- 111 8 ND
Table 6 3 IL-6 production by alginate encapsulated CHO-IL6 and CHO-CTRL 
cells in vitro» CHO-IL6 and CHO-CTRL cells were encapsulated in alginate and 
cultured in vitro Beads were removed from culture at varying time points and grown m 
HSM m separate wells for a 24h period Human IL-6 production was determined by 
performing ELISA on the culture media removed from these wells (n=4 per group) IL- 
6 concentrations below detectable levels were denoted not detectable (ND)
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Figure 6.8 IL-6 production by alginate encapsulated CHO-IL6 and CHO-CTRL 
cells in vitro. CHO-IL6 and CHO-CTRL cells were encapsulated in alginate and 
cultured in vitro. Beads were removed from culture at varying time points and grown in 
I ISM in separate wells for a 24h period. Human IL-6 production was determined by 
performing ELISA on the culture media removed from these wells (n=4 per group, 
*p<0.05. Day 7 versus Day 1; # p<0.05 Day 12 versus Day7).
p<0 05, Day 12 versus Day 7) Human IL-6 was not detectable m the media o f CHO- 
CTRL beads (Table 6 3)
6 3.2 Rat Implantation of Microencapsulated CHO-IL6 and CHO-CTRL 
Cells
CHO-IL6 and CHO-CTRL cells were microencapsulated and cultured for four 
days in vitro prior to implantation mtrapentoneally in male ACI rats Animals were 
maintained for 4 or 7 days at which point the animals were sacrificed A peritoneal 
lavage was performed on each animal after sacrifice to retrieve alginate beads 
Recovered beads were then washed in AMEM and the viability of encapsulated CHO 
cells was examined using a Live/Dead assay Peritoneal lavage released fibrotic tissue 
from both CHO-CTRL and CHO-IL6 implanted rats at 4 days after implantation 
(Figure 6 9a-d) Microscopic examination demonstrated that alginate beads were 
trapped within this fibrotic tissue (Figure 6 9b-d) Viability of encapsulated CHO cells 
was high in beads trapped within these tissues recovered 4 days after implantation 
(Figure 6 9c) Live/Dead assays performed on encapsulated CHO-IL6 and CHO-CTRL 
cells recovered from rats after 4 days demonstrated the presence of large viable CHO 
colonies in each bead type (Figure 6 10) Cells, most likely o f immunological origin, 
were also attached to the outside of all recovered CHO-CTRL and CHO-IL6 beads 
recovered at 4 days after implantation CHO-IL6 and CHO-CTRL beads recovered 7 
days after implantation did not contain viable CHO cells as determined by the presence 
of predommately red staining cells within these beads in Live/Dead assays (Figure 
6 11 a & b) Microscopic analysis demonstrated the presence o f living cells accumulated 
on the outer surface o f the washed CHO-IL6 and CHO-CTRL beads after recovery at 7 
days (Figure 6 1 la  & b)
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Figure 6.9 Fibrotie overgrowth present on CHO-CTRL and CHO-IL6 beads 
retrieved from rats 4 days after implantation. CHO-IL6 and CHO-CTRL alginate 
beads were implanted in rats. After 4 days, peritoneal lavage was performed. Fibrotie 
overgrowth was isolated and visualised, a) Representative photographic image of 
fibrotie overgrowth surrounding CHO-IL6 encapsulated beads retrieved 4 days after 
implantation in rats. b,c) Representative confocal images (4x) o f b) unstained and c) 
Live/Dead stained fibrotie tissue surrounding CHO-IL6 beads retrieved from rats 4 
days after implantation. After Live/Dead staining, live cells fluoresce green and dead 
cells appear red. d) Representative confocal image (lOx) o f fibrotie overgrowth 
surrounding CHO-CTRL encapsulated cells retrieved 4 days after implantation in rats.
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Figure 6.10 Appearance of CIIO-IL6 and CHO-CTRL beads retrieved from rats 4 
days after implantation. CHO-IL6 and CHO-CTRL alginate beads were implanted in 
rats. After 4 days, peritoneal lavage was performed. Beads were Live/Dead stained and 
visualised on a confocal microscope. After Live/Dead staining, live cells fluoresce 
green and dead cells appear red. a,b) Representative composite confocal images (lOx) 
of CHO-IL6 beads retrieved by peritoneal lavage 4 days after implantation. c,d) 
Composite confocal images (lOx) o f CHO-CTRL beads retrieved by peritoneal lavage 
4 days after implantation.
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Figure 6.11 Appearance of CHO-IL6 and CHO-CTRL beads retrieved from rats 7 
days after implantation. CHO-IL6 and CHO-CTRL alginate beads were implanted in 
rats. After 7 days, peritoneal lavage was performed. Beads were Live/Dead stained and 
visualised on a confocal microscope. After Live/Dead staining, live cells fluoresce 
green and dead cells appear red. a,b) Representative composite confocal images (lOx) 
of CHO-IL6 beads retrieved by peritoneal lavage 7 days after implantation. c,d) 
Composite confocal images (lOx) o f CHO-CTRL beads retrieved by peritoneal lavage 
7 days after implantation.
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Taking into consideration that cells attached to the outside of CHO-CTRL and 
CHO-IL6 beads were most likely o f immune origin it was next established whether 
alginate alone in the absence of cells could stimulate a similar response after 
implantation in rats Alginate beads were prepared and implanted for 4 or 7 days in 
male AC1 rats Beads were recovered by peritoneal lavage, washed in AMEM and 
examined microscopically after Live/Dead staining for the presence of externally 
attached cells Cells were not detected on the outer surface of these empty beads after 
either 4 or 7 days in the animals (Figure 6 12a-c)
Plasma was separated from blood collected from algmate bead implanted 
animals at 4 and 7 days after implantation ELISA for human IL-6 was performed on 
these samples Human IL-6 was detectable in the plasma of CHO-IL6 bead implanted 
rats at 4 days but not at 7 days after implantation (Table 6 4) 0 25mL packed volume 
of CHO-IL6 beads resulted in a plasma level o f human IL-6 of 0 92±0 18pg/mL/g rat 
body weight (n=4) while plasma concentration of IL-6 in animals implanted with 
0 5mL packed volume of beads increased further to 4 95±0 39 pg/mL/g rat body weight 
(n=4) at 4 days after implantation Human IL-6 was not detectable in the plasma of 
CHO-CTRL bead or empty bead implanted rats at either 4 or 7 days after surgery 
(Table 6 4, n=4) Beads retrieved from implanted animals were next washed and placed 
in culture in the presence of HSM The production rate of IL-6 over a 24h period was 
determined using a human IL-6 ELISA performed on the cell culture media Human IL- 
6 was detectable in the media removed from CHO-IL6 beads retrieved 4 days after 
surgery but not from cultures of CHO-IL6 beads recovered from rats at 7 days (Table 
6 5) Average rate of IL-6 production by these recovered CHO-IL6 beads (4 day) in 
culture was 2075 9±287 6pg/bead/day (n=4) Human IL-6 was not detectable in media 
from cultured CHO-CTRL or empty beads removed either at 4 or 7 days after 
implantation (Table 6 5)
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Figure 6 12 Empty alginate beads do not induce fibrotic overgrowth in vivo. Empty 
alginate beads were implanted in rats Peritoneal lavages were performed 4 and 7 days 
after implantation Beads were Live/Dead stained and visualised on a confocal 
microscope After Live/Dead staining, live cells fluoresce green and dead cells appear 
red a-c) Representative composite confocal images (lOx) o f empty beads a) before 
implantation, b) retrieved by peritoneal lavage 4 days or c) 7 days after implantation
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Days after 
Implantation
Packed 
Volume 
of Beads 
(mL)
CHO-IL6 Beads 
Implanted 
(pg/mL/g rat 
body weight)
CHO-CTRL Beads 
Implanted 
(pg/mL/g ra t body 
weight)
Empty Beads 
Implanted 
(pg/mL/g ra t body 
weight)
4 0 25 0 92+/-0 18 ND ND
0 5 4 95+/-0 39 ND ND
7 0 25 ND ND ND
Table 6 4 Plasma IL-6 levels in CHO-IL6, CHO-CTRL and empty bead implanted 
rats. CHO-IL6, CHO-CTRL and empty alginate beads were implanted in male ACI 
rats Plasma was separated from blood withdrawn by cardiac puncture 4 and 7 days 
after implantation Concentration of human IL-6 in collected plasma was determined by 
ELISA (n=4 per group) Plasma IL-6 concentrations below detectable levels were 
denoted not detectable (ND)
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Days after CHO-IL6 cells CHO-CTRL cells Empty Beads
Implantation Average IL-6 Average IL-6 Average IL-6
produced produced produced
(pg/bead/day) (pg/bead/day) (pg/bead/day)
4 2075 9+/- 287 6 ND ND
7 ND ND ND
Table 6.5 IL-6 production by CHO-IL6, CHO-CTRL and empty beads retrieved 
from rats in vitro. CHO-IL6, CHO-CTRL and empty alginate beads were implanted in 
male ACI rats Beads were retrieved from rats 4 or 7 days after implantation and grown 
in HSM in separate wells for a 24h period Human IL-6 production was determined by 
performing ELISA on the culture media removed from these wells (n=4 per group) IL- 
6 concentrations below detectable levels were denoted not detectable (ND)
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Preliminary experiments to establish the effects o f IL-6 administration on liver 
and HCC tumour growth in vivo were next performed HCC tumours were established 
in male ACI rats by direct injection of H4IIE cells into the left hepatic lobe Ten days 
after surgery, 0 5mL packed volume of empty, CHO-CTRL or CHO-IL6 alginate beads 
were implanted intrapentoneally in these rats for 4 days At this point the beads were 
retrieved by peritoneal lavage and the liver was removed and weighed Tumours were 
then resected and samples o f normal and tumour liver tissues were snap frozen on 
liquid nitrogen for western blot analysis
Body weight of rats in all treatment groups did not change significantly over the 
course of the experiment Liver weight was significantly increased in rats with CHO- 
IL6 bead implants (37 1+/-1 7mg liver wt/g body wt) compared to empty bead 
implanted httermates (31 2+/-1 4mg liver wt/g body wt, Table 6 6 & Figure 6 13, n=4 
per group, p<0 05) Liver weight was also higher m CHO-IL6 bead implanted animals 
compared to CHO-CTRL bead implanted animals (32 8+/-0 9mg liver wt/g body wt, 
n=4) but not significantly CHO-CTRL bead and empty bead implanted rat liver 
weights were not significantly different (Table 6 6  & Figure 6 13, n=4 per group) 
Tumour volume was highly variable even within treatment groups and no conclusions 
could be reached as to the effect o f IL-6 treatment on tumour size (Table 6 6 & 6 7)
Western blot analysis of lysates prepared from tumour and normal liver samples 
demonstrated that IL-6 was detectable in normal and tumour liver tissues from CHO- 
IL6 bead implanted rats (Figure 6 14, n=4) In contrast, IL-6 was not detectable in 
tumour or normal liver tissues from CHO-CTRL bead or empty bead implanted rats 
Immunoblot analysis for gpl30 expression demonstrated that gpl30 expression in 
tumour and normal liver tissues was not altered by IL-6 administration in vivo when 
compared with liver tissues resected from CHO-CTRL bead and empty bead implanted
6 3 3 Effects of IL-6 on L iver an d  H C C  T u m o u r G row th  In Vivo
2 0 0
Beads Implanted Liver Weight to Body 
Weight Ratio (mg/g)
Tumour Volume (mm3)
Empty Beads 31 2+/-1 4 604 6 +/-265
CHO-CTRL Beads 32 8+/-0 9 504 4+/-305 3
CHO-IL6 Beads 37.1+/-1 7 485+/-174 3
Table 6 6 Effects of CHO-CTRL, CHO-IL6 and empty alginate bead implantation 
on HCC tumour volume and rat liver weight. CHO-IL6, CHO-CTRL and empty 
alginate beads were implanted in tumour burdened male ACI rats 10 days after tumour 
inoculation Rat body and liver weights were determined 4 days after bead implantation 
(n=4 per group) Length, width and height o f HCC tumour mass were determined and 
used to calculate the tumour volume (n=4 per group)
201
RAT Liver to Body Weight 
Ratio (mg/g)
Tumour Volume (mm3)
Empty Rat 1 35 2 1380
Empty Rat 2 29 2 216
Empty Rat 3 30.0 319
Empty Rat 4 30 4 504
CTRL Rat 1 314 525
CTRL Rat 2 34 2 33
CTRL Rat 3 3 1 0 100
CTRL Rat 4 34 7 1360
IL-6 Rat 1 391 525
IL-6 Rat 2 35 9 945
IL-6 Rat 3 32 7 120
IL-6 Rat 4 40 6 350
Table 6 7 Effects of CHO-CTRL, CHO-IL6 and empty alginate bead implantation 
on HCC tumour volume and rat liver weight CHO-IL6, CHO-CTRL and empty 
alginate beads were implanted in tumour burdened male ACI rats 10 days after tumour 
inoculation Rat body and liver weights were determined 4 days after bead 
implantation Length, width and height of HCC tumour mass were determined and used 
to calculate the tumour volume
2 0 2
Brpty Beads CHO-CTR. Beads CHO-L6 Beads
Figure 613  Effects of CHO-CTRL, CHO-IL6 and empty alginate bead 
implantation on rat liver weight CHO-IL6, CHO-CTRL and empty alginate beads 
were implanted in tumour burdened male ACI rats 10 days after tumour inoculation 
Rat body and liver weights were determined 4 days after bead implantation (*p<0 05, 
n=4 per group)
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Figure 6 14 IL-6 was detectable in HCC and normal liver tissues resected from 
CHO-IL6 implanted rats. Representative Western blot analysis performed on lysates 
prepared from normal liver (NL) and HCC tissues resected from empty bead (EMPTY), 
CHO-CTRL bead (CTRL) and CHO-IL6 (IL6) bead implanted rats using an antibody 
specific against IL-6 HCC tumours were established by direct injection of H4IIE cells 
into the left hepatic lobe of male ACI rats Alginate beads were implanted 10 days after 
tumour inoculation Liver tissues were resected 4 days after bead implantation
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rats (Figure 6 15, n=4) Expression of gpl30 was decreased m tumour tissues as 
compared to pair matched normal livers tissue as previously established (chapter 3) 
Western blotting for IL-6Ra demonstrated that IL-6Ra expression was elevated but not 
significantly in normal liver tissues from CHO-IL6 bead implanted rats versus CHO- 
CTRL bead and empty bead implanted rat liver tissues (Figure 6 16) IL-6Ra 
expression was not sigmfcantly different between CHO-CTRL and empty bead 
implanted rat normal or tumour liver tissues IL-6Ra expression was significantly lower 
in tumour tissues compared to pair matched normal liver tissues as previously 
determined (chapter 3)
Immunoblotting using anti sera specific against pSTAT3 demonstrated that 
STAT3 was activated in normal and tumour liver tissues resected from CHO-IL6 
implanted rats in the absence of changes m total STAT3 expression (Figure 6 17, n=4, 
p<0 05) Phospho-STAT3 expression was higher m HCC tissues compared to pair 
matched normal liver tissues resected from CHO-CTRL bead or empty bead implanted 
rats as previously described (chapter 3) IL-6 treatment in vivo increased pSTAT3 
expression m HCC tissue Western blotting for pERK 1/2 determined that pERK 1/2 
expression was not significantly different in normal or tumour liver tissues from CHO- 
IL6 bead implanted rats compared to CHO-CTRL bead or empty bead implanted rats 
(Figure 6 18) Total ERK 1/2 and pERKl/2 expression was elevated in HCC tumours 
compared to pair matched normal liver tissues from all rats studied as previously 
described (McKillop et a l , 1997) Immunoblotting for PCNA demonstrated higher 
PCNA expression m HCC when compared with normal pair matched liver tissue in all 
animals studied (Figure 6 19) PCNA expression was not significantly different in 
normal liver tissue (Figure 6 19a, n=4) or HCC tumour tissue (Figure 6 19b, n=4) 
resected from CHO-IL6 bead implanted rats compared to CHO-CTRL or empty bead 
implanted rats
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Figure 6.15 G pl30 expression m HCC and normal liver tissues resected from 
CHO-IL6, CHO-CTRL and empty bead implanted rats Representative Western 
blot analysis performed on lysates prepared from normal liver (NL) and HCC tissues 
resected from empty bead (EMPTY), CHO-CTRL bead (CTRL) and CHO-IL6 (IL6) 
bead implanted rats using an antibody specific against gpl30 HCC tumours were 
established by direct injection of H4IIE cells into the left hepatic lobe of male ACI rats 
Alginate beads were implanted 10 days after tumour inoculation Liver tissues were 
resected 4 days after bead implantation
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Figure 6 16 IL-6Ra expression in HCC and normal liver tissues resected from 
CHO-IL6, CHO-CTRL and empty bead implanted rats Representative Western 
blot analysis performed on lysates prepared from normal liver (NL) and HCC tissues 
resected from empty bead (EMPTY), CHO-CTRL bead (CTRL) and CHO-IL6 (IL6) 
bead implanted rats using an antibody specific against IL-6Ra HCC tumours were 
established by direct injection of H4IIE cells into the left hepatic lobe of male ACI rats 
Alginate beads were implanted 10 days after tumour inoculation Liver tissues were 
resected 4 days after bead implantation
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Figure 6 17 PSTAT3 expression was increased in HCC and normal liver tissues 
resected from CHO-IL6 implanted rats Representative Western blot analysis 
performed on lysates prepared from normal liver (NL) and HCC tissues resected from 
empty bead (EMPTY), CHO-CTRL bead (CTRL) and CHO-IL6 (IL6) bead implanted 
rats using antibodies specific against a) pSTAT3 and b) total STAT3 HCC tumours 
were established by direct injection of H4IIE cells into the left hepatic lobe of male 
ACI rats Algmate beads were implanted 10 days after tumour inoculation Liver tissues 
were resected 4 days after bead implantation
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Figure 6.18 PERK 1/2 expression in HCC and normal liver tissues resected from 
CHO-IL6, CHO-CTRL and empty bead implanted rats Representative Western 
blot analysis performed on lysates prepared from normal liver (NL) and HCC tissues 
resected from empty bead (EMPTY), CHO-CTRL bead (CTRL) and CHO-IL6 (IL6) 
bead implanted rats using antibodies specific against a) pERK 1/2 and b) total ERK 1/2 
HCC tumours were established by direct injection of H4IIE cells into the left hepatic 
lobe of male ACI rats Alginate beads were implanted 10 days after tumour inoculation 
Liver tissues were resected 4 days after bead implantation
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Figure 6 19 PCNA expression in HCC and normal liver tissues resected from 
CHO-IL6, CHO-CTRL and empty bead implanted rats Representative Western 
blot analysis performed on lysates prepared from normal liver (NL) and HCC tissues 
resected from empty bead (EMPTY), CHO-CTRL bead (CTRL) and CHO-IL6 (IL6) 
bead implanted rats using an antibody specific against PCNA a) Western blot 
demonstrating PCNA expression in NL tissues b) Western blot demonstrating PCNA 
expression in HCC tissues HCC tumours were established by direct injection of H4IIE 
cells into the left hepatic lobe of male ACI rats Alginate beads were implanted 10 days 
after tumour inoculation Liver tissues were resected 4 days after bead implantation
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Microencapsulation of recombinant cells and their subsequent implantation in 
animals offers the possibility o f sustained delivery of biotherapeutic substances in vivo 
(Uludag et a l , 2000) In the current study alginate encapsulated IL-6 expressing CHO 
cells were used to deliver human IL-6 in an immune competent rat model of HCC 
Encapsulated IL-6 expressing and control CHO cells remain viable and form large 
colonies in alginate beads up to 17 days after encapsulation in vitro Encapsulated 
CHO-IL6 cells retain the ability to produce and secrete high levels of human IL-6 
Implantation of encapsulated CHO cells intrapentoneally m rats results in an 
accumulation of living cells on the outer surfaces o f beads, fibrotic overgrowth and 
complete loss o f bead viability by 7 days However, at 4 days after implantation CHO 
cells remain viable and actively secrete human IL-6 resultmg in high plasma IL-6 
levels Increased plasma rhIL-6 in CHO-IL6 bead implanted rats is associated with 
increased STAT3 activity in both normal liver and HCC tissues ERK 1/2 activity was 
not altered in normal and HCC tissues from CHO-IL6 bead implanted rats compared to 
controls IL-6Ra expression was elevated in normal liver tissues from CHO-IL6 
implanted rats but not significantly Total liver weight was significantly increased in 
CHO-IL6 bead implanted rats compared to empty bead implanted rats Liver weight 
was also increased compared to CHO-CTRL bead implanted rats however not 
significantly HCC tumour volume was highly variable within groups and hence no 
conclusion on the effect o f IL-6 on HCC tumour progression can be drawn
Alginate encapsulation is a single step process which is carried out under mild 
conditions making it suitable for microencapsulation of living cells (Uludag et a l , 
2000) In the current study CHO-IL6 and CHO-CTRL cells were encapsulated in 
alginate beads which were crosslinked using Ca2+ Cell viability was retained in these 
capsules and large colonies of CHO cells developed within these beads in vitro
6.4 Discussion
211
demonstrating the suitability of this environment to sustain cell growth and allow 
transfer of both nutrients and oxygen to these cells However, noticeable leakage of 
CHO-IL6 and CHO-CTRL cells was observed from these beads at day 7 post- 
encapsulation Living cells were capable of escaping the beads and could begin further 
growth outside of the bead environment In an effort to limit this cell shedding the 
beads were PLL coated, followed by the reliquefication of the alginate core using 
citrate Liquefication of the core did allow dispersal of the growing CHO cell colonies 
and provided more space for cell proliferation however the bead integrity was 
diminished by this procedure Previous reports have demonstrated cell shedding from 
alginate beads in particular when cells with high proliferation rates, such as 
recombinant cell lines, are used (Visted et a l , 2003, Rokstad et a l , 2003, Rokstad et 
a l , 2002) Proliferating cells can disrupt the alginate network resulting in bead rupture 
and cell escape (Rokstad et a l , 2003) Strengthening the beads with PLL without 
subsequent liquefication may assist in the prevention of bead rupture (Thu et a l , 1996b, 
Thu et a l , 1996a) Furthermore, the use of Ba2+ in the place of Ca2+ in the 
encapsulation process has been reported to result in a stronger bead due to a higher 
degree of crosshnkmg withm the alginate structure (Gaumann et a l , 2001, Visted et a l , 
2003, Uludag et a l , 2000) Inhomogeneous beads have also proved to be more stable 
and are less permeable thereby reducing cell escape These beads have a higher alginate 
concentration at the bead surface than in the core To create these beads alginate is 
dropped into a low Ca2+ concentration solution which results in alginate diffusion 
towards the surface of the bead due to its affinity for the rare Ca2+ ions (Thu et a l , 
1996b, Thu et a l , 1996a, Visted et a l , 2003) In addition to these modifications other 
reports have suggested the potential to reduce the proliferative capacity of encapsulated 
cells as a method to prevent cell leakage (Rokstad et a l , 2003) This can be achieved 
through the transfection of a multicistromc expression unit for a cell cycle arrest gene
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and the gene of the product o f interest under the control o f a regulatory promoter (Fux 
et a l , 2001, Mazur et a l , 1999) or through the use o f genetically engineered primary 
cells such as myoblasts that differentiate to a non proliferative state while still 
expressing the protein of interest (Cirone et a l , 2002, Garcia-Martin et a l , 2002) The 
use of contact inhibited cells (Ritt et a l , 2000, Takahashi and Suzuki, 1996) for 
encapsulation offers another possible method to minimise bead rupture due to cells with 
high proliferative capacity These techniques may help to minimise the cell leakage 
observed in the current model allowing the development of a more suitable structure for 
implantation in vivo
Successful implantation of microencapsulated cells in vivo requires the 
avoidance of the detrimental effects of the host immune response and fibrotic 
overgrowth (Uludag et a l , 2000) Beads which are not biocompatible result in fibrotic 
overgrowth which interferes with the diffusion of nutrients and oxygen to the 
encapsulated cells In general, the alginate composition, bead size, smoothness and 
integrity determine the biocompatibility of implanted beads (de Groot et a l , 2004) 
Tails and craters in the bead outer structure, the presence of impurities in alginate and 
cell shedding have all been linked to decreased biocompatibility in vivo (De Vos et a l , 
1993, De Vos et a l , 1997, De Vos et a l , 1996) In the current model fibrotic 
overgrowth was apparent on beads retrieved at 4 days and increased further at 7 days 
after implantation In general this appeared as the build up of living cells on the exterior 
surface o f individual beads however gross presentation of vascularised fibrotic tissue 
surrounding multiple beads was also observed in peritoneal lavages from several 
implanted animals Graft failure was apparent at 7 days post-implantation The 
encapsulation process in the current study was optimised to provide uniform spherical 
beads within a desired size range (diameter 297-500pm) Furthermore, the beads were 
manufactured from commercially available ultrapure sodium alginate optimised for cell
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encapsulation by the removal of endotoxins Empty alginate beads produced using this 
optimised procedure in the current study do not initiate a foreign body response after 
implantation in rats which excludes bead composition and integrity as causative factors 
for the observed fibrotic overgrowth This suggests that in the current study the 
presence o f encapsulated cells is the most important factor leading to decreased 
biocompatibility in vivo Cell leakage and antigen shedding from the encapsulated cells 
are the most probable initiators o f this foreign body response (de Groot et a l , 2004) 
Macrophages act as the mam cell type recruited to the bead surface after initiation of 
the host reponse resulting from graft disruption of host vasculature or passive antigen 
shedding from encapsulated cells (Uludag et a l , 2000, de Groot et a l , 2004) 
Macrophages secrete cytokines such as interleukin-1 P (IL-ip), TNF-a and mterferon-y 
(IFN-y), nitric oxide (NO) and oxygen radicals which diffuse into the beads resulting in 
encapsulated cell death (Gray, 2001, Omer et a l , 2003, King et a l , 2000) Furthermore, 
fibroblasts migrate to the bead surface and mediate matrix production coupled with a 
neo-vasculansation response (Uludag et a l , 2000) This ultimately leads to the 
ensheathing of the implant in fibrous materials and glycosaminoglycans The fibrotic 
build up prevents diffusion of oxygen and nutrients to the encapsulated cells and leads 
to cell necrosis The current model utilises a xenograft implanted mtraperitoneally in 
rats The implantation of encapsulated xenogeneic cells has been shown to pose greater 
problems than those seen after allograft implantation (de Groot et a l , 2004) Virtually 
every protein shed from xenogeneic cells is different than the host These xenoantigens 
not only attract macrophages but also are presented to responder T cells via an indirect 
pathway resulting in the initiation of an immune response against the graft Past studies 
demonstrate CD3+ T cells and MHCI1 expressing macrophages constitute the most 
prominent cell types present in the peritoneum dunng xenotransplantation indicating 
the specific recognition of the xenograft despite the capsule (Siebers et a l , 1999)
214
Prevention of cell shedding as descnbed above will assist in the minimisation of these 
host responses however, no method currently exists to prevent antigen shedding from 
the encapsulated CHO cells This makes sustained survival of encapsulated cells 
difficult to achieve in vivo The use o f genetically modified allogeneic rather than 
xenogeneic cells may assist in overcommg these problems Other research suggests the 
genetic engineering of cells to acquire resistance to deleterious molecules such as 
cytokines and NO through the forced expression of anti-apoptotic proteins as a method 
to avoid xenograft rejection (Rabinovitch et a l , 1999, Contreras et a l , 2001) The 
potential for co-encapsulation with other cells such as Sertoli cells which are capable of 
inducing local immuno-suppressive effects has also been proposed to extend graft 
survival in vivo (Yang and Wnght, 1999)
Sustained IL-6 delivery greater than 4 days was not possible using the current 
system in vivo However, high plasma levels of human IL-6 were achieved 4 days afer 
implantation in rats Furthermore, increased levels of plasma human IL-6 were 
associated with an increase in detectable IL-6 m both normal and tumour liver tissues 
This was further correlated with increased STAT3 activity in both normal and tumour 
liver tissues This data demonstrates that CHO-IL6 encapsulated cells can produce and 
deliver biologically active human IL-6 in a rat model Moreover, this data indicates that 
H4IIE tumour cells respond to IL-6 in vivo despite decreased receptor expression 
While the IL-6 receptors are downregulated in HCC tissue compared to normal liver, 
the cells do express the receptor and hence can retain responsiveness to IL-6 In the 
current study, tumour cells were inoculated directly into the liver parenchyma After 10 
days, CHO-IL6, CHO-CTRL or empty beads were implanted m these animals 
Characterisation of the H4IIE tumour model in vivo has shown that the mean latent 
period following injection of 1 x 106 H411E cells into male ACI rats is 8-10 days (Evans 
and Kovacs, 1977) As a result, 10 days after inoculation was considered an appropriate
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time for implantation of encapsulated CHO cells as this is the beginning of the 
exponential tumour growth phase in vivo While no tumour mass was visible at the time 
of mtrapentoneal implantation of the alginate beads, the current study based the time of 
bead implantation on a study performed using a subcutaneous injection site on the back 
of male ACI rats rather than the liver as the site of tumour development (Evans and 
Kovacs, 1977) The kinetics and efficiency of tumour development in the liver differs 
from the site studied in past research Indeed, in the current study, tumour volumes 
were considered to be highly variable within treatment groups and as a result no direct 
effects on tumour volume attributed to IL-6 treatment could be concluded Tumour size 
variability was not reported as being considerably high at the subcutaneous tumour site 
(Evans and Kovacs, 1977) The reasons for selection of the liver as a site of tumour 
formation rather than a subcutaneous site in this study are twofold The current research 
aims to provide a more physiologically relevant analysis o f liver tumour development 
in vivo which it is believed could not be achieved at a subcutaneous site Secondly, the 
current approach recognises that the liver is the site o f the highest levels of IL-6 in vivo 
due to its role in IL-6 degradation Past research has demonstrated that injected IL-6 is 
cleared efficiently with a plasma half life of approximately 2 minutes and that after 20 
minutes approximately 80% of the administered IL-6 is located in the liver (Castell et 
a l , 1988, Castell et a l , 1990a)
Despite the inability to draw conclusions on the effects of sustained high levels 
of rhIL-6 on HCC tumour development in vivo, the current study did determine an 
increase in liver weight in CHO-IL6 implanted rats, which could not be accounted for 
by tumour volume IL-6 is a key cytokine in injury stimulated liver regeneration where 
increased IL-6 levels prime resting hepatocytes to respond to growth factors such as 
epidermal growth factor, hepatocyte growth factor and transforming growth factor-a 
(Fausto, 2000) Sustained systemic administration of IL-6 using CHO-IL6 cell tumours
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in a nude mouse model resulted in dramatic hepatomegaly and hepatocyte hyperplasia 
in the absence of liver injury (Zimmers et a l , 2003) This was associated with increased 
STAT3 and ERK2 activity in addition to increased PCNA expression in the liver 
Furthermore IL-6Ra expression was increased in this model while gpl30 expression 
remained unchanged In the current model sustained rhIL-6 admistration in an immune 
competent rat also resulted in mcreased STAT3 activity It is worth noting that PCNA 
expression was elevated in normal liver tissues from two of the four animals treated 
with IL-6 in the current study Furthermore lL-6Ra expression was elevated but not 
significantly in all of the CHO-IL6 implanted rat normal liver tissues compared to 
control animals This may be suggestive of the initiation of similar phenomena as that 
observed in the nude mouse model (Zimmers et a l , 2003) The aim of this study was to 
optimise the procedure for rhIL-6 delivery in vivo The results demonstrating the effects 
o f rhIL-6 on normal liver and HCC growth can only be considered preliminary data and 
taking into consideration the variability associated with the in vivo environment do not 
incorporate a sufficient sample size to draw clear conclusions However, these initial 
findings suggest that this model constitutes a potentially useful method to study the 
effects of IL-6 on normal liver growth in the absence o f HCC in immune competent 
animals However, mcreased graft survival is required to sustain IL-6 delivery over 
longer periods to fully establish these effects
In conclusion, microencapsulation of recombinant CHO cells constitutes an 
effective method for systemic IL-6 delivery in vivo However, modifications to prolong 
graft survival are required in order to extend the delivery period This includes the 
development of techniques to prevent cell shedding, to strengthen the integrity of the 
bead and to decrease the responsiveness of these cells to host defence mechanisms 
Ultimately these alterations should decrease the intensity and effectiveness o f the host 
response and prolong the survival o f the encapsulated cells in vivo While the
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variability of H41IE tumour size prevented the determination of the effects of IL-6 on 
HCC tumour progression in vivo, this method of IL-6 delivery does have potential 
application in the study o f normal liver growth
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Chapter 7: Discussion
7.1 The Role of Interleukin-6 in Hepatocellular Carcinoma 
Progression
Hepatocellular carcinoma (HCC) is the most common malignant tumour of the 
liver (Parkin et a l , 2001) This cancer usually anses from defined causal factors the 
most common of which are viral hepatitis, aflatoxin exposure and chronic alcohol 
abuse (Kew, 2002, Okuda, 2000) Despite the identification of these aetiological agents 
hepatocarcinogenesis remains poorly understood Currently surgical resection or liver 
transplantation offer the best treatment for HCC however, these therapies are hindered 
by tumour recurrence and/or donor shortages (Kew, 2002, Okuda, 2000) A better 
understanding o f the molecular mechanisms involved in initiation and progression of 
HCC is essential to our understanding of HCC and in the potential design of new 
therapeutic strategies targeting this malignancy
Interleukin-6 is a pleiotropic cytokine with diverse biological functions IL-6 
acts as a key cytokine m normal hepatocyte proliferation during the process of injury 
stimulated liver regeneration (Fausto, 2000) Furthermore, a mitogemc role for IL-6 m 
hepatocyte proliferation m the absence of liver injury has been reported (Zimmers et 
a l , 2003) Double transgenic mice expressing human IL-6 and human soluble IL-6R 
under liver specific promoters also indicate hepatomegaly, hepatic hyperplasia and the 
emergence o f hepatic adenomas (Maione et a l , 1998, Schirmacher et a l , 1998) 
Hepatic adenomas are considered an absolute precursor o f hepatocyte transformation
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(Takayama et a l , 1990) Taking into consideration the links between IL-6 signalling 
and hepatocyte proliferation the current studies proposed to examine the relationship 
between IL-6 and HCC, a malignancy characterised by dysregulated proliferation of 
transformed hepatocytes
Previous research has determined growth inhibitory and stimulatory effects of 
IL-6 in HCC cells (Kim and Baumann, 1999, Lai et a l , 1999, Klausen et a l , 2000, 
Kumagai et a l , 2002) Furthermore, IL-6 has been linked to increased survival (Chen et 
a l , 1999) and increased metastatic potential (Reichner et a l , 1998) in HCC cells The 
current study aimed to establish the relationship between IL-6 signalling and HCC 
progression using complimentary in vitro and in vivo rat models An in vivo tumour 
model was established by the direct inoculation o f H4IIE rat hepatoma ceils into the 
liver parenchyma of male ACI rats Tissues from these tumours were characterised for 
components of the IL-6 signalling cascade and compared with expression in normal 
liver tissue Cells isolated from HCC tumours were then used in vitro to establish the 
effects of IL-6 signalling in these cells
This study identified differences in expression of IL-6 signalling cascade 
components between normal and HCC tissues HCC is characterised by decreased IL-6 
receptor expression and increased IL-6 expression compared to normal liver tissue 
Furthermore, STAT3 activity is increased in these tumours versus normal liver tissue 
SOCS-1 expression is upregulated while SOCS-3 expression is downregulated in HCC 
compared to normal liver tissue Analysis o f downstream effectors of IL-6 signalling 
demonstrates that p 2 lwafl/c,pl and p27Klpl expression are upregulated in HCC tissue IL-6 
treatment o f cells isolated from these tumours activates Jak-STAT and Ras-MAPK 
intracellular signalling pathways These pathways are also activated in isolated 
hepatocytes While the Jak-STAT pathway is activated similarly in each cell type, the 
Ras-MAPK pathway has a different activation profile after IL-6 treatment in H4IIE
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HCC cells than in isolated hepatocytes Interleukin-6 treatment in H4IIE cells 
stimulates the expression of the cdk inhibitors p 2 lwatl/cspl and p27K,pl, an effect which is 
not observed in isolated hepatocytes Inhibition of the Jak-STAT and Ras-MAPK 
pathways in H4IIE cells established that p21wafi/c,pl expression is STAT dependent 
however the pathway responsible for upregulated p27K,pl expression after IL-6 
treatment remains to be determined The expression of cdk inhibitors occurs 
concomitant with decreased cyclin dependent kinase 2 (cdk2) and cychn dependent 
kinase 4 (cdk4) activity in addition to decreased phosphorylation o f Retinoblastoma 
protein (Rb) Ultimately this sequence of events results in reduced entry o f H4IIE cells 
into the S phase of the cell cycle and as a result decreased cell proliferation in vitro
Interleukin-6 treatment o f H4IIE (HCC) cells blocks cell cycle progression in 
the G0/G1 phase Progression through the cell cycle is tightly controlled by cdks 
(Morgan, 1995) Cyclms associate with cdks and are the primary regulators o f cdk 
activity (Sherr and Roberts, 1999, Morgan, 1995) The activation of cdk4 plays an 
important role in the passage through the G1 restriction point when the cell becomes 
committed to proceed through the cell cycle while cdk2 activation plays an essential 
role in the transition into S phase and DNA synthesis Cyclin D1 expression is induced 
during G1 phase in response to various mitogens, complexes with and activates cdk4 
(Morgan, 1995) Cyclin dependent kinase 2 is regulated primarily by cyclin E and 
cyclin A during G l/S transition and S phase respectively (Sherr and Roberts, 1999, 
Morgan, 1995, Sherr and Roberts, 1995) Retinoblastoma is the major target for cyclin 
dependent kinase activity and is phosphorylated by both cyclin D dependent kinases 
and by cdk2 Hyperphosphorylation o f the Rb protein disrupts its association with E2F 
transcription factors which once released can stimulate the expression of a series of 
genes required for DNA synthesis (Sherr and Roberts, 1999, Morgan, 1995, Sherr and 
Roberts, 1995) Cyclin dependent kinase inhibitors further regulate the activity o f these
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cyclin/cdk complexes P27iC,pl and p21wafl/cipl are members o f the Cip/Kip family of cdk 
inhibitors that can affect the activity of cyclin D-, E- and A- dependent kinases through 
binding of both the cyclin and cdk subunits (Sherr and Roberts, 1999) Taking into 
consideration the roles of each of these regulatory proteins in cell cycle progression, a 
mechanism for IL-6 induced growth arrest in H4IIE cells has been proposed (Figure 
7 1) IL-6 treatment results in increased p21wafl/upl and p27Klpl protein expression which 
can then proceed to bind cyclin-cdk2 and cyclin-cdk4 complexes This results in 
decreased cdk2 and cdk4 kinase activity which is manifested in reduced Rb 
phosphorylation This prevents the release of E2F transcription factors required for 
DNA synthesis and thereby inhibits the exit of these cells from the G0/G1 phase of the 
cell cycle In order to further clarify the role of p 2 lwafl/c,pl and p27Kipl in this process it 
is recommended that further experimentation be performed While increased 
P21wan/C,pl and P27K,pl expression has been previously linked to similar G0/G1 growth 
arrests after IL-6 treatment m other transformed cells, the mechanisms of action may 
vary (Kortylewski et a l , 1999, Klausen et a l , 2000, Florenes et a l , 1999, Bellido et a l ,
1998) Immunoprécipitation of p21wafl/c,pl and p27Kipl from IL-6 treated H4IIE cell 
lysates and subsequent immunoblottmg for cychns and cdks would establish the 
particular cyclm-cdk complexes to which these inhibitors bind Furthermore, through 
the use of siRNA technology it may be possible to knockdown the expression of these 
cdk inhibitors and thereby establish the individual contribution o f each to this growth 
arrest Overall, these experiments should provide a greater insight into the interactions 
of cell cycle regulatory proteins after IL-6 stimulation in HCC
The current study aimed to establish the differences in intracellular signalling 
pathways activated in normal and malignant hepatocytes The activation of Jak-STAT 
pathways in normal hepatocytes and HCC cells followed a similar profile However, 
the ERK activation profile differed in each cell type A characteristic biphasic
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(a)
Figure  7.1 P roposed  m echan ism  fo r  IL-6 induced  g ro w th  a r r e s t  in H4IIF cells, a)
Passage through the G1 restriction point is controlled by cyclin-cdk complexes which 
phosphorylate Rb resulting in the release o f E2F transcription factors which can then 
stimulate the expression of genes required for DNA synthesis, b) IL-6 treatment of 
H4IIE cclls results in uprcgulatcd expression of p21WBfl upl and p27K,plwhich can then 
bind and inhibit cyclin-cdk2 and cyclin-cdk4 complexes. Phosphorylation o f Rb is 
reduccd preventing the release o f  E2F transcription factors and blocking entry into the 
S phase of the cell cycle.
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activation of ERK was observed in HCC cells compared to a monophasic activation of 
ERK in isolated hepatocytes Taking into consideration that the expression of 
p2 i wafl/cipi p27klP! following IL-6 treatment was limited to HCC cells it was 
considered possible that the observed alterations in ERK activation may account for 
these differences However, inhibition of the Ras-MAPK pathway in HCC cells did not 
alter the expression of either p 2 lwaf1/c,pl or p27K,pl Pharmacological inhibition of the 
Jak-STAT pathway did however ablate p 2 lwan/c,pl expression but had no effect on 
p2?Kipi eXpressl0n This demonstrates that the altered ERK activation profile in HCC 
cells was not responsible for the differences in cdk inhibitor expression observed 
between the normal and malignant cell type The current studies did not establish the 
responsible pathway for increased p27Kipl expression after IL-6 treatment in HCC cells 
Pharmacological inhibition of the Jak-STAT pathway using AG490 in these cells does 
not result in complete inhibition o f STAT3 activation while transient transfection of a 
dominant negative STAT3 into H4IIE cells did not alter STAT3 activation As such it 
is not possible to completely discount the potential involvement o f this pathway in the 
expression of p27K,pl Stable transfection o f H4IIE cells with dominant negative 
STAT3 expression vectors may enhance the level o f inhibition in the current model 
Furthermore, other pathways may be activated by IL-6 treatment m this cell type 
STAT3 and MAPK are the primary targets after IL-6 stimulation however STAT5 
(Klausen et a l , 2000), PI3K (Chen et a l , 1999) and STAT1 (Kortylewski et a l , 1999) 
have been shown to be activated in other models Furthermore, both PI3K and STAT5 
have the ability to modulate p27K,pl expression (Klausen et a l , 2000, Banerji et a l , 
2001, Zhu et a l , 2003, Barata et a l , 2004) The possible involvement of these 
pathways during IL-6 treatment o f H4IIE cells warrants further study
Taking into consideration that IL-6 is inhibitory on the proliferation o f H4IIE 
cells it is perhaps surprising that H4IIE cells secrete IL-6 and express the components
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of the IL-6 receptor However, IL-6 receptor expression is decreased in this HCC 
tissue STAT3 is constitutively activated in these tumours in vivo Furthermore, SOCS- 
1 is upregulated in HCC while SOCS-3 is downregulated in HCC These alterations in 
IL-6 signalling may decrease the responsiveness o f HCC cells to IL-6 While the 
SOCS-1 and SOCS-3 genes are silenced m many malignancies including some human 
HCCs (Watanabe et a l , 2004, Yoshikawa et a l , 2001a, He et a l , 2003), 
overexpression has been identified in other tumours and has been linked to cytokine 
resistance (Raccurt et a l , 2003, Sakai et a l , 2002, Tannapfel et a l , 2003) 
Downregulated SOCS-3 expression identified m these tumours may account for 
constitutive STAT3 activity due to inadequate negative regulation of Jak-STAT 
signalling Interestingly, the constitutive activation of STAT3 in murine plasmacytomas 
and hybridomas is associated with the acquisition of an IL-6 independent phenotype 
(Rawat et a l , 2000) Despite these changes the cells remain responsive to IL-6 both in 
vitro and in vivo
Alterations in IL-6 signalling components identified m HCC tumours may be 
due to persistent autocrine stimulation in the tumour cells H4IIE cells proliferate 
rapidly in culture despite the presence of endogenous IL-6 Analysis of tumour tissue 
demonstrates these HCC tumours have increased p 2 lwafl/cipl and p27Kipl expression IL- 
6 signalling could be the reason for constitutive STAT3 activation Downregulation of 
SOCS-3 expression could function to prolong STAT3 activation during this process 
Given that p21wafl/c,P1 and p27lc,pl are downstream targets of IL-6 signalling in H4IIE 
cells in vitro, and that SOCS-1 is also upregulated by IL-6 signalling in other cells, it is 
possible that IL-6 signalling ultimately results in the observed alterations in expression 
of these downstream proteins Indeed, autocrine IL-6 stimulation has been identified as 
the underlying mechanism for constitutive STAT3 activation in multiple myeloma cells 
(Bromberg, 2001) IL-6 has also been demonstrated to downregulate gpl30 and IL-
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6Ra expression, adding further support for this potential mechanism of action for IL-6 
in HCC (Zohlnhofer et a l , 1992, Wang et a l , 1998) Both p21wafl/cipl and p27K,pl genes 
contain STAT responsive elements and can be modulated by IL-6 type cytokines 
(Belhdo et a l , 1998, Kortylewski et a l , 1999, de Koning et a l , 2000) however, they 
are also subject to regulation via other factors P 2 lwafl/cipl and p27Kipl are cyclin 
dependent kinase inhibitors that inhibit G1 associated cyclin complexes such as 
cdk4/cyclin D and cdk2/Cyclin E and, in doing so, inhibit cell cycle progression At 
low stoichiometric concentrations p21wan/cipl and p27Kipl may serve as assembly factors 
for active cyclm-cdk complexes (LaBaer et a l , 1997) and have been implicated as 
regulators o f hepatocyte proliferation in the liver following partial hepatectomy where 
they determine the rate o f progression through the G1 phase of the cell cycle (Albrecht 
et a l , 1998) This evidence implies that the presence or absence of these cdk inhibitors 
is less important than the relative ratio between them and cyclin-cdk complexes 
Overexpression of both p21watl/c,pl and p27Kipl has been previously observed in human 
HCC specimens (Qin and Ng, 2001) Taking into consideration that H4IIE cells 
proliferate rapidly in vivo forming large tumour masses, the increased expression of 
p21wafl/c,pi and p27IClpl does not appear to be inhibitory on their proliferation While 
p21wafl/cipI and p27Klpl could have a role in cyclin-cdk complex assembly in vivo, the 
treatment of H4IIE cells with IL-6 in vitro may result in an imbalance of p21wafl/c,pl and 
P27Kipl expression resulting in the inhibition of cdk-cyclin complexes
These data could also suggest a role for IL-6 as an autocrine negative growth 
regulator in the current HCC model IL-6 has been demonstrated to be an autocrine 
growth inhibitor in human meningioma (Todo et a l , 1994) and lung cancer cells 
(Takizawa et a l , 1993) In the latter case, the cells have a relatively low IL-6 sensitivity 
as compared with noncarcinogemc human bronchial epithelial cells suggesting that 
escape from growth regulation of this inhibitory factor may be involved in lung
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oncogenesis Similarly, H4IIE cells are characterised by decreased IL-6 receptor 
expression supporting potentially evasive cellular mechanisms from IL-6 growth 
inhibition Interestingly, IL-6 does not induce complete inhibition of H4IIE cell 
proliferation This raises the possibility that subpopulations of treated H4IIE cells have 
resistance to IL-6 induced growth arrest The mechanism by which these cells achieve 
this resistance to growth inhibition is not completely clear however it may be 
associated with even further decreases in receptor expression compared to their IL-6 
sensitive counterparts Autocrine negative growth regulation by cytokines in other 
cancer models has been established Transforming growth factor-|3 has growth 
inhibitory effects on low grade gliomas yet stimulates the growth of high grade gliomas 
(Jennings et al , 1991) The acquisition of multicytokine resistance during the process 
of oncogenesis has also been linked to clonal dominance of primary tumours by 
metastatically competent cells (Lu et a l , 1992, Kerbel, 1992, Wu et a l , 1992) 
Interleukin-6 has a similar effect in melanoma cells, acting as a growth inhibitor in 
early stage melanoma and a growth factor for late stage melanoma (Florenes et a l , 
1999, Lu et a l , 1992, Lu and Kerbel, 1993) In the case o f melanoma, as seen with 
TGF-(3, the development o f IL-6 resistance coincides with the acquisition o f metastatic 
competence Overall the proliferation of neoplastic cells is dependent on the interaction 
and balance between both growth stimulatory and inhibitory factors During the process 
of tumour progression, the cells which are most adapted to growth at the primary 
tumour site and in other foreign environments of the body become the dominant clones 
of primary tumours (Kerbel, 1992)
Other functions o f endogenously produced IL-6 in the current model are 
possible Interleukin-6 stimulates the expression of anti-apoptotic proteins (Chen et a l ,
1999) and has been associated with an increase in metastatic potential (Reichner et a l , 
1998) in other HCC models However, IL-6 is associated with multiple roles in the
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progression of a variety o f other cancers In addition to its function as a growth 
regulatory factor in many malignancies (Miki et a l , 1989, Nordan et a l , 1987, Kawano 
et a l , 1988, Jemberg et a l , 1991, Levy et a l , 1991, Okuno et a l , 1992, Miles et a l , 
1990, Novick et a l , 1992, Chen et a l , 1988) IL-6 is involved in the processes of 
angiogenesis, tumour invasion and the development of multidrug resistance IL-6 
stimulates the expression of vascular endothelial growth factor, a specific mitogen for 
vascular endothelial cells, demonstrating a role during neo-angiogenesis (Cohen et a l , 
1996, Dankbar et a l , 2000) The expression of matrix metalloprotemases is also 
modulated by IL-6 in several tumours (Kossakowska et a l , 1999, To et a l , 2002) 
Theses enzymes degrade extracellular matrix components allowing tumour invasion 
and are associated with clinical aggressiveness of many malignancies (Folgueras et a l , 
2004) IL-6 mediates an anti-apoptotic effect in many cancer cells including multiple 
myeloma and has been linked to the development of chemotherapy resistance 
(Lichtenstein et a l , 1995) Furthermore, autocrine production of IL-6 in breast cancer 
cells stimulates multidrug resistance protein 1 expression and subsequent resistance to 
chemotherapeutic agents (Conze et a l , 2001) In several human cervical carcinoma cell 
lines IL-6 production is increased while IL-6 receptors are decreased resulting in 
abrogation of constitutive monocyte chemoattractant protein-1 expression (Hess et a l ,
2000) This may constitute an immune escape mechanism for the tumour Overall, it is 
clear that IL-6 has diverse effects on tumour progression Further expenmentation is 
required to establish the function of IL-6 in the current model Inhibition of IL-6 
expression by siRNA or antisense in H4IIE cells would allow a better understanding of 
the progression and tumour formation of these cells both in vitro and in vivo
Serum levels o f IL-6 are often increased in human HCC patients (Goydos et a l , 
1998, Gianmtrapam et a l , 2002) and have been shown to correlate with the stage of 
HCC progression (Gianmtrapam et a l , 2002) Furthermore, IL-6 production in human
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HCC cells has been linked to the degree of cell differentiation Interleukin-6 is not 
constitutively produced by the well differentiated human HCC HepG2 cell line or the 
moderately differentiated human HCC Li7A cell line However, IL-6 is constitutively 
synthesised by scarcely differentiated HA22T/VGH human hepatoma cells (Paroli et 
a l , 1993) H4IIE cells are poorly differentiated rat HCC cells which were originally 
derived from the well differentiated H-35 hepatoma cell line (Evans and Kovacs, 1977) 
The cytokine expression profile for H-35 cells has not been reported However, H-35 
cell proliferation is inhibited by IL-6 treatment albeit through mechanisms which do not 
involve increased expression of p21wan/cipl or p27K,pl (Kim and Baumann, 1999, Lai et 
a l , 1999) The determination o f IL-6 expression in H-35 cells would give a greater 
insight into whether this tumour model correlates with that observed in human HCC in 
relation to level o f differentiation and IL-6 expression In any case, these data 
demonstrate the heterogeneity in expression and function of IL-6 in HCC
In conclusion, IL-6 treatment of H41IE HCC cells is inhibitory on cell cycle 
progression in vitro Nevertheless, H4IIE cells secrete IL-6 and express the IL-6 
receptor The effects o f autocnne IL-6 stimulation in these cells remain to be 
determined The data presented suggests a possible role for IL-6 in autocrine negative 
growth regulation of H4IIE cells where it could potentially “select” cells with the 
highest levels o f resistance to the growth inhibitory effects o f IL-6 Tumour progression 
is associated with the acquisition o f dominance by the most aggressive cell type In 
HCC this is further correlated with decreased differentiation A relationship between 
the level of differentiation and IL-6 expression in HCC implies that further studies on 
IL-6 signalling in HCC must incorporate cell types from various stages of HCC 
progression as the effects may vary It is tempting to speculate that IL-6 may have 
different roles m HCC progression at various stages throughout HCC tumour 
formation Further studies using rodent tumour models as used in this study will better
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the understanding of the role of IL-6 in hepatocarcinogenesis Ultimately this research 
should be performed in human HCC cells using the knowledge gained from these 
models The complete characterisation of the role of IL-6 in HCC will allow the 
potential for manipulation of this pathway as a means of therapeutic intervention in 
HCC
1.2 Cell Microencapsulation for IL-6 Delivery In Vivo
In order to deliver sustained high levels o f IL-6 in a rat model o f HCC, rhIL-6 
expressing CHO cells (CHO-IL6) were encapsulated in sodium alginate and implanted 
in HCC tumour burdened male ACI rats CHO cells remained viable and formed large 
colonies m alginate beads up to 17 days after encapsulation in vitro Encapsulated 
CHO-IL6 cells retained the ability to secrete rhlL-6 Beads were implanted 
mtrapentoneally in male ACI rats Viability of encapsulated cells was sustained up to 4 
days after implantation resulting in high serum levels o f rhIL-6 However, analysis of 
beads retrieved 7 days after implantation demonstrated complete loss of encapsulated 
cell viability accompanied by the accumulation o f living cells on the outer surface of 
the beads Fibrotic overgrowth was observed 4 days after encapsulation however this 
did not appear to affect cell viability Empty alginate beads did not stimulate a host 
response at 4 or 7 days after encapsulation At 4 days after implantation rhIL-6 was 
detectable in normal and HCC liver tissues This resulted in the activation of the Jak- 
STAT signalling pathway in normal and HCC liver tissues Analysis of IL-6 receptor 
expression demonstrated IL-6Ra was increased but not significantly in normal liver 
tissue from CHO-IL6 implanted rats while gpl30 expression was not affected by rhlL-6 
treatment Liver weight o f CHO-IL6 implanted animals was increased compared to
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control animals Tumour volume was highly variable and as a result no conclusions on 
the effect of rhIL-6 on HCC progression in vivo could be determined
Alginate, derived from brown algae, has ideal characteristics for cell 
encapsulation Alginate forms an extensive gel network on contact with divalent cations 
allowing encapsulation of cells in the absence o f extreme heat or harsh chemicals 
(Uludag et a l , 2000) Furthermore, ultrapure alginates are not immunoreactive allowing 
safe implantation in vivo The principle of microencapsulation is to create a physical 
semi-permeable barrier between the encapsulated cells and the host immune system 
This membrane allows diffusion of oxygen and nutrients to the encapsulated cells while 
preventing contact with host immune cells or large molecules such as immunoglobulins 
(Uludag et a l , 2000) Alginate microencapsulation systems have been used effectively 
as therapy in many models o f disease Most notably alginate encapsulation of 
xenogeneic and allogeneic pancreatic islets has been used to establish normoglycemia 
in diabetic rodents (O'Shea and Sun, 1986), dogs (Soon-Shiong et a l , 1992), monkeys 
(Sun et a l, 1996) and m a human diabetic patient (Soon-Shiong et a l , 1994) In 
diabetes therapy the alginate membrane allows the free transport of glucose and insulin 
providing a system that is highly responsive to the host plasma glucose levels 
Similarly, alginate encapsulated cells have been successfully used to deliver 
biotherapeutic substances in vivo such as Factor IX for haemophilia therapy (Hortelano 
et a l , 1996), parathyroid hormone for the treatment of hypoparathyroidism (Hasse et 
a l , 1997) and dopamine in experimental models o f Parkinson’s disease (Aebischer et 
a l , 1994)
The aim of the current study was to deliver systemically high levels of rhIL-6 in 
HCC tumour burdened rats using alginate microencapsulated CHO-IL6 cells This 
study has established an inhibitory effect of rhIL-6 on H4IIE HCC cell proliferation in 
vitro, as a result the effects o f IL-6 administration on HCC tumour progression in vivo
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were of particular interest Encapsulated CHO-IL6 and CHO-CTRL (mock transfected 
CHO cells) cells exhibited long term survival and proliferation in vitro Implantation of 
these beads in vivo however resulted in complete loss of viability 7 days after 
implantation Closer examination demonstrated the presence of living cells on the outer 
surface of these beads Furthermore, fibrotic overgrowth of many beads retrieved 4 and 
7 days after implantation was observed Typically macrophages are the mam cell type 
recruited to the bead surface after initiation of the host response resulting from graft 
disruption o f host vasculature or passive antigen shedding from encapsulated cells 
(Uludag et a l , 2000, de Groot et a l , 2004) Macrophages secrete cytokines such as 
interleukin-ip (IL-1P), TNF-a and mterferon-y (IFN-y), nitric oxide (NO) and oxygen 
radicals which diffuse into the beads resulting in encapsulated cell death (Gray, 2001, 
Omer et a l , 2003, King et a l , 2000) Furthermore, fibroblasts migrate to the bead 
surface and mediate matrix production coupled with a neo-vasculansation response 
(Uludag et a l , 2000) This ultimately leads to ensheathmg of the implant in fibrous 
materials and glycosaminoglycans The fibrotic build up prevents diffusion of oxygen 
and nutrients to the encapsulated cells and leads to cell necrosis
The microencapsulation system used for rhIL-6 delivery in this study requires 
optimisation to improve cell viability in vivo Ultimately this should involve alterations 
that minimise the host’s foreign body/immune response after implantation Empty 
alginate beads did not elicit a noticeable host response suggesting that in the current 
study the presence o f encapsulated cells is the most important factor leading to 
decreased biocompatibihty in vivo The use of CHO cells for this encapsulation process 
presents at least two major problems, CHO cells proliferate rapidly m these beads and 
once implanted in rats constitute a xenograft in vivo Examination of CHO-IL6 and 
CHO-CTRL beads after encapsulation demonstrated that these cells can escape through 
the walls o f the alginate beads The proliferative capacity o f these cells is a major factor
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leading to cell leakage Two approaches could potentially be used to remedy this 
problem Strengthening of the alginate beads could possibly prevent bead rupture and 
thereby reduce cell escape Various methods to enhance the strength of these beads are 
currently in use including the use of Ba2+ as crosslinking cations rather than Ca2+ which 
were used m the current model (Gaumann et a l , 2001, Visted et a l , 2003, Uludag et 
a l , 2000), poly-L-lysine coating of alginate beads (Thu et a l , 1996b, Thu et a l , 1996a) 
and the use o f mhomogenous beads in place of the standard homogenous beads used in 
the current study (Thu et a l , 1996b, Thu et a l , 1996a, Visted et a l , 2003) The second 
approach is to reduce the proliferative capacity o f the encapsulated cells as a method to 
reduce cell leakage This can be achieved through the transfection of a multicistronic 
expression unit for a cell cycle arrest gene and the gene of the product o f mterest under 
the control o f a regulatory promoter (Fux et a l , 2001, Mazur et a l , 1999) or through 
the use o f genetically engineered primary cells such as myoblasts that differentiate to a 
non proliferative state while still expressing the therapeutic protein o f interest (Cirone 
et a l , 2002, Garcia-Martin et a l , 2002) The use o f contact inhibited cells (Ritt et a l , 
2000, Takahashi and Suzuki, 1996) for encapsulation offers another possible method to 
minimise bead rupture due to cells with high proliferative capacity However, this 
delivery system constitutes a xenograft in rats which is associated with a stronger host 
response than is typically seen with similar implantation of allografts in vivo (de Groot 
et a l , 2004) Virtually every protein shed from xenogeneic cells differs from that of the 
host These xenoantigens allow recognition o f the xenograft despite the presence o f the 
alginate capsule (Siebers et a l , 1999) Prevention of cell shedding as described above 
will assist in the minimisation of these host responses however, no method exists to 
prevent antigen shedding from the encapsulated CHO cells This makes sustained 
survival o f these encapsulated cells difficult to achieve in vivo The use of genetically 
modified allogeneic rather than xenogeneic cells may assist in overcoming these
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problems Other research suggests the genetic engineering of cells to acquire resistance 
to deleterious molecules such as cytokines and NO through the forced expression of 
anti-apoptotic proteins as a method to avoid xenograft rejection (Rabinovitch et a l , 
1999, Contreras et a l , 2001) The potential for co-encapsulation with other cells such 
as Sertoli cells which are capable o f inducing local immuno-suppressive effects has 
also been proposed to extend graft survival in vivo (Yang and Wright, 1999)
Microencapsulated cells have been successfully used to administer anti-cancer 
agents such as angiostatin, endostatin and iNOS in vivo (Read et a l , 2001, Cirone et a l , 
2003, Xu et a l , 2002) This method is particularly suited for the delivery of 
biologically active agents such as cytokines which typically display short plasma half 
lives and are relatively expensive for continual administration However, administration 
of cytokines is often associated with dose limiting toxicities (Fyfe et a l , 1995, 
Rosenberg et a l , 1993, Lienard et a l , 1992, Atkins et a l , 1997) Previous reports 
demonstrate the potential of systemic IL-6 administration to decrease tumour burden of 
other cancers in vivo in the absence of discernible side effects or toxicity (Eisenthal et 
a l , 1993, Givon et a l , 1992, Mule et a l , 1992) Human IL-6 administered to mice with 
transplantable acute myeloid leukaemia (AML) and irradiation/dexamethasone induced 
AML results in reduced leukaemia development and increased animal survival (Givon 
et a l , 1992) This may be due to direct effects on tumour cells and/or through an 
enhancement of the host immune system Recombinant IL-6 administration also 
reduces the number o f established métastasés from colon adeonocarcinoma and 
fibrosarcoma tumours in vivo, an effect mediated via the enhancement of tumour 
specific CD8+ cytotoxic T lymphocyte (CTL) activity (Eisenthal et a l , 1993, Mule et 
a l , 1992) Furthermore, IL-6 administration in combination with cyclophosphamide, a 
chemotherapeutic agent, ameliorates the majority of C57BL/6 mice with advanced, 10 
day subcutaneous or pulmonary sarcoma tumour nodules (Mule et a l , 1992) The effect
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of systemic administration of IL-6 on HCC progression in the current model is unclear 
Tumour size was highly variable making it difficult to ascertain the effects due to IL-6 
alone It was clear that biologically active IL-6 was released in vivo up to 4 days after 
implantation resulting in activation of the Jak-STAT pathway in both normal and 
tumour liver tissues This data indicates that H4IIE tumour cells respond to IL-6 in vivo 
despite decreased receptor expression While the IL-6 receptors are downregulated in 
HCC tissue compared to normal liver, the cells do express the receptor and hence can 
retain responsiveness to IL-6 Cell cycle analysis using propidium iodide staining and 
subsequent FACS analysis on IL-6 treated tumour tissue may help to determine the 
effects of IL-6 on cell cycle progression in vivo It is worth noting that IL-6 treatment 
of H4IIE cells in vitro does not result in complete inhibition of proliferation Sub­
populations o f H4IIE cells do appear to be resistant to IL-6 induced growth arrest 
which may become a relevant factor in vivo Furthermore, the in vivo environment is 
complex comprising multiple cell types and the presence of multiple cytokines and 
growth regulatory agents The interplay between IL-6 signalling and other growth 
regulatory pathways will need to be established m order to ascertain the full effects of 
IL-6 treatment on HCC For example, IL-6 has been shown to inhibit transforming 
growth factor-p (TGF-p) induced apoptosis in hepatoma cells (Chen et a l , 1999) while 
TGF-P can augment IL-6 induced STAT3 activity in HCC cells (Yamamoto et a l ,
2001) Investigation using H4IIE cells implanted subcutaneously would provide an 
easier method to measure tumour volume during IL-6 treatment and should have higher 
reproducibility due in part to a less complex cytokine profile associated with this 
environment However, this will be less physiologically relevant Ultimately, the use of 
microencapsulated cells to deliver IL-6 as a potential therapeutic in HCC appears 
difficult to regulate and may be associated with complications due to HCC cell 
resistance and the complex HCC environment
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Administration of high sustained levels of rhIL-6 m a nude mouse model using 
CHO-IL6 tumours results in massive hepatomegaly and liver growth in the absence of 
liver injury (Zimmers et a l , 2003) Plasma levels o f rhIL-6 were elevated in these mice 
to 80ng/mL This increase in liver growth did not involve other growth factors such as 
epidermal growth factor or hepatocyte growth factor and was the first demonstration of 
IL-6 acting as a complete mitogen for liver growth This effect was accompanied by an 
increase in STAT3 and ERK 2 activity m addition to increased PCNA and IL-6Ra 
expression in liver tissues These effects have not yet been demonstrated in an immune 
competent animal In the current study a significant increase in liver weight which 
could not be accounted for by tumour volume was observed in rhIL-6 treated animals 
compared to controls It is worth noting that PCNA expression was elevated in normal 
liver tissues from two of the four ammals treated with IL-6 in the current study 
Furthermore IL-6Ra expression was elevated but not significantly in all of the CHO- 
IL6 implanted rat normal liver tissues compared to control animals This data correlates 
with events in the nude mouse model (Zimmers et a l , 2003) and is suggestive of 
similar phenomena in immune competent ammals during sustained rhIL-6 delivery 
Taking into consideration the variability associated with the in vivo environment, these 
preliminary results demonstrating the effects of rhlL-6 on normal liver and HCC 
growth do not incorporate a sufficient sample size to draw clear conclusions However, 
these initial findings suggest the use of encapsulated cells as an ideal method to study 
the effects of sustamed high levels of rhIL-6 on normal liver growth Moreover, the 
highest levels o f liver growth during rhIL-6 treatment were observed between 8 and 16 
days after inoculation with CHO-IL6 cells in nude mice, as a result it is necessary to 
extend the survival of encapsulated CHO cells greater than 4 days to fully establish the 
effects of rhIL-6 on normal liver growth in the current model Furthermore, rat plasma 
levels of rhIL-6 in the current model reached approximately 1 25ng/mL This is less
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than levels used in the nude mouse study Implantation of encapsulated CHO-IL6 in 
immune competent mice instead of rats should allow greater levels of circulating rhIL-6 
in vivo
In conclusion, alginate beads can sustain the growth of encapsulated CHO cells 
in vitro This system to admimster rhIL-6 requires further optimisation to sustain cell 
viability in vivo This should include methods to reduce cell proliferative capacity, 
strengthening of the bead structure and the use o f allogeneic cells Overall, this system 
may have limited application in HCC therapy however may prove useful for the study 
of normal liver and HCC tumour growth in vivo
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